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Neurodegenerative diseases are associated with extensive physical and mental 
debilitation, significant costs to the healthcare system, as well as great emotional and 
financial burden to the patients, their families and care providers. Despite progress in 
our understanding of the mechanisms behind neurodegenerative diseases, the vast 
majority are still currently untreatable. Synapses are important pathological targets in 
a range of disorders, including Alzheimer’s disease, Parkinson’s disease, Huntington’s 
disease and lysosomal storage disorders, such as Batten disease. Loss of synaptic 
connections and impairments in synaptic function are present in the initial stages of 
neurodegenerative conditions and throughout the course of disease progression. 
Therefore, synaptoprotective strategies are regarded as a potentially key factor in the 
development of effective therapies aimed at preventing or halting neurodegeneration. 
Despite the continuously growing body of research elucidating the molecular 
mechanisms that modulate synaptic function and vulnerability, the contribution of 
these pathways to neurodegenerative diseases is far from fully characterized. In 
addition, there are frequent issues regarding the applicability of the research performed 
using in vitro and small animal models of disease to develop therapeutic strategies for 
use in human patients. In the work described in this thesis, we initially validated the 
involvement of a selection of key synaptic targets, previously identified as regulators 
of synaptic degeneration in lower animal models, including mice and Drosophila, in a 
large animal model of neurodegenerative disease: CLN5 Batten sheep. Subsequently, 
we explored two of these individual synaptic protein targets in more detail (calretinin 




Calretinin is a poorly characterized protein, primarily known for its calcium 
buffering capacities and high levels of expression in a subpopulation of interneurons. 
In this work, we show calretinin is expressed in previously unreported cell populations, 
including motor axons and synapses from the peripheral nervous system, and that it is 
enriched in synapses in vitro. Furthermore, we show calretinin responds dynamically 
to synaptic activity and is directly involved in neurodegenerative pathways, as 
demonstrated by its ability to influence the course of Wallerian degeneration and 
apoptotic cell death. 
α-synuclein plays a central role in the pathophysiology of Parkinson’s disease 
and contributes to the maintenance of synaptic transmission and mitochondrial 
function. However, questions still remain about how to effectively manipulate α-
synuclein to obtain therapeutic benefits. Therefore, we sought to explore downstream 
targets of α-synuclein in order to uncover new pathways through which this protein 
may influence synaptic stability. Using proteomics on mice lacking α-synuclein and 
in vitro cell systems we identified sideroflexin 3 (sfxn3). We show sfxn3 is localized 
at the inner mitochondrial membrane and that it functions outside the main canonical 
pathways of mitochondria energy production. In addition, overexpression of sfxn3 in 
Drosophila led to a significant loss of synaptic boutons at the level of the 
neuromuscular junction, suggesting regulated levels of sfxn3 are important for the 
maintenance of synaptic connections. 
Altogether, the work developed in this thesis provides novel insights into 
pathways regulating synaptic stability and function. We not only provide evidence that 
the molecular targets studied are affected in a large animal model of neurodegenerative 
disease, and are therefore likely to be relevant to studies in human conditions, but we 
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also uncover two new molecular targets capable of independently regulating synaptic 






Neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease 
occur when neurons in specific regions of the brain start malfunctioning and, 
eventually, die. Although we have gained significant insight into important aspects of 
how and why neurodegenerative diseases develop, treating the dysfunction of neurons 
and preventing their degeneration is not straightforward. As a result, we lack efficient 
therapies to delay the progression of disease. One important factor in the instigation 
and progress of neurodegenerative conditions is the correct function of synapses, the 
terminal connections of neurons which are responsible for transmitting information. 
Synapses form extensive networks of interconnected nerve cells which are responsible 
for maintaining normal motor and cognitive functions. Therefore, maintaining a 
healthy cohort of synapses in the nervous system is of extreme importance to our well 
being. In my work, I have explored new molecular mechanisms that contribute to the 
health and stability of synapses. Translating research performed in some common 
models of disease, such as genetically modified mice, into humans has not always been 
successful, likely due to the more complex form and function of the human nervous 
system. Therefore, I started my work by confirming that a short list of synaptic proteins 
we had previously shown to influence how neurons degenerate in mice were similarly 
affected in a large animal (sheep) model of a childhood form of neurodegeneration, 
known as Batten disease. This confirmed that the molecular targets we were looking 
at in synapses were relevant to neurodegenerative pathways conserved from small 
rodents through to large animals, and presumably humans. I then looked at two 
individual synaptic candidates in more detail, two proteins known as calretinin and α-
synuclein. The function of calretinin is currently very poorly understood. Here, I 
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demonstrated for the first time that calretinin is involved in synaptic function and 
directly contributes to instigate neurodegeneration in mice. α-synuclein is important 
for the development of Parkinson’s disease but it is very difficult to target from a 
therapeutic point of view. Hence, I focused on trying to find proteins related to α-
synuclein that could be used for therapeutic targets instead. I identified sfxn3 and 
showed that it can have a significant influence on the maintenance of synaptic 
connections. Taken together, my work provides novel insights into how to maintain 
healthy and functional synapses in the nervous system, which is important for 
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Chapter 1. General Introduction 
1.1. The socioeconomic impact of neurodegenerative 
diseases 
Neurodegenerative diseases are caused by the progressive dysfunction, and 
ultimately death, of neuronal populations. They can cause extensive physical and 
mental debilitation and yet the vast majority are currently untreatable. Some of the 
most prevalent neurodegenerative conditions include dementias (such as Alzheimer’s 
disease (AD)), Parkinson’s disease (PD), Multiple Sclerosis, and neuromuscular 
disorders such as Amyotrophic Lateral Sclerosis (ALS) (Gustavsson et al., 2011).  
Dementias, in particular, are a growing concern due the current steady increase 
in life expectancy and demographic shift towards an aged population, which naturally 
increases the incidence of age-related disorders (Brookmeyer et al., 2007, Dorsey et 
al., 2007). It is estimated that over 6 million people suffer from dementia in Europe, 
and over 4 million in North America (ADI, 2010, Gustavsson et al., 2011), with these 
numbers expected to more than double by 2030 (ADI, 2010). The healthcare and 
indirect costs associated with dementia have been estimated to reach an annual sum of 
100 billion euros and 200 billion US dollars in 2010, in Europe and North America 
respectively (ADI, 2010, Gustavsson et al., 2011). PD, another very prevalent 
neurodegenerative condition affects over 1% of the aged population in both Europe 
and the US, and costs the respective healthcare systems nearly 14 billion euros and 14 
billion US dollars per year (Gustavsson et al., 2011, Kowal et al., 2013). In addition to 
the financial costs to the patients and healthcare system and the physical impairments 
often associated with neurodegenerative conditions, these disorders also impart a great 
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deal of emotional suffering to the patients, families and care providers (WHO). 
Therefore, it is of extreme importance we further our understanding of the mechanisms 
behind neurodegeneration and develop effective therapeutic strategies that can 
minimize the human and financial costs associated with neurodegenerative disorders. 
 
Table 1.1: Key prevalence and financial facts about Alzheimer's disease and Parkinson's disease. 
 Region  Parameter Dementia Parkinson's Disease References 
UK Prevalence (population over 66) 7.73% 1.15% [1] 
UK Number of people affected 738,415 109,806 [1] 
UK Cost per person (PPP EURO) 30,016 21,500 [1] 
UK Total cost (Million PPP EURO) 22,164 2,361 [1] 
Europe Prevalence (population over 66) 1.23% 0.24% [1] 
Europe Number of people affected 6,341,179 1,249,312 [1] 
Europe Cost per person (PPP EURO) 16,949 4,417 [1] 
Europe Total cost (Million PPP EURO) 105,163 13,933 [1] 
US Prevalence (population over 60) 6.50% * 1-2% [2, 3] 
US Number of people affected 4,383,057 * 630,000 [2, 3] 
US Cost per person (USD) 48,605 * 22,851 [2, 3] 
US Total cost (Million USD) 213,040 * 14,327 [2, 3] 
* North America High Income Population. 
PPP: purchasing power parity. 
Statistics related to 2010. 
Cost categories include direct health care costs, direct non-medical costs and indirect costs.  
Dementia section includes CID10 codes F00-F03: Alzheimer's disease, vascular dementia, dementia in other diseases such as 
Huntington's and Parkinson's Diseases, and unspecified dementias. 
[1] (Gustavsson et al., 2011); [2] (ADI, 2010); [3] (Kowal et al., 2013) 
 
1.2. Therapies for neurodegenerative diseases 
1.2.1. Current therapies and limitations 
Current drug therapies for the management of neurodegenerative diseases, 
such as AD and PD, focus on the symptomatic treatment of the conditions and act 
mainly by controlling the levels of particular neurotransmitters in the brain. The 
effectiveness of these therapeutics is based on the principle that specific neuronal 
populations degenerate preferentially in AD and PD, leading to a reduction in the 
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available neurotransmitters and excitatory capacity of the affected neuronal 
populations, with consequent weakening of downstream neuronal circuits and 
ultimately loss of connectivity (AS, 2015).  
In AD, the marked loss of cholinergic neurons in early stages of the disease led 
to the Cholinergic Hypothesis of Alzheimer’s and to the development of drugs that 
could improve cholinergic signalling (Francis et al., 1999, Schliebs and Arendt, 2011). 
Currently, donepezil, rivastigmine and galantamine are amongst the medications used 
to treat patients with AD. These drugs act as cholinesterase inhibitors, resulting in 
reduced breakdown of acetylcholine in the brain and boosting the excitatory capacity 
of the degenerating cholinergic neurons. These lines of treatment have some small 
positive effects on cognition and are able to temporarily alleviate and stabilize 
symptoms of AD. However, they do not alter the underlying cause of pathology and 
do not prevent further degeneration from occurring (Becker and Greig, 2012, Bentham 
et al., 1999, Selkoe, 2013). A similar rationale underlies the available treatments for 
PD. In PD, however, the dopaminergic neurons of the substantia nigra are the most 
affected in early stages of the disease. Therefore, dopamine agonists, dopamine 
precursors (eg. Levodopa) and inhibitors of dopamine degradation (eg. MAO-B and 
COMT inhibitors) have been developed to manage the disease. Although able to 
temporarily ameliorate motor symptoms, these drugs do not show long-term benefits 







1.2.2. New therapeutic approaches 
At present, treatment for most neurodegenerative diseases is delivered 
symptomatically. Consequently, when symptoms are reported by patients the 
degenerative process has already been active for a period of time. For instance, motor-
symptoms in PD are perceived when over 50% of the dopaminergic neurons in the 
substantia nigra have already degenerated (Fearnley and Lees, 1991), and in 
Huntington’s disease (HD) motor and cognitive impairments are detected in patients 
carrying the HD-causing mutation years before the onset of the characteristic motor 
symptoms (Paulsen et al., 2008, Stout et al., 2007). Strikingly, the pre-clinical period 
of AD has been estimated to be as long as 17 years, when deposition of amyloid-beta 
is predicted to start, while hippocampal atrophy and cognitive impairments are first 
detectable up to 5 years before the clinical diagnosis of AD (Villemagne et al., 2013). 
These facts highlight two major challenges that need to be addressed in 
neurodegeneration research: the early diagnosis of neurodegenerative diseases, which 
requires better screening tools and the improvement of biomarkers and diagnostic 
criteria for each condition; and the development of disease-modifying drugs that target 
the pathophysiology of the disease and halt disease progression (DeKosky et al., 2011, 
Hampel et al., 2010, Herrmann et al., 2011). 
One strategy that has been widely explored is the clearance of protein 
aggregates, which are a hallmark of several neurodegenerative conditions. The 
deposition of Amyloid-beta (Aβ) plaques is a key feature found in the brain of patients 
with AD. As a result, research has focused, for many years, on attempting to clear Aβ 
plaques. However, this has not yet proven beneficial in clinical trials (Amtul, 2016, 
Selkoe and Hardy, 2016). A similar approach has been adopted for PD, where 
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strategies to clear α-synuclein and prevent its aggregation, a hallmark of the disease, 
are currently the focus of much attention (Dehay et al., 2015).  
The use of antioxidants and neurotrophic factors are examples of other 
strategies that have been explored as possible therapeutic options for 
neurodegenerative diseases. Mitochondria are important modulators of neuronal 
function and survival, and play a crucial role in the control of reactive oxygen species 
(ROS). Elevated ROS levels and reduced capacity of mitochondria to neutralize ROS 
are important during the instigation and progress of neurodegeneration (Barnham et 
al., 2004, Lin and Beal, 2006). In agreement, antioxidants have been shown to 
ameliorate neuronal death in some models of disease (Nistico et al., 2012, Valera and 
Masliah, 2016). Neurotrophic factors, on the other hand, play an important role in the 
development, survival and repair of neurons, and there is increasing evidence 
indicating the loss of trophic support might contribute to the pathology of 
neurodegenerative diseases (Connor and Dragunow, 1998, Levy et al., 2005, Lu et al., 
2013). Administration of neurotrophic factors has indeed been shown to promote 
neuronal survival and repair in animal models of PD, AD and HD (Decressac et al., 
2012, Nagahara et al., 2013, Nagahara et al., 2009, Simmons et al., 2009).  
 
Despite promising research regarding new therapeutic approaches, no drugs 
have yet passed clinical trials and the urgent requirement to develop novel disease-
modifying drugs for the treatment of neurodegenerative conditions persists 
(Cummings et al., 2014, Lu et al., 2013). However, the lack of knowledge about the 
mechanisms contributing to the initiation and progression of neurodegeneration is 
hindering the drug-development progress. Neurons and neuronal compartments are 
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very dynamic and complex structures, with countless factors contributing not only to 
their function and stability but also to their vulnerability and degeneration. A variety 
of proteins and pathways cooperate to regulate these processes and, therefore, new 
therapeutic strategies aiming to ameliorate neurodegeneration will benefit from a 
multifactorial approach that targets multiple pathways simultaneously. One of the 
areas predicted to have a positive and broad impact is the maintenance of synaptic and 
axonal integrity (Coleman, 2005, Gillingwater and Wishart, 2013, Lu et al., 2013). 
 
1.3. Synaptic pathology in neurodegenerative 
conditions 
1.3.1. Synapses 
Synapses are specialized structures that allow the transfer of information 
between individual neurons or between neurons and other cell types, such as muscle 
fibers (in this case, synaptic connections are termed neuromuscular junctions (NMJs)). 
Synapses can be electrical or chemical, with the latter subtype being the most well 
studied. Chemical synapses work by releasing neurotransmitters and are composed of 
a pre-synapse in the axonal terminal of a neuron, a synaptic cleft and a post-synaptic 
area in a dendritic spine of the receiving neuron (Figure 1.1). The correct functioning 
of the pre-synapse relies on the precise regulation of the synaptic vesicle cycle 
(Sudhof, 2004, Sudhof, 2012). When an action potential arrives at the pre-synapse, 
calcium channels open and allow the increase in intracellular calcium levels which 
activates the SNARE complex machinery at the active zone, leading to the fusion of 
vesicles with the pre-synaptic membrane and exocytosis of neurotransmitters into the 
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synaptic cleft. At the edge of the active zone, synaptic vesicles and their associated 
proteins are recycled through endocytic mechanisms. Simultaneously, at the post-
synaptic density receptors such as glutamate (NMDAR and AMPAR) and 
acetylcholine receptors (AChR) are activated by the released neurotransmitters and 
prompt a response in the target neuron (Figure 1.1). Although the process of 
neurotransmission is tightly regulated, it is also incredibly plastic, which allows for 
the specialization of synapses to meet the particular requirements of the neuronal 
networks they are integrated in. Synaptic plasticity is referred to as the capacity of 
synapses to strengthen or weaken over time in response to their activity, and is believed 
to underlie processes such as learning and memory. Synaptic plasticity comes in the 
forms of short- or long-term depression or potentiation and is regulated by both pre 
and post-synaptic mechanisms (Citri and Malenka, 2008).  
 
Given the requirement of synapses for neuronal function, it is essential to 
maintain synaptic form and function under homeostatic conditions. As outlined in the 
next sections, imbalances in the synaptic proteome, failure of pre- or post-synaptic 
mechanisms, and/or defects in synaptic plasticity can cause neurological and 





Figure 1.1: Synapse and the synaptic vesicle cycle. Synapses are the functional units of the nervous 
system responsible for the transmission of information between neurons. They are formed by a pre-
synaptic nerve terminal, the synaptic cleft and a post-synaptic region. At the pre-synapse, synaptic 
vesicles undergo a cycle during which they are filled with neurotransmitters, docked to the active zone, 
primed for fusion and finally fused with the synaptic membrane upon a rise in calcium levels following 
an action potential. The exocytosis of synaptic vesicles releases neurotransmitters which activate 
receptors at the post-synaptic cell. To complete the synaptic vesicle cycle, vesicles are recovered by 
endocytosis and refilled with neurotransmitters. Figure adapted from (Rossetto et al., 2014). 
 
1.3.2. Synapses are important pathological targets in diverse 
neurodegenerative conditions 
Synapses have emerged as important sites of neuronal dysfunction in a wide 
range of neurodegenerative diseases (Gillingwater and Wishart, 2013, Henstridge et 
al., 2016). Loss of synapses and impairments in synaptic function are present in many 
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conditions, including AD (Sheng et al., 2012), PD (Picconi et al., 2012), HD 
(Milnerwood and Raymond, 2010) and lysosomal storage disorders, such as Batten 
disease (Kielar et al., 2009). 
In AD degeneration is prominent in the hippocampus and association cortices. 
Early studies in human patients not only revealed that synapse loss was occurring in 
these areas during the course of disease progression, but also revealed a 
disproportionately large loss of synaptic connections, when compared to the loss of 
neuron cell bodies, indicating that synapse loss was likely occurring before neuronal 
death (Davies et al., 1987, Scheff and Price, 1993). In addition, the degree of synapse 
loss is often one of the best correlates of cognitive decline (DeKosky and Scheff, 1990, 
Ingelsson et al., 2004, Terry et al., 1991). Loss of hippocampal synapses and reduced 
levels of synaptic markers, such as the protein synaptophysin, haven been shown to 
correlate with cognitive function in patients suffering from AD and mild-cognitive 
impairment (Heinonen et al., 1995, Scheff et al., 2006, Sze et al., 1997). It is not yet 
fully understood why synapses degenerate in AD, although the accumulation of 
soluble forms of Aβ and hyperphosphorylated-tau are thought to play an important 
role (Spires-Jones and Hyman, 2014). These are believed to destabilize synapses and 
affect numerous downstream molecular mechanisms, such as AMPA and NMDA 
receptor mediated signalling (Hsieh et al., 2006, Shankar et al., 2007) and synaptic 
plasticity (Li et al., 2009, Shankar et al., 2008, Walsh et al., 2002). 
In PD the corticostriatal and nigrostriatal pathways are particularly affected 
during the course of the disease. In agreement, impairments in synaptic function in 
these areas have been reported in various models of PD and found to precede neuronal 
loss (Day et al., 2006, Janezic et al., 2013, Stephens et al., 2005, Villalba et al., 2015). 
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Mice expressing mutations associated with familial forms of PD present defects in 
neurotransmission and synaptic plasticity (Sweet et al., 2015, Tong et al., 2009). 
Furthermore, increased levels and accumulation of α-synuclein, a protein central to the 
pathophysiology of PD, disrupt synaptic excitability and connectivity in models of the 
disease (Garcia-Reitbock et al., 2010, Nemani et al., 2010, Scott et al., 2010, 
Volpicelli-Daley et al., 2011).  
Further evidence of how impairments in synaptic function underlie neuronal 
dysfunction in neurodegenerative conditions can be found in studies of HD. Although 
atrophy of the striatum, which precedes a generalized atrophy of the brain, is a key 
feature of the disease (Halliday et al., 1998), morphological defects in spines and 
synapses are evident before signs of neuronal death in both human post-mortem tissue 
and mouse models of the disease (Ferrante et al., 1991, Graveland et al., 1985, Spires 
et al., 2004). In addition, in HD patients cortical excitability is found to be altered 
before the onset of motor symptoms (Schippling et al., 2009), whereas animal models 
of the disease show early signs of deregulated synaptic plasticity and network activity 
(Cummings et al., 2006, Miller et al., 2008, Milnerwood et al., 2006, Walker et al., 
2008).  
 
1.3.3. Molecular mechanisms affecting synaptic stability 
Neurodegenerative diseases display, early in the course of disease, 
impairments in synaptic function and structure. Although degeneration occurs in 
preferential neuronal populations and is initiated by different triggers, common 
pathways are disturbed in degenerating synaptic nerve terminals through the course of 
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disease. In the next subsections I will outline some of the major areas that affect 
synaptic stability and contribute to synaptic dysfunction. 
 
1.3.3.1. Synaptic function 
The correct functioning of the neurotransmission machinery is crucial to the 
maintenance of synaptic stability. Not only genetically modified animals that fail to 
express components of the SNARE machinery, such as SNAP-25 and VAMP2, are 
prenatally lethal (Schoch et al., 2001, Washbourne et al., 2002), but impaired SNARE 
function is also associated with extensive neurodegenerative phenotypes. Two proteins 
that have been shown to influence synaptic stability through this mechanism are CSP-
α and α-synuclein. Deletion of CSP-α, a presynaptic chaperone, destabilizes SNAP-25 
activity and compromises synaptic transmission (Fernandez-Chacon et al., 2004, 
Sharma et al., 2012). This results in widespread progressive neurodegeneration in 
CSP-α knock-out (KO) mice, which affects the neuromuscular system, GABAergic 
synapses and photoreceptor integrity, and leads to premature death before 4 months of 
age (Chandra et al., 2005, Fernandez-Chacon et al., 2004, Garcia-Junco-Clemente et 
al., 2010, Schmitz et al., 2006, Sharma et al., 2012). Interestingly, increasing α-
synclein expression ameliorates degeneration and rescues lethality of the CSP-α KO 
mice (Chandra et al., 2005).  
α-synclein itself has been repeatedly implicated in neurodegenerative 
mechanisms, initially due to its key contribution to the pathophysiology of PD 
(Stefanis, 2012). However, although aggregation of α-synclein is neurotoxic, deletion 
of proteins from the synuclein family in mice results in reduced dopamine levels in the 
brain and this family of proteins has been shown to contribute to the regulation of 
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neurotransmission during ageing (Burre et al., 2010, Chandra et al., 2004a). In fact, in 
its native conformation α-synclein acts as a chaperone for the assembly of SNARE-
complexes and facilitates vesicle fusion (Burre et al., 2012, Burre et al., 2015).  
 
Not only the pre-synapse but also the post-synapse contributes to the 
maintenance of neuronal function and stability. Defects in the function or abundance 
of post-synaptic receptors, such as AMPA and NMDA receptors, are associated with 
defects in synaptic plasticity in several neurodegenerative conditions, including PD, 
AD and HD (Henstridge et al., 2016). For instance, α-synuclein oligomers promote the 
internalisation of NMDA receptors and lead to reduced NMDA-dependent currents, 
resulting in impaired long-term potentiation (LTP) in hippocampal and dopaminergic 
cells (Chen et al., 2015, Cheng et al., 2011, Diogenes et al., 2012). Similarly, 
administration of oligomeric Aβ to hippocampal slices or in vivo microinjection into 
the hippocampal area results in disrupted LTP and enhanced long-term depression 
(LTD) (Li et al., 2009, Walsh et al., 2002). Impaired LTP and excessive LTD are 
associated with weakening and shrinking of synapses, which contribute to synapse 
elimination (Zhou et al., 2004). In addition, preferential loss of synaptic NMDA 
receptors, which occurs in AD models (Li et al., 2011), or an increase in extra-synaptic 
receptor signalling, as demonstrated for HD (Milnerwood et al., 2010), can have 
deleterious consequences for neuronal health. NMDA receptor signalling activates 
pro-survival pathways, including reduction of oxidative stress and induction of 
expression of survival genes, such as bdnf. On the other hand, extra-synaptic NMDA 
receptors mediate pro-death mechanisms, such as activation of calpains and apoptotic 
pathways (Hardingham and Bading, 2010). As a result, impaired synaptic plasticity 
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can have consequences not only for synaptic function and maintenance of neuronal 
networks, but may also shift the balance between pro-survival and pro-death pathways, 
leaving neurons more vulnerable to degeneration (Hardingham and Bading, 2010). 
 
1.3.3.2. Mitochondrial function 
Mitochondria are the main source of metabolic energy in cells. Nonetheless, in 
addition to producing ATP via oxidative phosphorylation (OXPHOS), mitochondria 
also play crucial roles in the maintenance of calcium homeostasis, control of reactive 
ROS and induction of apoptotic mechanisms. Moreover, mitochondria are extremely 
dynamic organelles. They constantly undergo fission and fusion and need to be 
transported between axons/synapses and the cell soma, where mitochondria biogenesis 
and degradation primarily occurs. As a result, many pathways contribute to the 
maintenance of mitochondrial homeostasis, including: adequate functioning of the 
OXPHOS chain and production of ATP; control of mitochondria DNA replication, 
transcription, translation and repair; maintenance of a low oxidative environment and 
control of ROS; mitochondrial quality control through fission and fusion mechanisms 
and removal of damaged mitochondria by mitophagy; and control of intracellular 
calcium levels. Failure of any of these pathways leads to pathology (DiMauro and 
Schon, 2008, Scheibye-Knudsen et al., 2015).  
 
Synaptic mitochondria are particularly sensitive to insults and several factors 
have been proposed to account for their increased vulnerability. For instance, most 
mitochondria are produced in the cell soma and need to be transported along axons 
until they reach synapses (Sheng, 2014). Consequently, synaptic mitochondria may 
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have a longer life span than non-synaptic mitochondria and may accumulate more 
damage as a result. In addition, synapses are sites of high calcium fluctuations and 
energetic demand, and rely on mitochondria for sustaining synaptic activity (Marland 
et al., 2016, Pathak et al., 2015, Tong, 2007). Impaired mitochondrial function can 
therefore significantly affect synaptic function (Ly and Verstreken, 2006). Moreover, 
the demanding environment of synapses contributes to oxidative damage and Ca2+ 
overload, to which synaptic mitochondria seem to be particularly vulnerable (Brown 
et al., 2006, Yarana et al., 2012).  
Synaptic mitochondria form a subpopulation of mitochondria with distinct 
morphological, molecular and functional characteristics (Chang and Reynolds, 2006, 
Lai et al., 1977, Stauch et al., 2014b). Mitochondria at the synapse carry an adapted 
proteome, which may provide advantage towards the functional requirements of the 
synaptic environment but also contribute to the vulnerability of synapses to 
mitochondrial dysfunction. In fact, analysis of synaptic and non-synaptic mitochondria 
has shown synaptic mitochondria have lower basal OXPHOS activity and reduced 
levels of proteins responsible for Ca2+ handling (Almeida et al., 1995, Stauch et al., 
2014b). These changes may underlie the increased vulnerability of synaptic 
mitochondria to OXPHOS inhibition and Ca2+ overload, with consequences for the 
vulnerability of synapses to neurodegeneration (Brown et al., 2006, Davey et al., 1997, 
Davey and Clark, 1996, Yarana et al., 2012). During aging, in contrast to what happens 
to most populations of non-synaptic mitochondria, which show decreased OXPHOS 
activity and energy production, mitochondria in synapses have been shown to maintain 
their bioenergetic capacity constant by increasing basal OXPHOS activity levels 
(Boffoli et al., 1994, Ferrandiz et al., 1994, Gomez et al., 2009, Stauch et al., 2014a). 
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Whereas synaptic proteins in aged mice show increased signs of oxidative damage, 
several antioxidant proteins are increased in aged synaptic mitochondria, which could 
represent an adaptive mechanism for dealing with increased ROS production due to 
cumulative damage or increased basal OXPHOS activity (Martinez et al., 1996, Stauch 
et al., 2014a). 
 
Altered mitochondrial homeostasis is characteristic of several 
neurodegenerative disorders (DiMauro and Schon, 2008, Harris et al., 2012). For 
instance, mutations in genes encoding proteins from the mitochondria OXPHOS cause 
the childhood neurodegenerative disorder Leigh Syndrome (Lake et al., 2016), 
whereas mutations on the antioxidant protein SOD1 are associated with familial cases 
of ALS (Kiernan et al., 2011). In addition, mutations linked to PD, including in the 
snca, pink1 and dj-1 genes, have been shown to affect mitochondrial function and 
morphology (Haelterman et al., 2014), while toxins known to cause parkinsonian 
syndromes in humans, such as MPTP and rotenone, damage neurons by inhibiting 
mitochondria OXPHOS activity (Panov et al., 2005, Przedborski et al., 2004). In AD, 
the accumulation of A and tau has been shown to disrupt mitochondrial trafficking 
and increase mitochondrial fragmentation (Rui et al., 2006, Wang et al., 2009, Wang 
et al., 2008b).  Interestingly, synaptic mitochondria are affected by A accumulation 
earlier than non-synaptic mitochondria, and exhibit decreased trafficking, impaired 
OXPHOS activity and increased oxidative stress (Du et al., 2010). Ca2+ handling and 
mitochondrial trafficking are particularly affected in HD. In pre-symptomatic stages 
of the disease, mitochondria show disrupted Ca2+ uptake and increased susceptibility 
to Ca2+ overload (Choo et al., 2004, Milakovic and Johnson, 2005, Panov et al., 2002). 
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In addition, mutant huntingtin (mHtt) protein disrupts mitochondrial trafficking to 
synapses and promotes mitochondrial fragmentation (Kim et al., 2010, Shirendeb et 
al., 2012, Trushina et al., 2004). 
Altogether, mitochondria play an important role in the maintenance of neuronal 
homeostasis but are also important sites of pathology in neurodegenerative diseases. 
In particular, a growing body of evidence indicates synaptic mitochondria have distinct 
functional features from non-synaptic mitochondria and are particularly vulnerable to 
some forms of mitochondrial dysfunction. Therefore, given their key contribution to 
both synaptic function and vulnerability, mitochondria are promising targets for 
neuroprotective therapies.  
 
1.3.3.3. Protein aggregates and protein clearance pathways 
Many neurodegenerative disorders are characterized by the presence of 
intracellular aggregates and inclusion bodies, which are often considered pathological 
hallmarks of the disease (Ross and Poirier, 2004). For instance, A accumulates in 
plaques in the brain of patients with AD, -synuclein inclusions are present in PD and 
Dementia with Lewy bodies, and the mHtt protein has a high propensity to aggregate 
(Ross and Poirier, 2004). Whereas large protein inclusions tend to be nuclear, 
cytoplasmic or secreted extracellularly, synapses can similarly be affected by the 
presence of insoluble protein aggregates. That is the case in AD, where A and 
hyperphosphorylated-tau have been found in pre-synaptic compartments and dendritic 
spines (Hoover et al., 2010, Koffie et al., 2009, Takahashi et al., 2004), and in PD, in 
which aggregation of -synuclein has been reported in synapses (Kramer and Schulz-
Schaeffer, 2007, Spinelli et al., 2014). 
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The mechanisms behind the toxicity of protein aggregates are still 
controversial. On the one hand, it has been shown that the degree of inclusion bodies 
does not necessarily correlate with the severity of pathology in conditions such AD 
(Terry et al., 1991). In addition, several lines of evidence indicate that intermediate 
soluble oligomeric forms of aggregation-prone proteins, such as A, -synuclein and 
mHtt, are more damaging to cells than fibrils (Arrasate et al., 2004, Haass and Selkoe, 
2007, Lue et al., 1999, Luth et al., 2014, Winner et al., 2011). The formation of 
neuronal inclusions has indeed been proposed to represent a protective mechanism 
which evolved to safeguard cells from the neurotoxic effects of misfolded proteins 
(Ross and Poirier, 2005).  However, protein inclusions can affect synaptic function 
and interfere with protein quality control mechanisms (Bajic et al., 2012, Bence et al., 
2001). As a result, it remains to be established what is the best strategy to deal with 
protein aggregation in neurodegenerative conditions, since not only protein inclusions 
but also the intermediate stages of misfolded protein monomers, soluble oligomeric 
species and proto-fibrils are associated with toxicity.  
 
Clearance of protein aggregates and misfolded proteins is performed primarily 
by the ubiquitin-proteasome system (UPS) and autophagy mechanisms. The UPS 
degrades proteins that have been previously ubiquitinated, whereas autophagy is 
mediated by lysosomal degradation of proteins and has the capacity to deal with larger 
protein complexes than the UPS (Rubinsztein, 2006). Failure of any of these 
mechanisms results in neurodegenerative-like conditions. For instance, imbalances or 
mutations in components of the UPS, such as Parkin, Uba1 and Ufd2a, have been 
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linked to PD, X-linked spinal muscular atrophy and spinocerebellar ataxia type 3, 
respectively (Lucking et al., 2000, Matsumoto et al., 2004, Ramser et al., 2008). 
Degradation by the UPS is difficult for oligomeric and aggregated proteins, 
which tend to be degraded through autophagy (Berger et al., 2006, Iwata et al., 2005, 
Webb et al., 2003). However, ubiquitination of these proteins still occurs. Even though 
it may help prevent some of the toxic effects of misfolded proteins (Gray, 2001), 
excessive ubiquitination can also overload the UPS and interfere with its normal 
dynamics. Protein aggregates have been shown to directly inhibit UPS function, which 
has deleterious consequences for the normal homeostatic mechanisms controlling 
neuronal function (Bence et al., 2001). In agreement, inhibition of the UPS features in 
neurodegenerative conditions which present protein inclusions (Huang and 
Figueiredo-Pereira, 2010, Keller et al., 2000, Wang et al., 2008a). It is not clear why 
UPS inhibition occurs, but it could include overloading proteasomes with protein 
species that due to their conformation will not be degraded, sequestrating proteasome 
complexes into the protein aggregates themselves, and saturating the UPS system so 
that it is not able to cope with the regular cellular demands (Bence et al., 2001, 
Dantuma and Bott, 2014). In addition, mutant variants of proteins such as -synuclein 
have the ability to directly bind the proteasome and impair its function (Snyder et al., 
2003). 
Whether protein aggregation is a cause or consequence of UPS failure, or vice-
versa, is not clear, as the relationship between the two seems to function in a toxic loop 
(Bence et al., 2001, Dantuma and Bott, 2014). Misfolded proteins impair proteasome 
functions, which in turn prevents the efficient clearance of toxic species, aggravating 
protein aggregation and further inhibiting the UPS. On the other hand, impairments in 
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the UPS, due to normal ageing or genetic mutations, may promote the formation of 
protein aggregates responsible for neurodegenerative diseases such as AD and PD. 
Nonetheless, it is clear that protein aggregation and protein clearance mechanisms are 
a central theme in the field of neurodegeneration and can contribute to the impairment 
of neuronal function, and synaptic function in particular (Bingol and Schuman, 2005, 
Speese et al., 2003). Hence, strategies looking at stabilising non-toxic protein species, 
increasing the clearance or stabilisation of toxic protein aggregates and managing 
protein quality control mechanisms are attractive targets for the treatment of 
neurodegenerative conditions.  
 
1.4. Synaptoprotective strategies for the treatment of 
neurodegenerative diseases 
1.4.1. The importance of synaptoprotective strategies 
Given the important role of synapses in neurodegenerative diseases it has been 
proposed that synaptoprotective therapies might be the key to preventing or halting 
neurodegeneration. In fact, this approach has several major advantages, as outlined by 
Lu and colleagues (Lu et al., 2013): 
- Synapses are a common target of disease pathophysiology in a variety of 
conditions. Thus, synaptoprotective therapies have the advantage of being 
suitable to a wide range of neurodegenerative disorders, virtually 
regardless of the initial trigger of neuronal dysfunction; 
- Synapses are essential for the maintenance of neuronal networks, which in 
turn underlie normal physiology and behaviour. Protecting neuronal 
20 
 
circuits is therefore expected to provide both functional and behavioural 
benefits; 
- Synaptic dysfunction and loss are, to some extent, reversible. Therapies 
aiming to prevent synaptic dysfunction, to repair damaged synapses or to 
promote synaptogenesis and replace compromised networks are all 
expected to have therapeutic benefits; 
- Synaptic dysfunction starts pre-symptomatically and is present throughout 
the progress of disease. Consequently, there is a wider therapeutic window 
for promoting the stability and repair of synapses than there is to address 
the pathogenesis of neurodegenerative disorders (Figure 1.2). 
 
 
Figure 1.2: Disease progression and therapeutic window for synaptoprotective interventions. 
Graphical representation of disease progression (A) and examples of events in neurodegeneration (B). 
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During disease progression (A: red line) there is a small window of intervention when therapeutic 
strategies that target the pathogenic mechanisms of the disease may slow down disease progression (A: 
blue line; B: a). However, if the main pathophysiological mechanisms of the disease are targeted, there 
is an enhanced window of opportunities, with the possibility of repair or regeneration of the affected 
nervous tissue (A: green line; B: b, c). In particular, targeting synapse loss has the advantage of 
providing therapeutic benefits within a reasonable time frame during disease progression, and before 
reaching a potentially irreversible stage of neuronal loss. When the progression of disease reaches a 
critical symptomatic stage, therapies are aimed at ameliorating symptoms and do not halt disease 
progression (A: purple line; B: d). Figures obtained from (Lu et al., 2013). 
 
1.4.2. Challenges 
Studying synaptoprotective mechanisms is a promising route to the 
development of a new generation of drug treatments for neurodegenerative diseases. 
There are, however, important challenges that need to be considered. It is crucial that 
researchers continue to identify common pathways that affect synaptic stability and 
contribute to the pathophysiology of neurodegenerative diseases. In addition, we must 
acknowledge the complexity of the nervous system and the interdependency of the 
biological mechanisms that regulate neuronal function. It is, therefore, expected that 
multi-target approaches and combination therapies will be required to promote 
neuronal repair and homeostasis (Barabasi et al., 2011, Gillingwater and Wishart, 
2013). Furthermore, in order to achieve effective translation of fundamental research 
into successful clinical trials we must not only be able to integrate the knowledge 
obtained from animal and in vitro models of disease with studies in human cohorts, 
but we also need to invest in research models that realistically recreate features of the 





Given the established role of synapses as important targets of pathophysiology 
in many neurodegenerative conditions and the need to develop synaptoprotective 
therapies designed at halting disease progression, the aim of the work presented in this 
thesis was to explore novel mechanisms and molecular targets with the ability to 
modulate synaptic stability and degeneration in vivo. In order to achieve that goal, this 
thesis was divided into three main aims, resulting in three results chapters: 
Aim 1 (Chapter 3): Promote translational research by validating the 
involvement of molecular targets, previously identified to influence synaptic 
degeneration in lower animal models (Wishart et al., 2012), in a large animal model of 
neurodegenerative disease, the CLN5 Batten sheep; 
Aim 2 (Chapter 4): Study one of the candidates validated in Aim 1, calretinin, 
which has not been comprehensively explored in the published literature regarding its 
ability to modulate synaptic function and neurodegenerative mechanism; 
Aim 3 (Chapter 5): Explore downstream targets of a well-known regulator of 







Chapter 2. General Materials and Methods 
2.1. Materials 
Unless otherwise stated, reagents were obtained from Sigma-Aldrich and tissue 
culture specific reagents were obtained from Invitrogen. The list of primary and 
secondary antibodies used can be found in Table 2.1 and Table 2.2, respectively. 
 
Table 2.1: Primary antibodies. 
Target Species Supplier Cat No ICC  IHC WB 
2H3 mouse DSHB 2H3   1:100  
α-synuclein rabbit Santa Ccruz sc-7011-R   
 
1:5000 
ATP5A rabbit abcam ab176569   
 
1:5000 
β-actin mouse abcam ab8226    1:1000 
β III tubulin rabbit abcam ab18207 1:1000  
  
Calretinin rabbit Swant 7697 1:200  1:100 1:5000 
CNPase rabbit abcam ab27695   
 
1:250 
NDUFB8 mouse Mitosciences MS105   
 
1:1000 
COX IV mouse abcam ab14744   
 
1:1000 
CSP rabbit abcam ab79346   
 
1:1000 
Dynamin 1 goat Santa Cruz sc-6402   
 
1:500 
GAPDH mouse abcam ab9484   
 
1:1000 







323-005-021   1:200 
 
Neurofascin rabbit abcam ab31457   
 
1:5000 
ROCK2 rabbit abcam ab125025   
 
1:200 
sfxn3 rabbit sigma HPA008028 1:10  
 
1:300 
SIRT2  rabbit abcam ab75436   
 
1:500 
SV2 mouse DSHB SV2 1:200  1:50 1:5000 
Synapsin 1 goat Santa Cruz sc-8295   
 
1:300 
Ubr4 goat Santa Cruz sc-162376   
  
VDAC 2 rabbit abcam ab47104   
 
1:500 
vGAT guinea-pig Synaptic Systems 131004   
 
1:250 
vGLUT 1 guinea-pig Synaptic Systems 135304   
 
1:1000 
ICC, IHC, WB: Dilutions used for immunocytochemistry (ICC), immunohistochemistry (IHC) and 




Table 2.2: Secondary antibodies. 
Target Species Supplier Cat No ICC IHC WB 
anti-Guinea Pig IgG (H+L) 
Secondary Antibody, Alexa 
Fluor® 594 conjugate 
Goat Invitrogen A-11076 1:500 
  
anti-Mouse IgG (H+L) 
Secondary Antibody, 
Alexa Fluor® 488 
conjugate 
Donkey Invitrogen A-21202 1:500 1:500  
anti-Mouse IgG (H+L) 
Secondary Antibody, Alexa 
Fluor® 594 conjugate 
Goat Invitrogen A-11032 1:500 
  
anti-Mouse IgG (H+L) 
Secondary Antibody, Alexa 
Fluor® 680 conjugate 
Goat Invitrogen A-21058  1:500  
anti-Rabbit IgG (H+L) 
Secondary Antibody, Alexa 
Fluor® 488 conjugate 
Donkey Invitrogen A-21206 1:500 1:500 
 
anti-Rabbit IgG (H+L) 
Secondary Antibody, 
Alexa Fluor® 594 
conjugate 
Donkey Invitrogen A-21207 1:500 
  
Cy3 AffiniPure Goat Anti-








IRDye® 680RD Donkey anti-








IRDye® 680RD Donkey anti-





  1:5000 
IRDye® 800CW Donkey anti-








ICC, IHC, WB: Dilutions used for immunocytochemistry (ICC), immunohistochemistry (IHC) and 
Western blotting (WB). 
 
2.2. Methods 
This section contains a small selection of methods used across the various 
chapters of this thesis. For specific techniques used in individual chapters please refer 
to the Methods section included in Chapters 3 to 5. 
 
2.2.1. Genotyping 
Genomic DNA was extracted by digesting ear clips in 5 μg/mL Proteinase K 
in Lysis Buffer (100 mM Tris, 200 mM NaCl, 5 mM EDTA, 0.2% SDS, pH 8.0) 
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overnight at 55°C. The digestion samples were spun at 20,000g for 5 min, the 
supernatant collected and the DNA precipitated by addition of an equal volume of 
isopropanol. Following centrifugation at 20,000g for 5 min, the pellet was washed 
twice in 70% ethanol and spun at 20,000g for 5 min. The pellet was then allowed to 
air dry for at least 1 h and the DNA dissolved in 25 µL H2O. 
2 µL of genomic DNA were used for each PCR reaction. The amplified PCR 
products were separated by gel electrophoresis in 2% w/v agarose (SeaKem LE) gels 
in TAE buffer (40 mM Tris, 40 mM Glacial Acetic Acid, 1 mM EDTA, pH 8.0) and 
visualized in an UV chamber. The genotype of each mouse was determined according 
to the presence or absence of the WT or KO bands of appropriate size.  
 
2.2.2. Isolation of crude synaptosomes 
Crude synaptosomes were isolated as described in (Wishart et al., 2007, 
Wishart et al., 2012). Synaptosomes were prepared from fresh brain tissue whenever 
possible. For frozen sheep tissue, samples were incubated in a water bath at 37°C for 
up to 2 min to ensure they were completely thawed before proceeding. 
Brain samples were homogenized in ice-cold sucrose buffer (320 mM sucrose, 
1 mM EDTA, 5 mM Tris-HCl, pH 7.4) and centrifuged for 10 min at 900g and 4°C. 
The supernatant (S1) was collected and the pellet (P1) resuspended in sucrose buffer 
and centrifuged as before. The resulting pellet (P1’) was kept as the non-synaptic 
fraction. The supernatant (S1’) was combined with S1 and centrifuged at 20,000g for 
15 min at 4°C to pellet out the synaptosomes (P2). 
 Synaptic and non-synaptic fractions were either directly used for subsequent 




2.2.3. Western Blotting 
Western blotting was performed essentially as described in (Eaton et al., 2013). 
Protein was extracted from cells or tissue by homogenization in RIPA buffer 
(ThermoScientific) with Halt Protease Inhibitor Cocktail (ThermoScientific), unless 
otherwise stated. The resulting homogenate was centrifuged for 20 min at 20,000g and 
4°C and the supernatant, consisting of the soluble protein extract, was used for Western 
blotting. Protein concentration was determined by BCA assay (ThermoScientific). 
5-100µg of protein per lane were prepared in NuPage® LDS Sample Buffer 
(Invitrogen), heated to 98°C for 5 min and loaded on pre-cast NuPage® Novex® 4-
12% Bis Tris gradient gels (Invitrogen). Gels were run in XCell SureLock® Mini-Cell 
systems (Invitrogen) in Bolt® MES SDS Running Buffer (Invitrogen) for 15 min at 
80 V and for 1 h at 150 V. Proteins were then transferred to PVDF membranes using 
the iBlot® or iBlot2® Dry Blotting System (Invitrogen). The membranes were 
blocked in Odyssey blocking buffer (Li-COR Biosciences) for at least 30 min, 
incubated in primary antibody overnight at 4°C and secondary antibody for 1 h at room 
temperature (RT). All antibodies were diluted in Odyssey blocking buffer with 0.1% 
Tween-20 and between incubations membranes were washed 3x in phosphate-buffered 
saline (PBS; in mM: 137 NaCl, 2.7 KCl, 10 Na2HPO4, 1.8 KH2PO4) for 10 min. Blots 
were imaged in an Odyssey Infrared Imaging System (Li-COR Biosciences) at a 
resolution of 169 μm and quantified using the ImageStudio Software (Li-COR 
Biosciences). The intensity of each fluorescent band was measured in triplicate, in 
order to minimize user variability. 
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For use with anti-α-synuclein and anti-calretinin antibodies, the membranes 
were fixed in 0.4% paraformaldehyde (PFA; Electron Microscopy Sciences) in PBS 
for 20 min and washed 3x for 5 min in PBS prior to blocking. This method has been 
shown to increase the sensitivity of α-synuclein detection (Lee and Kamitani, 2011) 
and we also found it improves the labelling of calretinin. 
 
2.2.4. Statistical analysis 
Quantitative data were collected and analysed in Microsoft Excel®. Statistical 
analysis was performed using GraphPad Prism® software. Details of individual 
statistical tests are outlined during the results sections or figure legends. Statistical 





Chapter 3. Molecular neuropathology of the 
synapse in sheep with CLN5 Batten disease 
3.1. Introduction 
3.1.1. Translational studies in large animal models of 
neurodegenerative disease 
Our growing understanding of the mechanisms regulating synaptic 
pathophysiology opens doors to the possibility of developing synaptoprotective 
therapies for the treatment of a variety of neurodegenerative disorders. However, one 
important issue concerning this type of translational research is the current 
predominance of studies using small animal models, such as mice, as these animals do 
not fully replicate crucial features of the human nervous system, including size and 
complexity (Aigner et al., 2010, Dolezalova et al., 2014, Morton and Howland, 2013, 
Pouladi et al., 2013). One solution to this problem might arise from the increasing 
availability of large animal models of neurodegeneration, such as sheep and pigs. Not 
only it is becoming more commonplace to use genetically-modified large animals in 
neurodegenerative research (Aigner et al., 2010, Morton and Howland, 2013), but 
there are also several human conditions where there is an equivalent endogenous 
disorder in a large animal species. One good example is the CLN5 New Zealand 







3.1.2. Neuronal Ceroid Lipofuscinosis; Batten Disease 
Neuronal Ceroid Lipofuscinosis (NCLs), commonly referred to as Batten 
disease, is a group of autosomal-recessive progressive neurodegenerative disorders. 
NCLs are amongst the most common neurodegenerative diseases of childhood, with 
an incidence of up to 1:12500, and are currently untreatable (Santavuori et al., 2000). 
Mutations in several genes (CLN1 to CLN10) have been identified to cause NCL 
variants which differ with regards to the age of onset of the disease, but that are 
characterized by a similar progression of clinical symptoms. Visual impairments and 
retinal degeneration, ultimately leading to blindness, are some of the earliest 
symptoms. Motor and cognitive dysfunction, seizures and an abnormal EEG rapidly 
follow and the disease invariably leads to premature death (Jalanko and Braulke, 2009, 
Santavuori et al., 2000). 
Despite the fact that the genetic causes of NCLs have been identified, the 
molecular mechanisms underlying the pathophysiology of the disease remain unclear. 
A pathological hallmark of NCLs is the widespread accumulation of autofluorescent 
lysosome-derived storage material, most often composed of the subunit c of the 
mitochondrial ATP synthase (Palmer et al., 1992, Westlake et al., 1995). However, 
even though these inclusions are found in several neuronal and peripheral tissues of 
patients and animal models of the disease they are not the best correlate of disease 
severity, nor the main cause of pathology. In fact, the nervous system and subsets of 
neuronal populations, such as the thalamus in mice (Kielar et al., 2007, Partanen et al., 
2008) and hypothalamus and cortical areas in human and ovine NCLs (Oswald et al., 
2008, Tyynela et al., 2004), are preferentially affected. Glia activation most often 
precedes the onset of neurodegeneration and is, so far, the best cellular correlate of 
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disease progression in animal models of NCLs (Jalanko and Braulke, 2009, Mitchison 
et al., 2004, Palmer et al., 2013).  
 
3.1.3. Animal models of NCLs: The CLN5 Batten sheep 
Advances in the understanding of the pathogenesis and progression of NCLs 
have benefited from several animal models of the disease that are currently available. 
Various mouse models have been engineered (Jalanko and Braulke, 2009) and natural 
occurring mutations in CLN genes have been identified in a number of different 
species, including dogs, cows and sheep (Jolly et al., 1992, Jolly et al., 1997, Moroni-
Rawson et al., 1995, UCL, 2015). When compared to rodent models of NCLs, large 
animal models, such as sheep, replicate better the human progression of the disease 
and are particularly useful to dissect region-specific pathophysiological features of the 
disease due to their brain size and CNS complexity (Jolly et al., 1989). In addition, 
their longer life span allows for a clinical progression that closely resembles the human 
disease and for better assessment of long-term effects of therapeutic strategies.  
One specific Batten disease sheep model, the CLN5 Batten sheep, has been 
particularly well characterized. This model was initially identified in a flock of New 
Zealand Borderdale sheep which carry a nucleotide substitution at the consensus splice 
site c.571+1G>A of the CLN5 gene (Jolly et al., 2002). The mutation leads to deletion 
of exon 3 of the CLN5 transcript and, consequently, no transcripts of full-length CLN5 
and only a small amount of mutant CLN5 transcripts are detectable in diseased animals, 
resulting in lack of a functional CLN5 protein (Frugier et al., 2008). By 21 months of 
age, the CLN5-deficient sheep show extensive degeneration of the cerebral cortex, 
positive GFAP staining and abundant cellular inclusions positive for the subunit-c of 
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mitochondrial ATP synthase. Such inclusions are also observed in cultured neurons 
from CLN5 fetal sheep brains and are reversed by lentiviral expression of full-length 
functional CLN5, indicating that CLN5 deficiency is key to the onset and progression 
of this NCL variant (Hughes et al., 2014, Hughes et al., 1999). 
 
3.1.4. The function of the CLN5 protein 
The function of the CLN5 protein is still poorly understood. CLN5 is expressed 
in a variety of peripheral tissues and in the brain, where it is found in both neurons and 
glia (Holmberg et al., 2004). Like many other CLN proteins, it is present in lysosomes 
and CLN5 deficiency leads to the accumulation of subunit-c of the mitochondrial ATP 
synthase in storage bodies (Frugier et al., 2008, Isosomppi et al., 2002, Tyynela et al., 
1997). Although the function of the CLN5 protein remains unknown, it likely 
contributes to the production of the enzymatically active forms of TPP1/CLN2 and 
Cathepsin D/CLN10, two other lysosomal proteins involved in variants of NCL 
(Frugier et al., 2008). An interconnection between CLN5 and other CLN proteins has 
also been proposed by immunoprecipitation studies, where CLN5 was found to form 
complexes with CLN1, CLN2, CLN3, CLN6 and CLN8 (Schmiedt et al., 2010, Vesa 
et al., 2002). In addition, co-expression of CLN1 restores the detrimental effects 
caused by loss of functional CLN5 due to a common Y392X mutation in the protein 
(Lyly et al., 2009). CLN5 and CLN3 have further been implicated in endosome-Golgi 
trafficking through recruitment of Rab7 and gene expression profiling of knockout 
mice for both genes has suggested a common role in the stabilization of neuronal 




3.1.5. Synaptic pathology in NCLs 
Synaptic pathology is an established early feature of several neurodegenerative 
disorders and there is increasing evidence supporting an important role of synapses in 
NCLs. NCL rodent models present synaptic dysfunction, progressive synapse loss and 
alterations in the balance of the synaptic proteome (Kielar et al., 2009, Kim et al., 
2008, Partanen et al., 2008), while the CLN6 ovine model of NCL shows synaptic 
dysfunction and loss with higher incidence in the brain regions affected earlier during 
the progression of disease (Kanninen et al., 2013). However, it has not been established 
whether equivalent molecular mechanisms are consistently affected across rodent and 
sheep models of Batten disease. 
 
3.1.6. Aims 
The aim of the work presented is this chapter was to establish whether known 
molecular regulators of synaptic pathophysiology, previously identified in rodent and 
Drosophila models of neurodegeneration (Wishart et al., 2012), were similarly present 
and modified in the brain of a large animal model of neurodegenerative disease, the 
CLN5 Batten sheep. This will allow us to identify whether molecular mechanisms of 
synaptic pathophysiology are conserved across species and if rodents can be used with 
confidence in translational studies aimed at developing synaptoprotective therapies for 




3.2. Materials and methods 
3.2.1. Animals 
Ovine tissue was obtained from Professor David Palmer (Lincoln University, 
New Zealand) and Professor Jennifer Morton (University of Cambridge, UK).  
CLN5 homozygous (Batten sheep) and heterozygous controls were born, 
raised and diagnosed from a flock of Borderdale sheep at Lincoln University (New 
Zealand) (Frugier et al., 2008). All procedures were carried out in accordance with 
National Institute of Health (NIH) guidelines and the New Zealand Animal Welfare 
Act 1999 as approved by the Lincoln University Animal Ethics committee. 
A cohort of heterozygous control and pre-symptomatic CLN5 sheep for 
Magnetic Ressonance Imaging (MRI) and molecular analyses were shipped by air 
from Lincoln University (New Zealand) to the University of Cambridge (UK). 
Animals were housed in a barn with windows and supplementary additional artificial 
light from 6am to 6pm. All animals had free access to hay feed and water, with 
additional pellet supplements provided every morning. Experimental procedures 
performed in Cambridge were conducted in accordance with the UK Animals 
(Scientific Procedures) Act 1986 and were approved by a University of Cambridge 
internal ethical review board. 
 
3.2.2. Gross neuropathology 
Sheep for gross neuropathological analyses were sacrificed at Lincoln 
University, in accordance with National Institute of Health guidelines and the New 
Zealand Animal Welfare Act 1999 and as approved by the Lincoln University Animal 
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Ethics committee. Sheep were stunned with a captive bolt, in a manner that did not 
damage the brain itself, and exsanguinated. Following confirmation of death, the head 
was perfused with saline (0.9% NaCl, 37 ºC) via one of the carotid arteries, to remove 
excess blood, and perfused-fixed with 10% formalin in saline, pH 7.4. The brain was 
removed and dissected at the sagittal midline, further fixed for 7 days in 10% formalin, 
equilibrated in cryoprotective solution (10% ethylene glycol, 20% sucrose in 0.9% 
NaCl) and stored at -80ºC until required.  
Cryopreserved perfusion fixed frozen brain hemispheres were processed as 
described in (Oswald et al., 2005).  Briefly, each hemisphere was serially sectioned at 
50 µm on a sliding microtome (Microm, Germany), the sections were mounted on 
slides, stained with Nissl and then coverslipped. Images were captured using an upright 
microscope (Nikon Eclipse 50i) and analysed using NIS-Elements Software (Nikon 
Instruments Inc., Melville, NY, USA). To determine the cortical thickness, at least 25 
measurements were made for each animal from the pial surface to the white matter 
(cortical layers I-VI) in the primary motor cortex and from the pial surface to the 
granular boundary with the white matter in the anterior lobe of the cerebellum. 
The experiments described in this section were performed by Nadia Mitchell 
at the laboratory of Prof. David Palmer, Lincoln University. 
 
3.2.3. Magnetic Resonance Imaging 
Animals used for magnetic resonance imaging (MRI) were sacrificed at the 
University of Cambridge (UK) by an intravenous overdose of barbiturate-based 
anaesthetic and the brains perfuse-fixed in 4% PFA in saline. Heads were trimmed to 
remove the jaw and orbits but the brains were not removed from the cranium to 
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preserve the cortical surface. Brains were imaged in a 4.7T Bruker BioSpec 47/40 
using a rapid acquisition with relaxation enhancement protocol with a field of view of 
128×85.2×66.6 mm3 and a matrix of 384×256×200 with two-fold anti-aliasing in all 
three directions to provide an isotropic resolution of 333 µm. The repetition time was 
1.2 s with an affective echo time of 50 ms, an echo train length of 5 and a bandwidth 
of 50 KHz. Total scan time was 13.5 h per brain. For comparison, reconstructed images 
were rigidly-registered together using SPM12 (Wellcome Trust Centre for 
Neuroimaging, University College London) and the SPMMouse toolbox (Sawiak et 
al., 2013).  
The experiments described in this section were performed by Stephen Sawiak 
and Roger Mason, in the laboratory of Prof. Jennifer Morton, University of Cambridge. 
 
3.2.4. Quantitative western blotting 
Tissue used for quantitative western blotting was obtained from Prof. Jennifer 
Morton (University of Cambridge, UK). Tissue was obtained from eight 20-24 month 
old CLN5 female sheep, and five heterozygous controls, four females and one 
castrated male, of comparable age.  
Animals were sacrificed at the University of Cambridge (UK) by an 
intravenous overdose of barbiturate-based anaesthetic. Selected brain regions (motor 
cortex and cerebellum) were flash-frozen, within 15-20 min of time of death, by 
immersion in liquid nitrogen and stored at -80°C. At the University of Edinburgh, the 
tissue was used for the preparation of crude synaptosomes or whole brain lysates, and 
submitted to quantitative western blotting. Please see General Materials and Methods 




3.3.1. Identification of brain regions affected by 
neurodegeneration in CLN5 sheep brain 
To identify areas of the brain subject to substantial neurodegeneration at late 
stage disease, as well as an area that was relatively spared from neurodegeneration, 
gross neuropathological changes were analysed in complete sagittal sections of late 
stage CLN5 Batten sheep. While atrophy of all cortical regions was obvious 
macroscopically at 24 months, both subcortical nuclei and the cerebellum of CLN5 
brains retained a normal appearance (Figure 3.1). Cortical atrophy appeared most 
severe, in descending order, in the primary visual, parieto-occipital and motor cortex 
regions of the CLN5 sheep brain. Cortical thickness was analysed in Nissl stained 
sections and revealed progressive thinning of the neuronal layers, particularly the 
upper layers (II-III). By 24 months of age few cortical neurons remained (Figure 3.2). 
At this age, the cortical thickness of the primary motor area of CLN5 animals was 
reduced by 44% from that observed in normal controls (Figure 3.2). In contrast, no 
cytoarchitectural differences were apparent in the cerebellum between control and 
CLN5 animals, and there was no detectable difference in cerebellar cortical 





Figure 3.1: Reduced cortical volume in CLN5 Batten sheep. Nissl stained sections showed marked 
atrophy of the cortical mantle in affected sheep at 19 months of age, which was more pronounced by 24 
months of age (see arrowheads). In contrast, the cerebellum and subcortical structures were relatively 




Figure 3.2: Atrophy of motor cortex in CLN5 sheep brains. Microscopic comparison of the motor 
cortex of Nissl stained sections (shown in Figure 3.1). Upper arrows mark the layer I/II boundary, the 
middle arrows indicate layer IV, and the lower arrow marks the layer VI/white matter boundary. Scale 





Table 3.1: Cortical thickness measurements from 24 month old normal control and CLN5 Batten 
sheep brains. Table produced in collaboration with NL Mitchell and DN Palmer. 
  Mean thickness (µm ± SEM)*   
Layers Normal control CLN5 affected P value*** 
Cerebellar cortex 502 ± 10 493 ± 11 (98% ± 2.1)** NS 
Motor cortex (I-VI) 1692 ± 45 940 ± 21 (56% ± 1.2)** ≤ 0.001 
* Measurements from 3 animals per group and >25 measurements per brain/region. 
** % from control    
*** Unpaired two-tailed t-test   
 
 
To further validate these gross neuropathological findings, we used MRI 
techniques to extend our investigations of neuropathological changes in CLN5 sheep. 
Compared to brains of control sheep, brains from CLN5 affected Batten disease sheep 
at 22 months of age had a striking reduction of neocortical volume, with relative 
sparing of subcortical structures and the cerebellum (Figure 3.3). 
Taken together, these studies confirmed that CLN5 deficiency in sheep affects 
brain areas in a differential manner, with the cerebellum being mostly spared from 





Figure 3.3: MRI analyses of CLN5 Batten sheep brain confirms targeting of the cortex and 
sparing of the cerebellum. Representative MR images of control (A, C, E, G) and CLN5 affected 
sheep (B, D, F, H). Sections are shown in sagittal (A-B), horizontal (C-D) and two coronal cuts (E-F 
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and G-H at the levels marked in A-D). The scale bar is 2 cm. Label abbreviations: Fr frontal lobe; Pa 
parietal lobe; Occ occipital lobe; Te temporal lobe; LV lateral ventricle, Th thalamus, H hippocampus; 
Cb cerebellum; Cd caudate; Pu putamen. Image produced in collaboration with J Morton, R Mason and 
SJ Sawiak. 
 
3.3.2. Synapse loss in the motor cortex of CLN5 Batten sheep 
Loss of synapses has been identified as a feature of CLN5 pathology in mouse 
models (von Schantz et al., 2009). We therefore wanted to verify whether synapses 
were also being targeted in the CLN5 Batten sheep.  
In order to assess the relative density of synapses between CLN5 Batten sheep 
and control animals, we measured levels of the synaptic protein SV2 by quantitative 
fluorescent western blotting in whole brain tissue samples from the cerebellum and 
motor cortex. SV2 levels remained unchanged in the cerebellum of CLN5 sheep 
compared to controls, confirming the low vulnerability of synapses in this brain region 
(Figure 3.4). In contrast, SV2 levels were significantly reduced in the motor cortex, an 







Figure 3.4: Loss of synapses in affected brain regions from CLN5 Batten sheep. A) Quantitative 
fluorescent western blotting in preparations of whole tissue revealed relatively stable levels of SV2, a 
core synaptic protein, in the cerebellum of control and CLN5 sheep. In contrast, in the motor cortex of 
CLN5 Batten disease affected sheep the levels of SV2 are reduced by 60%, indicating there is severe 
synapse loss restricted to this brain area of the Batten affected sheep. (N=5 animals, n=10 distinct tissue 
samples from control sheep; N=8, n=16 from CLN5 sheep; ****P<0.0001, unpaired two-tailed t-test). 
B) Representative fluorescent western blots (N=5 animals per genotype) showing a consistent decrease 
in SV2 levels in the motor cortex of CLN5 Batten disease affected sheep when compared to controls. 
Note the relatively stable levels of SV2 in the cerebellum of CLN5 sheep. Actin was used as loading 
control. 
 
3.3.3. Preparation of synapse-enriched fractions from sheep brain 
tissue 
In order to perform a reliable analysis focused on synaptic pathology of CLN5 
Batten sheep, we wanted to establish whether we could generate tissue samples 
enriched with synaptic material (synaptosomes) from frozen brain tissue samples from 
sheep with a similar efficiency and reproducibility to that obtained when using fresh 
mouse tissue (Wishart et al., 2012). We adapted the sub-cellular fractionation protocol 
previously used for fresh mouse brain for application with frozen brain samples from 
sheep. Although larger volumes of buffer and a higher number of passages were 
required to completely homogenize the sheep tissue when compared to the mouse 
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whole brain, we were able to successfully isolate synaptic enriched fractions from 
various regions of the brain of sheep. Using fluorescent western blotting, we confirmed 
a robust enrichment of the synaptic protein SV2 and almost complete exclusion of the 
nuclear protein HDAC2 on synaptosome preparations from control and CLN5 sheep 
brains, in both the cerebellum and motor cortex (Figure 3.5). 
We thus concluded it is possible to use standard synaptosome protocols to 
generate preparations of synaptically-enriched tissue from sheep brains, even using 
samples that had been frozen and stored rather than freshly-harvested brain tissue. 
 
 
Figure 3.5: Characterization of synaptosome preparations from control and CLN5 Batten disease 
affected sheep brains. Representative western blots from synaptic (S) and non-synaptic (NS) fractions 
generated from the cerebellum and motor cortex of control and CLN5 Batten disease affected sheep 
brains. Immunoblotting with SV2 and HDAC2 demonstrates, respectively, the synaptic enrichment of 
the synaptic fractions and their low contamination with nuclear components. Actin was used as a loading 






3.3.4. Identification of synaptic proteins in mouse and sheep 
synaptosomes 
The ability to isolate synaptosome preparations from the cerebellum and motor 
cortex of sheep brains offered us the possibility to examine whether known molecular 
regulators of synaptic pathophysiology, previously identified in Drosophila and mouse 
models (Wishart et al., 2012), were also expressed in and localized to synapses in the 
sheep brain. 
We chose to compare the levels of eight individual proteins previously shown 
to be present in mouse synapses, and whose expression levels were found to be 
robustly modified in synapses undergoing degeneration: -synuclein, Calretinin; 2',3'-
cyclic nucleotide 3' phosphodiesterase (CNP); Cysteine-string protein alpha (CSP-; 
DNAJC5); Neurofascin; Rho-associated, coiled-coil containing protein kinase 2 
(ROCK2); Sirtuin 2 (SIRT2); and Ubiquitin protein ligase E3 component n-recognin 
4 (UBR4) (Wishart et al., 2012). Direct comparison of these proteins in synaptosome 
preparations from wild-type mice and sheep using fluorescent western blotting 
confirmed that all eight proteins were conserved between the two species and that all 






Figure 3.6: Identification of synaptic proteins in synaptosome preparations from mice and sheep. 
Representative fluorescent western blots confirming the expression and detection, in both mouse and 
sheep synaptosomes, of eight synaptic proteins implicated in the regulation of synaptic stability and 
degeneration, as well as a loading control (actin). Note that all synaptic proteins previously identified 
in mouse synapses were similarly present, and detectable using the same primary antibodies, in sheep 
synapses. 20μg of protein were loaded per lane. Mouse synaptosomes were prepared from whole brain, 
whereas sheep synaptosomes were prepared from cerebellum or motor cortex. 
  
3.3.5. Region-specific modifications in known regulators of 
synaptic stability in CLN5 Batten sheep 
The ability to detect and measure levels of individual proteins implicated in the 
regulation of synaptic degeneration (Figure 3.6) allowed us to directly assess whether 
molecular pathways being instigated in degenerating synapses from the sheep brain 
are the same as those previously reported in the mouse (Wishart et al., 2012). 
Therefore, we generated region-specific synaptosome preparations from the brains of 
5 control and 8 CLN5 Batten disease affected sheep. Due to the large volume of the 
sheep brain, and to ensure a representative fraction of it was studied, for each brain 
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region from each individual sheep two synaptosomes fractions were prepared and 
assayed independently. 
Quantitative fluorescent western blotting revealed that the levels of the eight 
proteins studied were not significantly altered in the cerebellum of CLN5 sheep when 
compared to unaffected controls (Figure 3.7). This analysis not only confirmed we 
could repeatedly detect and measure all eight synaptic proteins across samples from 
multiple animals, but also demonstrated that levels of these proteins are relatively 
stable in healthy areas of the brain from CLN5 Batten sheep. In striking contrast, a 
comparison of protein levels in the severely affected brain region (motor cortex) 
revealed significant changes for seven out of the eight proteins examined (Figure 3.8). 
Most proteins showed a reduction of over 50% in CLN5 synaptosomes when compared 
to controls (-synuclein, CSP-, Neurofascin, ROCK2, and SIRT2). In contrast, levels 
of Calretinin were almost twice those observed in synapses from control sheep.  
 
 
Figure 3.7: Stable expression of synaptic proteins in the cerebellum of CLN5 sheep. A) Levels of 
the eight synaptic proteins in synaptosome preparations generated from the unaffected cerebellum of 
control and CLN5 Batten disease affected sheep were measured by quantitative fluorescent western 
blotting. Actin was used as loading control. Quantitative data shown as mean ± SEM (N=5, n=10 
control; N=8, n=16 CLN5). Statistical analyses revealed no significant differences (P>0.05 in unpaired 
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Figure 3.8: Modified expression levels of synaptic proteins in motor cortex from CLN5 Batten 
disease affected sheep. A) Levels of the eight synaptic proteins in synaptosome preparations generated 
from the unaffected cerebellum of control and CLN5 Batten disease affected sheep were measured by 
quantitative fluorescent western blotting. Actin was used as loading control. Quantitative data shown as 
mean ± SEM (N=5, n=10 control; N=8, n=16 CLN5). * p<0.05, **p<0.01, ****p<0.0001 in unpaired 
two-tailed t-test. B) Representative western blots. 
 
Altogether, these results confirm that synaptic proteins previously implicated 
in synaptic degeneration pathways in mice and Drosophila show dynamic alterations 
to their expression levels in a large animal model of neurodegenerative disease, the 
CLN5 Batten sheep, and that synaptic pathology in this model is selectively found in 






3.4.1. Overview of results 
We investigated whether molecular aspects of synaptic pathophysiology 
previously identified in Drosophila and mouse models of a range of neurodegenerative 
diseases (Wishart et al., 2012) are recapitulated in a large animal model of 
neurodegenerative disease, the CLN5 Batten sheep. We observed a regionally specific 
atrophy of the brain with pronounced degeneration of the motor cortex and sparing of 
the cerebellum. In agreement, we have shown there is an equivalent disruption of 
synaptic integrity, as assessed by the levels of SV2 protein in whole brain lysates, in 
the motor cortex, with the cerebellum being relatively spared from synapse loss. In 
addition, we demonstrated the ability to generate synaptosome preparations from 
frozen samples of sheep brain, and used this technique to confirm the conserved 
expression of synaptic proteins between sheep and mouse tissues. Finally, we found 
that molecular pathways previously shown to regulate synaptic pathophysiology in 
Drosophila and mice were similarly perturbed in synapses from affected regions of 
CLN5 sheep brain. Taken together, these findings suggest that molecular mechanisms 
underlying synaptic pathophysiology are conserved in an established sheep model of 
Batten disease. 
 
3.4.2. Synaptic pathology is a feature of Batten Disease 
Our initial findings confirmed the regionally-restricted nature of disruption to 
synaptic integrity in areas of the brain of CLN5 sheep undergoing significant 
neurodegeneration (e.g. loss of SV2 was observed in the affected motor cortex but not 
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in the spared cerebellum). Previous studies using mouse models of Batten disease have 
revealed that synaptic disruption is intimately linked to the regional onset of 
neurodegeneration (Kielar et al., 2009, Koch et al., 2011, Luiro et al., 2006), with our 
findings demonstrating that the relationship between synaptic pathology and 
neurodegeneration is likely to be similarly conserved in CLN5 sheep, and conceivably 
as well in human patients. However, given the symptomatic nature of the sheep 
investigated in this study, further studies addressing synaptic changes at pre and early-
symptomatic time points will be required to establish whether synaptic loss precedes 
or occurs concurrently with gross neuropathological changes. 
 
3.4.3. Molecular mechanisms of synaptic pathology are 
conserved across disease models 
A second aim of this study was to investigate whether the same molecular 
regulators we had previously found to be involved in synaptic and axonal stability in 
Drosophila and mouse models (Wishart et al., 2012) were similarly altered in synapses 
from CLN5 Batten sheep. Whereas the levels of the proteins analysed were relatively 
stable in the cerebellum (Figure 3.7), a region not affected by gross morphological 
changes, 7 out the 8 proteins analysed showed significantly altered expression 
restricted to the motor cortex (Figure 3.8). Thus, the results indicate that there are 
molecular features of synaptic pathology preserved across various animal models of 
neurodegenerative disease. Moreover, these features are specific to synapses 
undergoing degeneration and are not widespread consequences of the disease process.  
The proteins analysed in this study are involved in diverse cellular 
mechanisms, including synaptic transmission (eg. -synuclein, CSP-), calcium 
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buffering (Calretinin) and axonal growth (ROCK2) (Donnelier and Braun, 2014, 
Lashuel et al., 2013, Riento and Ridley, 2003, Schwaller, 2014). This illustrates the 
complexity of processes affecting synapse stability and supports the hypothesis that 
therapeutic strategies for neurodegenerative diseases are likely to require targeting of 
multiple molecular processes in order to obtain therapeutic benefit (Van der Schyf and 
Geldenhuys, 2011, Youdim, 2010a). Nonetheless, our findings points toward the 
existence of common pathways involved not only in variants of NCLs but also 
common to other neurodegenerative conditions. 
Of particular interest, -synuclein is a known regulator of synaptic function 
which has been highly implicated in the pathophysiology of Parkinson’s disease 
(Stefanis, 2012). We found the levels of the -synuclein protein to be downregulated 
by 50% in the motor cortex of CLN5 sheep. Interestingly, changes in -synuclein have 
also been reported in several other studies of Batten disease, particularly in CLN1 and 
CLN10 (cathepsin D) deficient mice (Blom et al., 2013, Cullen et al., 2009), and 
recently in Atp13a2-deficient (CLN12) mice (Schultheis et al., 2013).  In addition, -
synuclein is known to modulate synaptic pathology in mice, at least in part through 
interactions with another synaptic protein, CSP- (Chandra et al., 2005). Levels of 
CSP- were also significantly modified in synapses from affected regions of CLN5 
sheep brain. Deletion of CSP- causes extensive neuromuscular degeneration in mice, 
due to defects in the assembly of SNARE complexes at the synapse (Fernandez-
Chacon et al., 2004, Sharma et al., 2012, Sharma et al., 2011) and mutations in CSP-
 lead to a dominant adult form of NCL, Kuf’s disease (CLN4; (Benitez et al., 2011, 
Noskova et al., 2011)).  
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Other proteins analysed in this study, such as ROCK2 and SIRT2, have not 
previously been directly implicated in the pathophysiology of NCLs. They have, 
nonetheless, been studied regarding their contribution to other neurodegenerative 
conditions. Modulating the activity of SIRT2, which belongs to a family of protein 
deacetylases, has proven beneficial in attenuating neurodegeneration in disorders such 
as Parkinson’s and Huntington’s diseases (Donmez and Outeiro, 2013, Luthi-Carter et 
al., 2010, Outeiro et al., 2007). Whereas ROCK2, which is involved in the regulation 
of actin dynamics and cytoskeleton stability, is also regarded as a promising target for 
neuroprotective therapies (Kubo et al., 2008, Tonges et al., 2011). ROCK inhibitors 
have indeed shown promising results in animal models of various neurodegenerative 
conditions, including spinal muscular atrophy, Alzheimer’s disease, Huntington’s 
disease and Parkinson’s disease (Bowerman et al., 2012, Shao et al., 2008, Song et al., 
2013, Tönges et al., 2012).  
 
Altogether, these results indicate that molecular features of synaptic pathology 
are conserved across various animal models of neurodegenerative disease. The 
recognition that common pathways are affected in etiologically diverse 
neurodegenerative conditions is central to the development of broad-range 
synaptoprotective strategies. Moreover, the fact that these pathways are conserved 







3.4.4. Use of large animal models in neurodegenerative research 
The considerable overlap in the molecular characteristics of synaptic pathology 
between sheep and small animal models supports the notion that therapies designed to 
target these pathways resulting from rodent studies could be taken forward into sheep 
models, better placed to replicate the size and age-related aspects of the human nervous 
system (Aigner et al., 2010, Dolezalova et al., 2014, Morton and Howland, 2013, 
Pouladi et al., 2013). The ability to demonstrate the therapeutic effectiveness of a 
treatment in a large animal model would provide a strong basis for subsequent 
translation to clinical trials with human patients. This approach is likely to reduce the 
financial waste associated with failed clinical trials based on studies in small animal 
models (Perrin, 2014), and accelerate the identification of the best candidate therapies 





Chapter 4. Novel role for calretinin in synaptic 
function and stability 
4.1. Introduction 
4.1.1. Calretinin interneurons 
Calretinin (CR) is a calcium-binding protein, encoded by the Calb2 gene, best 
known as a marker of a subpopulation of inhibitory interneurons in the CNS. CR-
immunoreactive cells (CR-IR) represent a subpopulation of around 20% of 
GABAergic interneurons, depending on the species and brain regions analysed. For 
example, while CR-IR neurons in the cortex account for 15-25% of the GABAergic 
population in rodents, this fraction rises to 20-45% in primates (Dzaja et al., 2014). 
CR-IR cells have been identified not only in various areas of the cerebral cortex and 
hippocampus, but also in the cerebellum, substantia nigra compacta, ventral tegmental 
area, thalamus, olfactory and optic tracts, and other regions (Jacobowitz and Winsky, 
1991, Schiffmann et al., 1999). Their morphological features are varied, ranging from 
bipolar to multipolar cells and, in the hippocampus, presenting dendrites either densely 
populated with spines or spine free (Cauli et al., 2014, Gulyas et al., 1992, Miettinen 
et al., 1992). Although most CR-IR neurons are thought to be GABAergic, not all co-
express GABA (Meinrenken et al., 2003). In addition, the neurochemical properties of 
CR-IR neurons are not unique, as CR-IR cells may co-express a variety of 
neuropeptides, including somatostatin, vasoactive intestinal polypeptide and 
neuropeptide Y (Cauli et al., 2014). The electrophysiological properties of CR-IR 
neurons are similarly not uniform, but seem to be associated with their morphology. 
For instance, whereas multipolar neurons display a regular firing pattern, bipolar 
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neurons tend to show bursting firing patterns (Caputi et al., 2009). Taken together, the 
existing literature points towards the existence of a heterogeneous population of CR-
IR neurons for which characteristic morphological and functional features have yet to 
be fully defined. 
 
4.1.2. Calretinin is a Ca2+-binding protein with dynamic Ca2+ 
properties 
CR belongs to the calbindin sub-family of calcium binding proteins, which are 
characterized by the presence of 6 structural motifs, known as EF-hand Ca2+-binding 
domains, and are recognized for their Ca2+ binding properties and buffer capacity 
(Camp and Wijesinghe, 2009, Schwaller, 2014). In CR, the 6th of these domains is 
inactive while the 5th has a low Ca2+ affinity, acting mainly as a binding site for other 
proteins and thus conferring CR properties of a Ca2+ sensor (Arendt et al., 2013). The 
first 4 motifs, however, are responsible for CR’s Ca2+ buffering capabilities and bind 
Ca2+ ions in a cooperative manner (Faas et al., 2007). This results in a non-linear 
kinetics of Ca2+ regulation in which, upon an increase in intracellular calcium [Ca2+]i, 
CR behaves like a slow buffer when the initial [Ca2+]i is at a basal level of ~100nM but 
acts as a fast-buffer when [Ca2+]i is elevated to the order of ~1μM. This property has 
been shown to have functional consequences at sites of neurotransmitter release 
(Schmidt et al., 2013), where [Ca2+]i is elevated during action potentials, and suggests 
that CR may play differential roles within subcellular regions according to the local 
[Ca2+]i. 
Further evidence for a dynamic role for CR comes from studies addressing its 
Ca2+-dependent localization and conformational changes (Table 4.1). At low [Ca2+]i 
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CR is predominantly cytosolic. However, Winsky and Kuznicki found that, in rat brain 
preparations, when [Ca2+]i is increased CR translocates to synaptic vesicles and the 
synaptic membrane (Winsky and Kuznicki, 1995). In another study using chick 
embryonic cultures, CR was shown to increase its membrane localization at a 
developmental stage coincidental with the onset of spontaneous synaptic activity, and 
hence with the onset of frequent Ca2+ currents through the plasma membrane (Hack et 
al., 2000). CR’s translocation within cell compartments might be attributed to its 
potential recruitment by different proteins in response to changes in [Ca2+]i levels. CR 
undergoes significant conformational changes according to the local [Ca2+]i and its 
mobility is decreased in the presence of high Ca2+ levels, potentially reflecting the 
establishment of interactions at high [Ca
2+]i (Arendt et al., 2013, Kuznicki et al., 1995). 
These interactions might lead to the recruitment of CR to membrane sites and result in 
a specialization of CR function to meet the demands of a high Ca2+ environment.  
 
Table 4.1: Properties of CR according to the intracellular Ca2+ levels. 
Parameter Low [Ca2+]i High [Ca2+]i Reference 
Ca2+ buffering Slow Fast (Faas et al., 2007) 
Mobility Slow Very slow (Arendt et al., 2013) 
Subcellular 
localization 
Mainly cytosolic  Enriched in membranes (Hack et al., 2000, Winsky 
and Kuznicki, 1995) 
 
 
4.1.3. Calretinin modulates neuronal excitability 
From a fundamental neuroscience research perspective, CR has mainly been 
used a marker for a subpopulation of interneurons, with few studies addressing its 
functional role in the nervous system. It has been shown, nonetheless, that CR might 
be an important modulator of neuronal excitability and synaptic plasticity.  
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The first indication that CR might be implicated in modulating synaptic 
function came from studies in CR knock-out (CR-/-) mice. Schurmans and colleagues 
developed the CR-/- mice in 1997 and showed that these mice have impaired long-term 
potentiation in the dentate gyrus, likely due to excessive release of GABA in the region 
(Schurmans et al., 1997). In addition, the lack of CR expression in these mice was later 
shown to lead to increased excitability of cerebellar granule cells with consequences 
for motor coordination, which can be restored by rescue of CR expression exclusively 
in this cell type (Bearzatto et al., 2006, Gall et al., 2003, Schiffmann et al., 1999). 
Further evidence for a role of CR in synaptic function is exemplified by its interaction 
with the calcium channel Cav2.1, preferentially in the presence of Ca
2+, which 
contributes to modulate the activity of Cav2.1 and, consequently, of Ca
2+ signals 
(Christel et al., 2012). Moreover, triple knock-out of calretinin, calbindin and 
parvalbumin, three Ca2+-binding proteins of the same family, results in excessive 
exocytosis in Inner Hair Cells, presumably due to poor spatial restriction of Ca2+ 
signals to the active zone (Pangrsic et al., 2015). 
Altogether, several lines of evidence indicate CR may play an important role 
in modulating Ca2+ signals and neuronal excitability, via Ca2+ buffering and/or by 
establishing Ca2+-dependent interactions. The consequences of CR’s function to 
synaptic function and stability are still, nevertheless, a field poorly explored.  
 
4.1.4. The role of calretinin in neurodegeneration 
It has previously been shown in this thesis (Chapter 3) that CR expression is 
altered in synaptic terminals of a sheep model of Batten disease, specifically in the 
brain regions most affected by the disease. In addition, our group has previously 
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demonstrated that altered expression of CR is characteristic of other neurodegenerative 
scenarios (Table 4.2), suggesting this protein might play an important role in 
modulating synaptic stability across a range of diseases and model systems. 
 
Table 4.2: Changes in CR expression in animal models of neurodegenerative disease. 
Condition Tissue Expression Reference 
Cortical injury Synaptosomes (Mouse) down (Wishart et al., 2012) 
Batten disease Synaptosomes (Sheep) up Chapter 3 
Axonal injury Olfactory Receptor Neurons 
(Drosophila) 
detrimental (Wishart et al., 2012) 
 
The available literature, however, provides conflicting evidence as to whether 
the expression of CR is preferentially protective or detrimental to neuronal stability. 
Some studies report CR positive interneurons to be spared in patients or experimental 
models of Alzheimer’s, Parkinson’s or Huntington’s disease (Cicchetti and Parent, 
1996, Fonseca and Soriano, 1995, Pike and Cotman, 1995), while others show the 
opposite effect, with significant loss of CR interneurons in Alzheimer’s disease, 
amyotrophic lateral sclerosis or following ischemic injury (Baglietto-Vargas et al., 
2010, Freund and Magloczky, 1993, Hsu et al., 1994, Morrison et al., 1996, Morrison 
et al., 1998). Most importantly, the majority of these studies focused on the 
subpopulation of CR immunoreactive interneurons and did not address the remaining 
neuronal subtypes nor the molecular mechanisms that might underlie CR’s role in 
neuronal stability. This gap in the literature has just begun to be filled by two recent 
studies: Wishart and colleagues (Wishart et al., 2012) demonstrated that CR plays a 
role in synaptic degeneration in the mouse corticostriatal system and in axonal 
degeneration in Drosophila, extending the level of influence of CR outside the 
interneuron subpopulation; whereas Dong and colleagues (Dong et al., 2012) revealed 
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that CR plays a protective role during oxidative stress in a Huntington’s disease in 
vitro model.  
 
4.1.5. Aims 
Research is slowly revealing an important role for CR in synaptic function and 
neurodegenerative pathways. Given the current evidence suggesting CR may 
contribute to modulate synaptic stability across various models of neurodegenerative 
disorders, including our large animal of model of Batten disease, we wanted to further 
explore the poorly understood function of CR and its contribution to the modulation 
of neurodegenerative mechanisms and synaptic function. Therefore, we set two main 
aims: 
 Confirm the ability of CR to modulate neurodegeneration in a mouse 
model of in vivo peripheral nerve degeneration; 
 Explore the function of CR in central synapses and how it may 






4.2. Materials and methods 
4.2.1. Animals 
Wild-type (WT) CD1 and C57Bl/6J mice were obtained directly from the 
University of Edinburgh managed rodent colonies. CR-/- mice were imported from the 
laboratory of Prof. Serge Schiffmann (University of Brussels, Belgium) and 
maintained on a C57Bl/6J background (Schurmans et al., 1997).  
All rodents were kept under standard husbandry conditions in animal facilities 
at the University of Edinburgh. All procedures were performed under license from the 
UK Home Office and approved by the University of Edinburgh Veterinary Services. 
All animals were sacrificed by Schedule 1 methods, either by cervical dislocation or 
overdose of anaesthetic by inhalation of isoflurane (Abbot). 
 
4.2.2. Genotyping 
Genotyping was performed as described in the General Materials and Methods 
section. Details of the primers, reaction mixes and PCR programs used can be found 
in Table 4.3, Table 4.4 and Table 4.5, respectively. 
 
Table 4.3: Primers used for genotyping of CR-/- mice. 
Primer Sequence 5' - 3' Size bp 
WT forward (cr-ex2) GTTCTCTAGCTCTTTACCTTCAATGTACCCA   
WT Reverse (cr-it1) GCTGGCTGAGTACTCCAAGGGTACACATT 243 
KO forward (cr-it1) GTTCTCCGTGGAGGTGGTGACTTCCTAGTC 
 








Table 4.4: PCR reagent mix for 1 reaction. 
Reagent  μl per 1 reaction 
ddH20  9.6 
5x Green GoTaq Flexi Buffer 
(Promega) 
3.5 
MgCl2 25mM (Promega) 0.9 
dNTP mix 10mM (Invitrogen)  0.4 
Forward Primer 10μM 0.7 
Reverse Primer 10μM  0.7 
GoTaq Flexi DNA polymerase 
(Promega)  
0.2 
DNA  2 
Total  18 
 
 
Table 4.5: PCR program used for genotyping of CR-/- mice. 
Step Temperature (°C) Time 
1. Separation 94 5 min 
2. Denaturation 94 30 sec 
3. Annealing 61 45 sec 
4. Polymerization 72 45 sec 
    Repeat 2-4 34x 
  
5. Final 72 5 min 
  12 ∞ 
 
 
4.2.3. Peripheral nerve lesions 
Peripheral nerve lesions were performed in mice 4-5 months old, as described 
previously (Gillingwater et al., 2002). Mice were initially anaesthetized in an induction 
chamber with 5% of isoflurane and maintained thereafter with 2-3% of isoflurane 
delivered via a face mask, or anaesthetised via intra-peritoneal injection of 240 mg/kg 
Tribromoethanol. A small skin incision was made at the level of the sciatic notch and 
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a 1-2mm section of the sciatic nerve was removed, ensuring complete transection. The 
wound was sutured and immediately following surgery all mice received an 
intramuscular injection of 4 mg/kg of the analgesic Rimadyl®. Mice were allowed free 
access to food and water and kept under standard husbandry conditions until sacrifice 
15 to 22 hours post-injury (hpi). To ensure comparability of results extra care was 
taken regarding the precision of the time point of analysis, anatomical location of the 
lesion and age of the mice. 
 
4.2.4. Immunohistochemistry of lumbrical muscles 
Lumbrical muscles were dissected in PBS and fixed in 4% PFA in PBS for 20 
min. Fixed muscles were permeabilised in 4% Triton X-100 in PBS for 90 min and 
blocked in 2% Triton X-100 with 4% w/v Bovine Serum Albumin (BSA) in PBS for 
30 min. Immunolabelling was performed by serial incubation with primary antibodies 
in block for 72 h at 4°C and secondary antibodies in PBS for 12 h at 4°C. Post-synaptic 
acetylcholine receptors (AchR) were labelled with α-bungarotoxin conjugated to 
tetramethylrhodamine (-BTX; Molecular Probes) 1.25 µg/ml in PBS for 10 min. 
Muscles were extensively washed in PBS between the staining steps. Finally, muscles 
were whole-mounted in Mowiol (Calbiochem) on glass slides and cover-slipped. 
 
4.2.5. Quantification of synaptic integrity 
Following sacrifice between 15 and 22hpi, lumbrical muscles from injured and 
contralateral non-injured hind limbs were rapidly dissected and processed for 
immunohistochemistry as described above, using antibodies against 2H3 and SV2 
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proteins. Synaptic integrity was manually assessed by using an integrity score adapted 
from (Murray et al., 2008), as follows: 0: no presence of any intact axons or fragments; 
1: no fully intact axons but fragmented debris or presence of a portion of the incoming 
nerve; 2: overall denervated muscle with presence of a few nerve ramifications in 
<25% of the muscle area but no visible occupied endplates; 3: overall denervated 
muscle with presence of a few nerve ramifications in <25% of the muscle area and a 
few visibly occupied endplates; 4: presence of nerve ramifications in 25%-50% of the 
muscle area and visibly occupied endplates; 5: presence of nerve ramifications in 50%-
75% of the muscle area and visibly occupied endplates; 6: apparently intact muscle or 
presence of nerve ramifications in >75% of the muscle area and visibly occupied 
endplates. Muscle area corresponds to the area of the muscle covered with post-
synaptic endplates. 
Quantification was performed at 40x magnification on a Nikon eclipse 50i 
microscope with double filter, on at least 3 muscles of each of 3 mice per condition 
and with the operator blind to the identity of each muscle. Representative images were 
captured in a Zeiss LSM 710 laser scanning confocal microscope. 
  
4.2.6. Immunohistochemistry of spinal cord sections 
Adult C57Bl/6J mice were deeply anaesthetized via an intraperitoneal injection 
of 300 mg/kg Sodium Pentobarbital and perfused-fixed with 4% PFA in PBS. The 
whole spinal cord was dissected, post-fixed in 4% PFA in PBS overnight and 
cryopreserved in 30% sucrose in PBS for 24 h before being embedded in 100% OCT. 




Tissue sections were incubated in blocking solution (1% Triton X-100, 4% 
BSA in PBS) for 30 min prior to incubation with primary antibodies overnight at 4°C 
and in secondary antibodies for 90 min at RT. The antibodies were diluted in blocking 
solution and the sections were thoroughly washed in PBS between incubations. 
Section were covered in Mowiol, protected with a glass coverslip and imaged in a 
Zeiss LSM 710 confocal microscope. 
 
4.2.7. Primary neuronal cultures 
Primary neurons were prepared from E17.5 C57Bl6/J mouse embryos as 
described previously (Gordon et al., 2011). Embryos were sacrificed by decapitation, 
the hippocampus rapidly dissected in ice-cold HBSS and the resulting tissue was 
incubated in a solution of 20 units/ml of Papain (Worthington Biochemicals) in HBSS 
(Invitrogen) for 20 min at 37°C. After removal of excess papain, the tissue was 
resuspended in DMEM/F12 media supplemented with 100 U/mL 
penicillin/streptomycin and 10% v/v foetal bovine serum (Sigma) and disaggregated. 
The cell suspension was centrifuged at 200g for 5 min at RT and the pellet resuspended 
in Neurobasal media supplemented with 2% v/v B-27, 0.5 mM L-Glutamine and 100 
U/mL penicillin/streptomycin.  
40x103 cells were plated on sterile glass coverslips coated with Poly-D-Lysine 
and laminin. To prepared coverslips, 50 μg/ml Poly-D-Lysine in 0.1 M Sodium Borate 
buffer pH 8.5 was applied for 2 h and thoroughly washed in H2O before addition of a 
50 uL drop of 10 μg/ml of laminin (Invitrogen) in supplemented Neurobasal media. 
Cells were platted in laminin spots, allowed to settled for 1 h in a 37°C, 5% CO2 
incubator, and thereafter grown in supplemented Neurobasal media. At day-in-vitro 
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(DIV) 3 the media was further supplemented with 1 μM cytosine β-D-
arabinofuranoside to prevent glial proliferation. At DIV 7 50% of culture media was 
replaced with fresh media. 
 
4.2.8. Immunocytochemistry 
Cells plated in glass coverslips were fixed for 10 min in warm 4% PFA in PBS, 
permeabilized for 5 min in 0.1% Triton-X100 in PBS and blocked for 30 min in 2.5% 
BSA in PBS. Cells were incubated in spots of primary antibody for 2 h at RT and in 
secondary antibody for 1 h at RT. All antibodies were diluted in 2.5% BSA in PBS. 
Coverslips were washed in PBS between incubations, mounted on Mowiol spots in 
glass slides and imaged in a Zeiss LSM 710 confocal microscope. 
 
4.2.9. Calretinin intensity distribution 
WT hippocampal neurons at DIV 14-16 immunolabelled with CR and β-III-
tubulin were imaged in a Zeiss 710 Confocal Microscope at constant laser settings. 
The intensity of CR staining was measured in regions of interests of identical area in 
the cell body of all individual neurons in each image. For each coverslip, the intensity 
of CR was normalized to the mean value of all the neurons imaged in the same 
experiment. Neurons were imaged at 40x magnification from each of 3 images per 






4.2.10. Puncta colocalisation analysis 
Colocalisation between SV2 and CR puncta was performed using the “spots 
colocalisation” tool on the IMARIS software. WT hippocampal neurons at DIV 14-16 
were immunolabelled for SV2 and CR and z-stacks were acquired at 63x 
magnification, on a Zeiss LSM 710 Confocal Microscope. Using the IMARIS “spots” 
tool, spots were created so as to colocalise with the CR or SV2 puncta. The “spots 
colocalisation” tool was then used to calculate the total number of spots and the 
number of spots colocalising between the two channels. Data was acquired from at 
least 15 fields of view from 2 coverslips per independent culture. 
 
4.2.11. Synaptic enrichment analysis 
WT hippocampal neurons at DIV 14-16 were stained for SV2 and CR and z-
stacks imaged at 63x magnification on a Zeiss LSM 710 Confocal Microscope. The 
enrichment of CR in synaptic sites was calculated as the ratio between the fluorescence 
of CR in SV2 puncta and in adjacent axonal regions. At least 100 synaptic sites from 
each of 2 images per coverslip were obtained and analysed for a total of 6 coverslips 
from 3 independent cultures.  
 
4.2.12. Calretinin K+-dependent distribution 
For analysis of K+ dependent distribution of CR, WT hippocampal neurons at 
DIV 14-16 were incubated with low or high levels of KCl in order to depolarize 
neurons and simulate an action potential. This method has been shown to depolarize 
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cells and lead to activity-dependent changes in cultured neurons and synaptosome 
preparations (Kohansal-Nodehi et al., 2016, Macias et al., 2001, Smillie et al., 2013).  
For stimulation experiments, the culture media was removed and neurons were 
washed once in warm PBS, incubated for 30 s with Low K+ (136 mM NaCl, 2.5 mM 
KCl, 2 mM CaCl2, 1.3 mM MgCl2, 10 mM Glucose, 10 mM HEPES, pH 7.4, 37°C) 
or High K+ (88.5 mM NaCl, 50 mM KCl, 2 mM CaCl2, 1.3 mM MgCl2, 10 mM 
Glucose, 10 mM HEPES, pH 7.4, 37°C) buffer and immediately fixed in warm 4% 
PFA in PBS. For recovery experiments, neurons were similarly incubated for 30 s in 
Low or High K+ buffer but further incubated 2x for 30 s in Low K+ prior to being fixed. 
Fixed neurons were immunolabeled with CR and SV2 antibodies and imaged at 63x 
magnification in a Zeiss LSM 710 confocal microscope. Images were analysed using 
the IMARIS software. Colocalisation of puncta was performed as described above. 
Data was acquired from at least 15 fields of view from 2 coverslips per independent 
culture. 
 
4.2.13. Transfection procedures 
Knockdown (KD) DsiRNA constructs were obtained from IDT (Integrate 
DNA Technologies) and transfected using Lipofectamine RNAiMAX reagent 
(Invitrogen) according to the manufacturers instructions. Briefly, 10 nM DsiRNA was 
incubated with 2 μl/ml of Lipofectamine RNAiMAX in MEM media at RT for 5 min 
before being added to the cells. Cy3 fluorescent control was used to label transfected 
cells and universal control NCI DsiRNA was used as negative control. Cells were 
incubated with the knock-down constructs (see Table 4.6) for 48 h before analysis.  
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Overexpression constructs were obtained from various sources (see Table 4.6) 
and transfected using Lipofectamine 2000 reagent (Invitrogen), as described in 
(Gordon et al., 2011). 0.2-1 μg of constructs were incubated, at the desired 
concentration, with 2 μl/ml of Lipofectamine 2000 in MEM media at RT for 20 min. 
The cell culture media was replaced with MEM and the cells incubated with the desired 
construct/Lipofectamine mix for 2 h. MEM was then removed and the cells allowed to 
grow in their own pre-conditioned culture media until required. 
 
Table 4.6: Constructs used for transfection of cultured neurons. 
Vector Type Supplier Cat No 
SypHy Plasmid Addgene. Gift from Prof. Mike 
Cousin 
24478 
GCaMP6f Plasmid Addgene. Gift from Prof. Mike 
Cousin 
40755 
GFP-Sypnaptophysin Plasmid Gift from Prof. Mike Cousin 
 
N1-mCer Plasmid Gift from Prof. Mike Cousin 
 
N1-mCer-Calb2 Plasmid Cloning from pCMV6-Calb2 
into N1-mCer 
 
pCMV6-Calb2 Plasmid Origene MR203611 
pCMV6-empty Plasmid Origene PS100001 
Calb2 DsiRNA IDT DNA MMC.RNA1.N007586.12.1 
Calb2 DsiRNA IDT DNA MMC.RNA1.N007586.12.3 
Cy3 DsiRNA IDT DNA Cy3 DS Transfection 
Control 
NC1 DsiRNA IDT DNA Negative Control (DS NC1) 
 
4.2.14. H2O2 treatment 
WT hippocampal neurons at DIV 13 were transfected with CR KD constructs. 
48 h after transfection cells were exposed to 0 µM or 100 µM H2O2 for 2 h. H2O2 100x 
dilutions were made fresh in Neurobasal media and further diluted directly into the 
culture media, as described in (Whittemore et al., 1995). After the 2 h treatment cells 
were fixed in 4% PFA, stained with DAPI for 5 min and mounted in glass slides in 
Mowiol. Slides were imaged in an epifluorescent microscope and live/dead cells were 
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identified according to the morphology of the nuclei, as described in (Whittemore et 
al., 1995): live cells have round nuclei, whereas dead cells have shrunken or collapsed 
nuclei, with condensed staining. At least 10 fields of view were analysed per individual 
slide. 
  
4.2.15. Synaptophysin-pHluorin imaging 
Synaptophysin-pHluorin experiments were performed as described in (Gordon 
et al., 2016, Gordon et al., 2011). Primary WT hippocampal neurons were transfected, 
at DIV 7, with 1 μg of synaptophysin-pHluorin (SypHy) and 1 μg of pCMV6-Calb2 
or pCMV6-empty. At DIV 12-15, cultures were mounted in an imaging chamber with 
embedded parallel platinum wires (RC-21BRFS, Warner Instruments) and positioned 
on the stage of a Zeiss Axio Observer D1 epifluorescence microscope. Neurons were 
visualized with a 40x oil-immersion objective at 500/530nm excitation/emission 
(ex/em). Cells were continuously perfused with Imaging buffer (119 mM NaCl, 2.5 
mM KCl, 2 mM CaCl2, 2 mM MgCl2, 30 mM glucose, 25 mM HEPES, 10 uM CNQX, 
50 uM APV, pH 7.4) and fluorescent images were captured every 4 s using a 
Hamamatsu Orca-ER digital camera. Neurons were imaged at rest for at least 60 s, 
stimulated with a train of 300 action potentials at a frequency of 10 Hz (100 mA, 1 ms 
pulse width), allowed to recover for 3 min and perfused with NH4Cl buffer (69 mM 
NaCl, 2.5 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 30 mM glucose, 25 mM HEPES, 50 
mM NH4Cl, pH 7.4) to reveal the maximum fluorescence of the pHluorin probes.  
Images were analysed using ImageJ software. Frames were aligned using the 
StackReg plugin (http://bigwww.epfl.ch/thevenaz/stackreg/) with rigid body 
algorithm. Nerve terminals were selected using regions of interest (ROIs) of identical 
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size (oval 5x5 pixels) and the total fluorescence intensity of each ROI was measured 
over time using the Time Series Analyzer plugin 
(https://imagej.nih.gov/ij/plugins/time-series.html). Changes in fluorescence (ΔF / F0) 
were calculated as ((F - F0) / F0), (F0: fluorescence of terminal at rest; F: fluorescence 
at a given time). The stimulation peak was calculated as the maximum fluorescence in 
data normalized to the maximum fluorescence during NH4Cl perfusion, to account for 
variations in pHluorin expression between cells. Endocytosis rate constants (τ) were 
determined from data normalized to the peak fluorescence using GraphPad Prism 
software. Traces between 100 s and 200 s were fitted to a non-linear one phase decay 
function of the type y = (yi - yf).e
(-x/τ) . Only curves fitted with R2 > 0.80 were accepted 
for further analysis. 
 
4.2.16. Real-time imaging 
Primary hippocampal neurons were transfected, 3 days prior to imaging, with 
a combination of one or more of the following constructs: 1 μg of SypHy, 0.2 μg N1-
mCer-Calb2, 1 μg of GCaMP6f or 1 μg GFP-synaptophysin. At DIV13-15, coverslips 
were mounted in an imaging chamber and imaged as described for Synaptophysin-
pHluorin imaging. Wavelength settings used were 500/530nm ex/em for SypHy, 
GCaMP6f and GFP-Synaptophysin, and 430/530nm ex/em for N1-mCer-Calb2. 
Analysis of CR intensity in boutons and axons was performed as described in 
(Chi et al., 2001). An oval ROI of 5x5 pixels was placed on nerve terminals (synapses) 
and adjacent regions (axons). The fluorescence was tracked over time and the change 
in fluorescence calculated as F / F0 (F0: fluorescence of terminal at rest; F: fluorescence 
at a given time). Dispersion rate constants (τ) were determined from data normalized 
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to the peak fluorescence using GraphPad Prism software. Traces between 100 s and 
200 s were fitted to a non-linear one phase association function of the type y = y0 + 
(plateau - y0).(1-e
(-x/τ)) . Only curves fitted with R2 > 0.80 were accepted for further 




Experiments for co-immunoprecipitation (co-ip) of CR and its synaptic binding 
partners were adapted from (Christel et al., 2012). Freshly prepared synaptosomes 
from adult CD1 mice were resuspended in IP Lysis buffer (50 mM Tris-HCl, 150 mM 
NaCl, 1% Triton-X, pH 7.6) with either 1 mM EGTA (Low Ca2+) or 1 mM CaCl2 
(High Ca2+) containing protease inhibitors. These Ca2+ and EGTA concentrations were 
chosen as they have previously been shown to alter the conformation of CR and its 
ability to form specific interactions (Christel et al., 2012, Schwaller et al., 1997). 
Samples were incubated on ice for 15 min, vortexing every 5 min, and centrifuged for 
20 min at 20,000g and 4°C.  
50 μl of Recombinant Protein G Sepharose (Generon), from a 50% slurry in 
Low/High Ca2+ Lysis buffer, were incubated with 3 μl of anti-calretinin antibody for 
1 h at 4°C on a roller and further incubated with synaptosomes for 2 h at 4°C. Control 
experiments for non-specific binding were performed without the addition of CR 
antibody. The beads were washed 2x in Low/High Ca2+ Lysis buffer and further 2x in 
Low/High Ca2+ buffer prepared without Triton-X 100 or protease inhibitors. At this 
point, the beads were either resuspended 1:1 in Low/High Ca2+ buffer (without Triton-
X 100 or protease inhibitors) and frozen, or the co-IP proteins were eluted by boiling 
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the beads in 2x NuPAGE® LDS Sample Buffer. Elution samples were readily used 
for western blotting and frozen beads were sent for mass spectrometry (MS) analysis 
at the Roslin Institute (University of Edinburgh). For each Ca2+/EGTA condition, 
samples were prepared in duplicates and processed independently for MS. 
The protein G agarose beads containing bait and interacting proteins were 
washed twice with 500µl of TBS. Washed beads were resuspended in 50 mM 
ammonium bicarbonate and digested with sequencing grade modified trypsin 
(Promega), following reduction with 5 mM dithiothreitol and alkylation with 10 mM 
iodoacetamide. The resulting peptide mixture was spun at 800g and the supernatant 
was collected. The digested peptides were cleaned up using Stagetips by following the 
standard protocol from (Rappsilber et al., 2007). 
Nanoflow LC-MS/MS was performed on a micrOTOF-II mass spectrometer 
(Bruker, Germany) coupled to a RSLCnano LC system (Thermo). A tryptic digest of 
each sample was delivered to a trap column (Acclaim PepMap100, 5 μm, 100 Å, 100 
μm i.d. × 2cm) at a flow rate of 20 μL/min in 100% solvent A (0.1% formic acid in 
LCMS grade water). After 4 min of loading and washing, peptides were transferred to 
an analytical column (Acclaim PepMap100, 3 μm, 100 Å, 75 μm i.d. × 25 cm) and 
separated at a flow rate of 300 nL/min using a 60-min gradient from 7% to 35% solvent 
B (solvent B, 0.1% FA in acetonitrile). The eluent from LC was passed onto the nano 
electrospray source of the micrOTOF-II, which was operated in data-dependent mode, 
automatically switching between MS and MS2 mode. The m/z values of tryptic 
peptides were measured using a MS scan (300-2000 m/z), followed by MS/MS scans 
of the six most intense peaks. Rolling collision energy for fragmentation was selected 
based on the precursor ion mass and a dynamic exclusion was applied for 30 sec.  
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Raw spectral data were processed with DataAnalysis (Bruker) software and the 
resulting peak lists were searched using Mascot 2.4 server (Matrix Science) against 
IPI Mouse sequence database containing 59,534 entries.  Mass tolerance on peptide 
precursor ions was fixed at 25 ppm and on fragment ions at 0.05 Da. The peptide 
charge was set to 2+ and 3+. Carbamidomethylation of cysteine was selected as a fixed 
modification and oxidation of methionine and de-amidation were chosen as variable 
modifications.  False discovery rate was limited to < 1% for peptide IDs after searching 
decoy databases. 
 
4.2.18. Label-free proteomics 
Synaptosomes were prepared as described in General Materials and Methods, 
from whole brain of CR+/+ and CR-/- adult mice. Synaptosomes were lysed in Label-
free buffer (100 mM Tris pH 7.4, 4% SDS, protease inhibitors), incubated on ice for 
20 min and centrifuged at 20,000g for 20 min to remove insoluble proteins. Protein 
concentration was calculated using BCA assay and a combination of 3 pooled samples 
per genotype were sent for Label-free proteomics at Dundee Fingerprints Proteomics 
(University of Dundee, UK). 
An equivalent of 300 µg of protein from each sample were reduced with 100 
mM DTT at RT for 10 min and samples were then processed using a filter-aided 
sample preparation (FASP) protocol adapted from (Wisniewski et al., 2009). After 
removal of SDS with 8 M urea, filters were washed twice with 200 µl 40 mM 
ammonium bicarbonate and the proteins captured on the filters were digested twice 
with trypsin (2x2 µg), first overnight and then for another 6 h in 200 µl, in ammonium 
bicarbonate at 40 mM at 30oC. Analysis of the resulting peptides was performed on an 
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LTQ Velos-Pro orbitrap (Thermo Scientific) mass spectrometer coupled with a Dionex 
Ultimate 3000 RS (Thermo Scientific). LC buffers were the following:  buffer A (2% 
acetonitrile and 0.1% formic acid in Milli-Q water (v/v)) and buffer B (80% 
acetonitrile and 0.08% formic acid in Milli-Q water (v/v). In addition to the CR+/+ and 
CR-/- samples, a pooled sample made from an equal amount of CR+/+ and CR-/- was 
generated to run as a quality control for the mass spectrometer and to increase the 
number of proteins identified and quantified. Samples were diluted 1/50 in 1% formic 
acid and aliquots of 10 μl of each sample was loaded at 5 μl/min onto a trap column 
(100 μm × 2 cm, PepMap nanoViper C18 column, 5 μm, 100 Å, Thermo Scientific) 
equilibrated in 98% buffer A. The trap column was washed for 3 min at the same flow 
rate and then the trap column was switched in-line with a Thermo Scientific, resolving 
C18 column (75 μm × 50 cm, PepMap RSLC C18 column, 2 μm, 100 Å). The peptides 
were eluted from the column at a constant flow rate of 300 nl/min with a linear gradient 
from 95% buffer A to 40% buffer B in 130 min, and then to 98% buffer B by 152 min. 
The column was then washed with 98% buffer B for 20 min and re-equilibrated in 98% 
buffer A for 17 min. Each of the three samples (CR+/+, CR-/- and pool of both samples) 
were run in triplicate using LTQ-Orbitap Velos in data dependent mode. A scan cycle 
comprised MS1 scan (m/z range from 335-1800) in the velos orbitrap followed by 15 
sequential dependant MS2 scans (the threshold value was set at 5000 and the minimum 
injection time was set at 200 ms) in LTQ with collision induced dissociation. The 
resolution of the Orbitrap Velos was set at to 60,000. To ensure mass accuracy, the 
mass spectrometer was calibrated on the first day that the runs are performed.  
The resulting raw mass spectrometry data was imported into Progenesis QI for 
proteomics (v2.0.5387.52102; Non Linear Dynamics, UK). Data sets were aligned to 
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the pooled control samples (alignment scores between 81.0% and 98.8%) and filtered 
to exclude peptides with power <0.8 and ANOVA p-value>0.05. Retention time was 
limited to 12-130 min and only the 3 most intense reads for each peptide were included. 
Data was exported as an mgf file and sent back to Dundee Fingerprints Proteomics for 
identification of individual peptide sequences using Mascot Search Engine (Swiss Prot 
database, with mouse species filter). Mascot generated data was re-imported into 
Progenesis and filtered to include only proteins identified by more than 1 unique 
peptide, with ANOVA p-value < 0.05 and expression levels altered by 10% in CR-/- 
synaptosomes when compared to control (KO/WT ratio -1.10≤ and ≥1.10). 
In silico analysis was performed using two tools:  Ingenuity Pathway Analysis 
(IPA; QIAGEN); and Database for Annotation, Visualization and Integrated 
Discovery (DAVID; National Institutes of Health, USA). More information on these 
tools can be found at http://www.ingenuity.com and http://david.abcc.ncifcrf.gov, 
respectively. 
The proteomics results were submitted to the IPA software (v27821452). 
Amongst other functions, IPA uses hand-curated experimental data to generate 
networks of proteins according to their involvement in known molecular mechanisms 
and calculates their statistical significance using the Exact Fisher’s Test. In order to 
get results as accurate as possible, we restricted the IPA mapping tools to only include 
data derived from experimental evidence and narrowed down the networks of proteins 
to contain a maximum of 35 proteins. We used the IPA software to determine the 
molecular pathways (Top Canonical Pathways) and disorders (Top Diseases and 
Disorders) most affected by loss of CR. 
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DAVID bioinformatics tools (v6.6) were used to complement the IPA results. 
Proteins that meet our filtering criteria were used to determine the Functional 
Annotation Clusters of the samples. Each cluster consists of at least 3 subcategories 
containing proteins functionally related. For each subcategory the DAVID software 
calculates a p-value using the Exact Fisher’s Test, and the mean value of the –log() of 
these is used to calculate an enrichment score for each cluster, so that a cluster enriched 
in a sample will have a low p-value and a high enrichment score. For ease of 
comparison between IPA and DAVID results, enrichment scores from Functional 
Annotation Clusters were converted back to p-values. In addition, DAVID was used 
to map the proteomics data to KEGG (Kyoto Encyclopedia of Genes and Genomes) 






4.3.1. Calretinin is expressed throughout the nervous system 
To date, the vast majority of studies addressing CR’s role in the nervous system 
have been carried out either in cell lines or restricted to the subpopulation of 
interneurons expressing high levels of CR. However, there are hints in the literature 
that CR may be more widely expressed in the nervous system. For example, CR is 
relatively abundant in the retina, in cerebellar granule cells and hippocampal neurons 
(Camp and Wijesinghe, 2009, Schurmans et al., 1997). Furthermore, studies have 
shown expression of CR in brain synapses (Winsky and Kuznicki, 1995, Wishart et 
al., 2012) and the presence of CR immunoreactive neurons in the spinal cord 
(Fahandejsaadi et al., 2004, Ren et al., 1993). However, the extent of CR’s expression 
in the nervous system has not been fully characterized. Therefore, we further explored 
the expression of CR in the central and peripheral nervous system of the mouse. 
 
In vivo, CR is widely expressed in both the CNS and PNS, with CR being found 
in synaptic and non-synaptic fractions of the brain, in the spinal cord and in the sciatic 
nerve. In contrast, CR was not detected in skeletal muscle (Figure 4.1). We further 
investigated the expression of CR in the spinal cord and demonstrated it is expressed 
in motor and sensory neurons, and that it is particularly abundant in neuronal 
projections of the ventral root (Figure 4.2). In addition, CR is found at the 





Figure 4.1: CR is expressed in tissues from the central and peripheral nervous system. Western 
blotting of tissues from the mouse central nervous system and neuromuscular system. CR is highly 
expressed in the central and peripheral nervous system, and is absent from skeletal muscle. All lanes 
were loaded with 30 µg of protein. GAPDH was used as a loading control. 
 
 
Figure 4.2: CR is expressed in the spinal cord. CR immunofluorescence in spinal cord sections of an 
adult mouse. Note the presence of CR positive neurons in the ventral and dorsal horns, as well as staining 





Figure 4.3: CR is expressed in motor axons and neuromuscular nerve terminals. Post-synaptic 
acetylcholine receptors, motor axons and nerve terminals from hind limb lumbrical muscles were 
immunolabeled with BTX and 2H3/SV2 antibodies, respectively. Note the CR staining resembling 
the pattern of 2H3/SV2 staining, indicating it is expressed in motor axons and nerve terminals. Scale 
bar = 50 µm. 
 
4.3.2. Loss of calretinin delays Wallerian degeneration 
We have identified CR as an interesting target for further study in (Wishart et 
al., 2012), where it was found that levels of CR were altered in mouse striatal synapses 
undergoing degeneration and that CR Drosophila mutants presented delayed 
Wallerian degeneration in olfactory receptor neurons. In addition, we have shown 
elevated levels of CR are characteristic of synapses from affected brains areas of sheep 
suffering from Batten disease, suggesting that excessive CR might contribute to the 
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neuropathology of the disease. Therefore, we wanted to further explore the 
contribution of CR to neurodegeneration pathways. 
 
To determine whether, similar to what was reported in Drosophila, loss of CR 
delayed Wallerian degeneration in mice, we performed peripheral nerve lesions in 
CR+/+ and CR-/- mice. We instigated Wallerian degeneration by transecting the sciatic 
nerve and assessed the preservation of axonal and synaptic structures in hind limb 
lumbrical muscles, which are innervated by branches of the sciatic nerve, at defined 
time-points following injury. Loss of CR did not block Wallerian degeneration from 
ultimately occurring, but significantly delayed the onset of axonal degradation (Figure 
4.4). Morphological characteristics of degeneration were first detected in CR+/+ mice 
after 15 hpi and by 20 hpi there were no traces of innervated neuromuscular junctions. 
In contrast, significant loss of innervation was only identified in CR-/- mice after 18 
hpi, indicating a ~3 h delay in the instigation of axonal breakdown in the absence of 
CR. Loss of axonal connections didn’t reach completion in CR-/- mice until 22 hpi.  
 
Overall, these results suggest that instigation of degeneration, as assessed by 
the loss of immunolabelled axonal connections, was delayed by around 3 h in CR-/- 
mice. CR did not, nonetheless, significantly affect the rate of Wallerian degeneration 
in the PNS, which was completed within 5 h in both CR+/+ and CR-/- mice. Thus, CR 





Figure 4.4: Loss of CR expression delays Wallerian degeneration in the PNS. A) Representative 
confocal micrographs of NMJs in lumbrical muscles at different time-points following sciatic nerve 
lesion. Green: axons/nerve terminals; red: acetylcholine receptors. Scale bar = 50 μm. B) Time course 
of integrity of the NMJ following sciatic nerve lesion. Note the moderate delay in instigation of 
degeneration in CR-/- mice. Data represented as mean  SEM, N3, **p<0.01, ****p<0.001 two-Way 
ANOVA with Bonferroni post-test. 
 
4.3.3. Calretinin is enriched in nerve terminals 
The previous results show CR is more widely expressed than previously 
believed and that it may play an active role in neurodegenerative pathways. However, 
the properties of CR and its function besides Ca2+ buffering are poorly understood. 
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Therefore, we wanted to further explore the function of CR in neurons so as to be able 
to understand how it may play a role in neurodegeneration. 
 
In order to study CR’s role in more detail, we used dissociated hippocampal 
neurons from wild-type mice. In contrast to the common belief that CR is essentially 
only expressed in a subpopulation of interneurons, in our in vitro system CR was 
ubiquitously expressed in the vast majority of hippocampal neurons (Figure 4.5 A). 
Nonetheless, a subpopulation of cells could be identified by its higher expression of 
CR, which accounted for ~3% of the overall neuronal population (Figure 4.5 B). This 
proportion in agreement with the previous knowledge (Cauli et al., 2014) about CR 
and we believe these cells constitute the population of CR-immunoreactive 
interneurons. However, as we are interested in the function of CR across all neuron 
types, we decided to focus our subsequent experiments on the population of 




Figure 4.5: CR is widely expressed in hippocampal neurons. A) Hippocampal neurons 
from WT mice cultured to DIV16. Immunolabelling of CR and -III-tubulin shows CR is present at 
detectable levels in the soma and projections of all neurons in culture. A small population of cells 
81 
 
expressed very high levels of CR compared to the remaining neurons (asterisk). Scale bar = 50 µm. B) 
Quantification of the intensity of CR in the soma of individual neurons highlights two populations of 
neurons: one expressing basal levels of CR and a second population expressing high levels of CR, 
presumably CR-immunoreactive interneurons, which accounted for 3% of the hippocampal neurons in 
our culture system. 
 
The pattern of CR expression evolved during the culture of hippocampal 
neurons, with puncta expressing relatively high levels of CR becoming more abundant 
as cells matured (Figure 4.6). Double immunolabelling of DIV 16 neurons with CR 
and the synaptic vesicle protein SV2 showed CR puncta colocalise with sites of SV2 
expression (Figure 4.7 A), where CR is expressed over 4 fold in comparison with 
neighbouring axonal areas (Figure 4.8). 
Colocalisation analysis between CR and SV2 puncta showed 90% of CR 
puncta are positive for SV2, confirming CR accumulates at synapses. On the other 
hand, only 30% of SV2 puncta were simultaneously positive for CR (Figure 4.7 B), 
suggesting CR is either expressed transiently at synapses or does not accumulate 
equally in all types of nerve terminals. Co-labelling of CR with anti vGAT and vGLUT 
antibodies, to identify inhibitory and excitatory synapses, respectively, showed CR 





Figure 4.6: The pattern of CR expression evolves as neurons mature. Hippocampal neurons cultured 
to DIV 6, DIV 10 and DIV 16 were immunolabelled for CR and -III-tubulin. Note the appearance of 
a punctate staining of CR as neurons mature. Right panel contains higher magnification images from 





Figure 4.7: CR is present in excitatory nerve terminals. A) CR and SV2 immunolabelling of DIV 
16 hippocampal neurons shows CR puncta colocalise with SV2. Scale bar = 20 µm (panels on the left), 
2 µm (panel on the right). B) Quantification of colocalisation between CR and SV2 puncta indicates 
90% of CR puncta colocalise with SV2, whereas only 30% of SV2 puncta are positive for CR. Data 
represented as mean  SEM, N=3. C) Hippocampal neurons at DIV 16 immunolabelled for CR and 
vGAT or vGLUT demonstrate CR puncta colocalise with vGLUT but not vGAT, suggesting CR is 





Figure 4.8: CR is enriched in synaptic terminals. Quantification of CR intensity in puncta 
colocalising with SV2 (arrows) and in adjacent axonal areas (arrow heads) confirms CR is enriched in 
synaptic terminals. N=3, **p<0.01 unpaired two-tailed t-test. Scale bar = 2 µm. 
 
4.3.4. Calretinin responds dynamically to synaptic activity 
After establishing that CR is enriched in nerve terminals we wanted to 
determine how it responded to synaptic activity. Therefore, we incubated hippocampal 
neurons in physiological media containing 2.5 or 50 mM KCl, as incubation with 50 
mM KCl leads to depolarization of neurons and activates activity-dependent pathways 
(Macias et al., 2001, Smillie et al., 2013). In low levels of K+ (2.5 mM KCl; Low K+), 
CR staining presented the punctate staining described above. However, when neurons 
where stimulated with High K+ (50 mM KCl; Stimulation), there was a striking 
reduction in the punctate appearance of CR (Figure 4.9 B). The number of CR puncta 
and the colocalisation between SV2 and CR puncta were reduced by 70% upon 
stimulation (Figure 4.9 C, D). Reapplying low K+ levels to cells (Recovery) reverted 
the dispersion of CR and restored its colocalisation with SV2 (Figure 4.9). Altogether, 
these results suggest CR responds dynamically to synaptic activity, by dispersing and 





Figure 4.9: CR disperses from nerve terminals during synaptic activity. A) Schematic of the 
protocol applied for assessing the response of CR to a potassium (K+) depolarisation stimulus. 
Hippocampal neurons at DIV 16 were stimulated for 30 s in Low or High K+ buffer and either readily 
fixed (Stimulation) or allowed to recover in Low K+ buffer for 60 s (Recovery). B) Representative 
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pictures from neurons incubated with low K+ (low K+) and from neurons exposed to high K+ 
immediately after depolarisation (Stimulation) or after recovery in low K+ (Recovery).  The subcellular 
localization of CR changed dramatically upon depolarization in High K+, with CR redistributing away 
from nerve terminals. Recovery in Low K+ restored CR’s high degree of co-localization with the 
synaptic marker SV2. Panels on the right are close-ups from the highlight regions of the images on the 
left. Scale bar = 20 µm (panels on the left), 2 µm (panel on the right). C) Number of CR puncta are 
greatly reduced upon stimulation of neurons. Recovery in Low K+ restores the number of CR puncta to 
control Low K+ levels. N=3, **p<0.01, ***p<0.001 in one-Way ANOVA with Tukey post-test. D) 
Colocalisation analysis between SV2 and CR puncta confirms the specific reduction in the number of 
CR puncta upon stimulation. N=3, ***p<0.001 in one-Way ANOVA with Tukey post-test. 
 
To confirm that dispersion of CR was indeed due to synaptic activity we 
performed real-time imaging of fluorescently tagged CR during stimulation with a 
train of action potentials. Transfecting low levels of CR lead to its colocalization with 
synaptophysin (syp), confirming the synaptic localisation of CR (Figure 4.10 A). After 
a train of 300 action potentials, at 10Hz, CR dispersed from nerve terminals (Figure 
4.10 B). Measuring the fluorescence intensity of the protein in synaptic puncta 
(synapses) and in adjacent axonal regions (axons) demonstrated an increase in axonal 
intensity and reduction of the fluorescence in synaptic areas, concomitant with the 
administration of the action potential stimulus (Figure 4.10 C). Recording of Ca2+ 
signals using the fluorescent Ca2+ indicator GCaMP6f showed the typical sharp rise in 
Ca2+ immediately after an action potential, and fast recovery of Ca2+ levels to basal 
levels during the post-stimulation period (Figure 4.10 D). The curve of CR 
fluorescence, however, is indicative of much slower kinetics of CR’s return to nerve 
terminals than that of the recovery of Ca2+ levels, suggesting CR may remain in the 
peri-active zone to buffer excessive Ca2+ after synaptic activity. Comparing the 
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activity-dependent behaviour of CR with that of a typical synaptic protein, 
synaptophysin, revealed the kinetics of dispersion of the two proteins from nerve 
terminals, following a train of action potentials, are very similar (Figure 4.10 E). 
However, the post-stimulation recovery of CR tended to be slightly slower that Syp, 
although it did not reach statistical significance (Figure 4.10 E, F).  
 
 
Figure 4.10: CR responds dynamically to synaptic activity. A) Hippocampal neurons transfected 
with Synaptophysin (Syp, green) and CR (CR, red). Note the colocalisation between Syp and CR. Scale 
bar = 5 µm. B) False colour images from neurons transfected with CR before (Rest) and after 
(Stimulation) stimulation with 300 action potentials, and over 2 min after stimulation (Recovery). 
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Arrows indicate nerve terminals and arrow heads indicate axonal areas. Scale bar = 5 µm. C) Mean 
fluorescent traces (F/F0) of CR in synapses and axons. Note the change in fluorescence during the action 
potential (10Hz). The opposite direction in the change of fluorescence for axons and synapses suggests 
CR disperses from nerve terminals to the adjacent axonal regions. Traces are represented as mean  
SEM, n28. D) Ca2+ imaging using GCaMP6f showing the fast kinetics of Ca2+ signals. Traces represent 
F/F0 mean  SEM, n=90. E) F/F0 fluorescence, normalized to the range of fluorescence, in hippocampal 
nerve terminals expressing CR or Syp. Traces represent F/F0 mean  SEM, N=6, n=59 (CR), n=89 
(Syp), p>0.05 two-way ANOVA with Holm-Šídák post-test. F) Mean time constant (τ) for post-
stimulation recovery of CR and Syp. Bars represent mean ± SEM, N=5, unpaired two-tailed t-test, 
p>0.05. 
 
4.3.5. Ca2+-dependent interactions of calretinin in nerve terminals 
We have shown thus far that CR is expressed in nerve terminals and responds 
dynamically to synaptic activity. The nature of this behaviour could be due to the 
ability of CR to act as a Ca2+ buffer during neurotransmission. However, it has been 
suggested CR also acts as a Ca2+ sensor and interactions have been published between 
CR and the Ca2+ channel Cav2.1 and the huntingtin protein (Christel et al., 2012, Dong 
et al., 2012). Ca2+ levels have, in addition, been shown to alter the conformation of the 
protein and have been proposed to influence the capacity of CR to form interactions 
(Arendt et al., 2013, Kuznicki et al., 1995, Schwaller et al., 1997). Therefore, we 
sought to explore Ca2+-dependent interactions of CR as an attempt to clarify its 
behaviour during synaptic activity. 
We isolated crude synaptosomes from WT mouse whole brain and performed 
co-immunoprecipitation experiments in the presence of Ca2+ or EGTA. Mass 
spectrometry identification of the interacting proteins revealed CR is present in 
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complexes with synaptic proteins, cytoskeletal proteins and proteins involved in 
immune response (Table 4.7).  
 
Table 4.7: CR interactions at the synapse. 
Protein Gene Accession Unique 
Peptides 
Actin, cytoplasmic 1 Actb IPI00110850 6 
Sodium/potassium-transporting ATPase subunitalpha-
3 
Atp1a3 IPI00122048 10 
complement C1q subcomponent subunit C precursor C1qc IPI00788462 3 
Clathrin heavy chain 1 Cltc IPI00169916 5 
Cathepsin B Ctsb IPI00113517 2 
Isoform 3 of Dynamin-1 Dnm1 IPI00465648 2 
Dihydropyrimidinase-related protein 2 Dpysl 2 IPI00114375 5 
Glyceraldehyde-3-phosphate dehydrogenase 
(Fragment) 
Gm2606 IPI00989722 5 
Isoform Alpha-2 of Guanine nucleotide-binding 
protein G(o) subunit alpha 
Gnao1 IPI00115546 2 
LOC100503273 Hemoglobin subunit epsilon-Y2 Hbb-y IPI00555131 2 
Heat shock cognate 71 kDa protein Hspa8 IPI00323357 6 
Inter-alpha-trypsin inhibitor heavy chain H2 Itih2 IPI00227834 2 
Isoform 5 of Myelin basic protein Mbp  IPI00223378 3 
Microtubule-associated protein 1B Mtap1b IPI00130920 2 
Isoform Ib of Synapsin-1 Syn1 IPI00136372 7 
Isoform Ia of Synapsin-1 Syn1 IPI00649886 10 
Thrombospondin-1 Thbs1 IPI00118413 2 
Tubulin beta-2A chain Tubb2a IPI00338039 11 
Tubulin beta-2C chain Tubb2c IPI00169463 12 
Description: Protein description;  
Gene: Gene coding the identified protein; 
Accession: IPI Accession number; 
Unique peptides: Number of unique peptides used to identify the protein. 
 
 
Using Western blotting, we confirmed the interaction of CR with the synaptic 
proteins synapsin 1 and dynamin 1 (Figure 4.11 A), which are important regulators of 
synaptic vesicle dynamics (Hilfiker et al., 1999, Smillie and Cousin, 2005). 
Interestingly, the interactions were stronger in the presence of EGTA (Figure 4.11 B). 
This suggests Ca2+ may compete with existing interactions or alter the ability of CR to 
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bind other proteins, possibly by altering its conformation or recruiting CR to areas 
other than the pre-synaptic active zone, as suggested by previous results (see Figure 




Figure 4.11: CR co-immunoprecipitates with synaptic proteins. A) Co-immunoprecipitation of CR 
in synaptosomal protein extracts in the presence or either Ca2+ or EGTA, confirms the interactions 
between CR and the synaptic proteins synapsin 1 and dynamin 1. Representative Western blots include 
lanes loaded with a fraction of the original protein extract (Pre-IP), a control experiment performed 
without the addition of CR anti-body (-Ab IP) and three replicates of co-ip experiments (+ Ab IP). B) 
Quantification of fluorescence signals from blots in A revealed that a higher fraction of synapsin 1 and 
dynamin 1, relative to CR levels, co-immunoprecipitated with CR in the presence of EGTA. Bars 
represent mean  SEM, N=3, *p<0.05, **p<0.01 in unpaired two-tailed t-test. 
 
 
4.3.6.  Label-free proteomics in CR-/- synaptosomes 
To further characterize the role of CR in synaptic function and gain clues about 
how it might contribute to synaptic function and stability, we performed Label-free 
proteomics on synaptosomal fractions isolated from CR-/- and CR+/+ mice. Of the 718 
proteins identified by mass spectrometry, 263 were identified by more than 1 unique 
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peptide and 141 had expression levels altered by more than 10% in CR-/- synaptosomes 
when compared to CR+/+ (Figure 4.12). The list of 141 proteins considered for further 
analysis can be found in Table 4.8. 
 
 
Figure 4.12: Label-free proteomics filtering steps. Y-axis represents the fold change in the levels of 
proteins between CR-/- (KO) and CR+/+ (WT) synaptosomes. X-axis columns contain all proteins 
included in the various stages of data analysis. 718 proteins were identified by label-free proteomics 
(Raw data column) and the data-set was filtered to include only proteins identified by more than 1 
unique peptide (>1 peptide column, 263 proteins). Of these, 141 proteins had expression levels altered 
by more than 10% in the KO synaptosomes compared to WT (fold change >1.1 column). 
 
Table 4.8: Proteins altered by more than 10% in CR-/- mice, as identified by label-free proteomics. 
KO/WT 
ratio 





-4.340 Calretinin  Calb2 Q08331 8 460.97 
-1.630 ATP synthase subunit delta, 
mitochondrial  
Atp5d Q9D3D9 2 100.39 
-1.473 Neurocalcin-delta  Ncald Q91X97 3 155.52 
-1.469 Fatty acid synthase  Fasn P19096 2 79.33 
-1.429 Calcium-binding 
mitochondrial carrier protein 
Aralar1  
Slc25a12 Q8BH59 6 398.36 
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-1.415 Vesicle-associated membrane 
protein-associated protein A  
Vapa Q9WV55 2 79.75 
-1.400 Electrogenic sodium 
bicarbonate cotransporter 1  
Slc4a4 O88343 2 77.97 
-1.365 Tubulin beta-2A chain  Tubb2a Q7TMM9 3 185.54 
-1.316 Reticulon-3  Rtn3 Q9ES97 2 151.45 
-1.299 Glucose-6-phosphate 
isomerase  
Gpi P06745 2 81.23 
-1.281 AP-2 complex subunit mu  Ap2m1 P84091 2 91.01 
-1.271 Vacuolar protein sorting-
associated protein 35  
Vps35 Q9EQH3 2 198.66 
-1.269 NADH dehydrogenase 
[ubiquinone] iron-sulfur 
protein 2, mitochondrial  
Ndufs2 Q91WD5 4 250.22 
-1.264 Glutathione S-transferase Mu 
1  
Gstm1 P10649 3 238.22 
-1.262 AP-2 complex subunit alpha-2  Ap2a2 P17427 3 228.46 
-1.260 Calcium/calmodulin-
dependent protein kinase type 
II subunit alpha  
Camk2a P11798 6 383.51 
-1.255 Synaptic vesicle glycoprotein 
2A  
Sv2a Q9JIS5 2 77.06 
-1.253 Dynamin-1-like protein  Dnm1l Q8K1M6 3 232.21 
-1.238 14-3-3 protein gamma  Ywhag P61982 2 83.87 
-1.238 Rab GDP dissociation 
inhibitor alpha  
Gdi1 P50396 5 352.86 
-1.237 Heat shock 70 kDa protein 1B  Hspa1b P17879 2 123.07 
-1.236 Immunoglobulin superfamily 
member 8  
Igsf8 Q8R366 2 117.71 
-1.231 Plexin-A4  Plxna4 Q80UG2 2 104.62 
-1.228 Succinate dehydrogenase 
[ubiquinone] iron-sulfur 
subunit, mitochondrial  
Sdhb Q9CQA3 2 120.12 
-1.228 Trafficking protein particle 
complex subunit 4  
Trappc4 Q9ES56 2 92.79 
-1.225 Protein piccolo  Pclo Q9QYX7 2 114.48 
-1.225 Glutamate receptor ionotropic, 
NMDA 2B  
Grin2b Q01097 2 91.95 
-1.224 Citrate synthase, 
mitochondrial  
Cs Q9CZU6 7 389.69 
-1.221 Cytochrome c oxidase subunit 
5A, mitochondrial  
Cox5a P12787 3 173.32 
-1.212 Neurofilament heavy 
polypeptide  
Nefh P19246 2 91.97 
-1.208 1-phosphatidylinositol 4,5-
bisphosphate 
phosphodiesterase beta-1  
Plcb1 Q9Z1B3 3 148.66 
-1.207 Calcineurin subunit B type 1  Ppp3r1 Q63810 2 125.78 
-1.206 Nucleosome assembly protein 
1-like 1  
Nap1l1 P28656 2 137.95 
-1.206 Glutathione S-transferase P 1  Gstp1 P19157 2 110.25 
-1.199 Cytoplasmic FMR1-
interacting protein 2  






Slc25a11 Q9CR62 3 137.11 
-1.197 Neuroplastin  Nptn P97300 2 79.2 
-1.196 Heat shock protein 105 kDa  Hsph1 Q61699 5 362.31 
-1.195 Ubiquitin carboxyl-terminal 
hydrolase isozyme L3  
Uchl3 Q9JKB1 2 109.08 
-1.194 Leucine-rich PPR motif-
containing protein, 
mitochondrial  




Abat P61922 6 306.77 
-1.189 MICOS complex subunit 
Mic60  
Immt Q8CAQ8 3 150.01 
-1.187 Neurofilament medium 
polypeptide  
Nefm P08553 5 347.7 
-1.183 4F2 cell-surface antigen heavy 
chain  
Slc3a2 P10852 4 202.53 
-1.178 Endoplasmic reticulum 
resident protein 29  
Erp29 P57759 2 75.33 
-1.177 NADH dehydrogenase 
[ubiquinone] iron-sulfur 
protein 3, mitochondrial  
Ndufs3 Q9DCT2 3 199.52 
-1.176 Macrophage migration 
inhibitory factor  
Mif P34884 2 131.29 
-1.176 V-type proton ATPase 116 
kDa subunit a isoform 1  
Atp6v0a1 Q9Z1G4 3 196.52 
-1.175 T-complex protein 1 subunit 
alpha  
Tcp1 P11983 2 97.54 
-1.172 Heat shock 70 kDa protein 
12A  
Hspa12a Q8K0U4 2 97.7 
-1.172 V-type proton ATPase subunit 
d 1  
Atp6v0d1 P51863 2 152.99 
-1.166 Serine/threonine-protein 
kinase PAK 3  
Pak3 Q61036 2 108.76 
-1.166 T-complex protein 1 subunit 
delta  
Cct4 P80315 2 148.57 
-1.165 Protein NDRG2  Ndrg2 Q9QYG0 2 89.11 
-1.164 Dihydropyrimidinase-related 
protein 5  
Dpysl5 Q9EQF6 2 83.05 
-1.162 Ubiquitin-like modifier-
activating enzyme 1  
Uba1 Q02053 3 189.85 
-1.159 Casein kinase II subunit alpha  Csnk2a1 Q60737 3 167.86 
-1.159 Actin, cytoplasmic 1  Actb P60710 5 320.23 
-1.156 Nucleoside diphosphate 
kinase B  
Nme2 Q01768 2 177.17 
-1.155 Cytoplasmic dynein 1 heavy 
chain 1  
Dync1h1 Q9JHU4 8 414.44 
-1.155 Sodium/calcium exchanger 1  Slc8a1 P70414 2 125.14 
-1.152 Glial fibrillary acidic protein  Gfap P03995 2 104.87 
-1.150 Stress-induced-
phosphoprotein 1  
Stip1 Q60864 7 401.04 
-1.148 Endoplasmin  Hsp90b1 P08113 2 158.22 
-1.147 Alpha-adducin  Add1 Q9QYC0 2 102.22 
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-1.144 Protein kinase C and casein 
kinase substrate in neurons 
protein 1  
Pacsin1 Q61644 2 75.17 
-1.143 Synaptopodin  Synpo Q8CC35 2 93.14 
-1.141 Heat shock protein HSP 90-
alpha  
Hsp90aa1 P07901 10 496.68 
-1.141 Catenin delta-2  Ctnnd2 O35927 2 105.36 
-1.140 ATP-citrate synthase  Acly Q91V92 3 160.48 
-1.138 Neurofilament light 
polypeptide  
Nefl P08551 11 693.1 
-1.137 78 kDa glucose-regulated 
protein  
Hspa5 P20029 7 488.49 
-1.135 Catenin alpha-2  Ctnna2 Q61301 4 258.12 
-1.135 Tumor protein p63-regulated 
gene 1-like protein  
Tprg1l Q9DBS2 2 81.76 
-1.133 Serine/threonine-protein 
phosphatase 2A 65 kDa 
regulatory subunit A alpha 
isoform  
Ppp2r1a Q76MZ3 4 170.65 
-1.133 NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 12  
Ndufa12 Q7TMF3 2 123.94 
-1.129 ATP synthase subunit O, 
mitochondrial  
Atp5o Q9DB20 4 276.74 
-1.125 Protein disulfide-isomerase 
A3  
Pdia3 P27773 2 94.75 
-1.123 Calnexin  Canx P35564 2 151.84 
-1.120 ADP-ribosylation factor 5  Arf5 P84084 3 202.89 
-1.120 Glutamate receptor 2  Gria2 P23819 2 147.75 
-1.119 Alpha-actinin-1  Actn1 Q7TPR4 3 214.65 
-1.119 Alpha-internexin  Ina P46660 7 488.54 
-1.118 Stress-70 protein, 
mitochondrial  
Hspa9 P38647 4 391.5 
-1.116 Septin-9  Sept9 Q80UG5 2 118.68 
-1.116 Spectrin beta chain, non-
erythrocytic 1  
Sptbn1 Q62261 15 806.7 
-1.115 14-3-3 protein eta  Ywhah P68510 2 142.17 
-1.114 Dynamin-1  Dnm1 P39053 3 164.25 
-1.114 Plectin  Plec Q9QXS1 5 294.42 
-1.114 Reticulon-1  Rtn1 Q8K0T0 2 124.29 
-1.113 Syntaxin-binding protein 1  Stxbp1 O08599 9 670.3 
-1.112 Beta-centractin  Actr1b Q8R5C5 3 220.12 
-1.112 Ras/Rap GTPase-activating 
protein SynGAP  
Syngap1 F6SEU4 3 162.33 
-1.112 Ganglioside-induced 
differentiation-associated 
protein 1  
Gdap1 O88741 2 81.87 
-1.111 Guanine nucleotide-binding 
protein G(o) subunit alpha  
Gnao1 P18872 2 145.14 
-1.111 Microtubule-associated 
protein 2  
Map2 P20357 6 390.1 
-1.110 Adenylate kinase isoenzyme 1  Ak1 Q9R0Y5 2 122.56 
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-1.110 F-actin-capping protein 
subunit beta  
Capzb P47757 2 105.56 
-1.108 Succinyl-CoA ligase [ADP-
forming] subunit beta, 
mitochondrial  
Sucla2 Q9Z2I9 4 241.99 
-1.108 Creatine kinase B-type  Ckb Q04447 4 281.26 
-1.107 Syntaxin-1B  Stx1b P61264 5 401.63 
-1.106 Sarcoplasmic/endoplasmic 
reticulum calcium ATPase 2  
Atp2a2 O55143 4 260 
-1.105 Myosin-10  Myh10 Q61879 4 289.79 
-1.104 Sorting and assembly 
machinery component 50 
homolog  
Samm50 Q8BGH2 3 156.87 
-1.104 Pyruvate kinase PKM  Pkm P52480 5 361.44 
-1.103 Sodium/potassium-
transporting ATPase subunit 
alpha-3  
Atp1a3 Q6PIC6 8 474.95 
-1.102 ADP/ATP translocase 1  Slc25a4 P48962 6 470.75 
-1.102 Tubulin beta-3 chain  Tubb3 Q9ERD7 5 350.43 
-1.102 Leucine-rich glioma-
inactivated protein 1  
Lgi1 Q9JIA1 2 88.53 
1.105 NADH dehydrogenase 
[ubiquinone] 1 beta 
subcomplex subunit 7  
Ndufb7 Q9CR61 2 108.21 
1.105 Microtubule-associated 
protein tau  
Mapt P10637 2 77.15 
1.106 Pyruvate dehydrogenase E1 
component subunit alpha, 
somatic form, mitochondrial  
Pdha1 P35486 4 173.63 
1.107 2',3'-cyclic-nucleotide 3'-
phosphodiesterase  
Cnp P16330 7 404.16 
1.111 Trifunctional enzyme subunit 
alpha, mitochondrial  
Hadha Q8BMS1 5 282.91 
1.116 Fatty acid-binding protein, 
epidermal  
Fabp5 Q05816 2 93.82 
1.122 Stathmin  Stmn1 P54227 2 119.28 
1.123 Ubiquitin-40S ribosomal 
protein S27a  
Rps27a P62983 2 73.51 
1.125 Alpha-enolase  Eno1 P17182 2 120.49 
1.126 Carbonic anhydrase 2  Ca2 P00920 3 150.22 
1.137 Cytochrome b-c1 complex 
subunit 1, mitochondrial  
Uqcrc1 Q9CZ13 2 118.94 
1.138 Peptidyl-prolyl cis-trans 
isomerase A  




Mthfd1l Q3V3R1 3 255.65 
1.152 Very long-chain specific acyl-
CoA dehydrogenase, 
mitochondrial  
Acadvl P50544 3 140.23 
1.155 Breast carcinoma-amplified 
sequence 1 homolog  
Bcas1 Q80YN3 3 140.93 
1.161 Acyl-CoA synthetase family 
member 2, mitochondrial  
Acsf2 Q8VCW8 2 105.98 




dehydrogenase, mitochondrial  
Bdh1 Q80XN0 2 90.24 
1.172 Secretogranin-2  Scg2 Q03517 2 110.02 
1.172 Long-chain-fatty-acid--CoA 
ligase ACSBG1  
Acsbg1 Q99PU5 2 118.99 
1.200 ATPase inhibitor, 
mitochondrial  
Atpif1 O35143 4 174.75 
1.205 Ectonucleotide 
pyrophosphatase/phosphodiest
erase family member 6  
Enpp6 Q8BGN3 2 99.38 
1.266 Myelin basic protein  Mbp P04370 2 72.78 
1.281 ATP synthase-coupling factor 
6, mitochondrial  
Atp5j P97450 4 166.86 
1.288 Acetyl-CoA acetyltransferase, 
mitochondrial  
Acat1 Q8QZT1 3 154.92 
1.290 Keratin, type II cytoskeletal 
1b  
Krt77 Q6IFZ6 2 118.92 
1.320 Histone H4  Hist1h4a P62806 4 196.54 
1.324 Endophilin-A1  Sh3gl2 Q62420 2 108.28 
1.362 NADH dehydrogenase 
[ubiquinone] iron-sulfur 
protein 6, mitochondrial  
Ndufs6 P52503 6 458.14 
1.384 cAMP-dependent protein 
kinase catalytic subunit alpha  
Prkaca P05132 2 102.6 
1.673 Keratin, type I cytoskeletal 10  Krt10 P02535 3 155.88 
6.383 Somatotropin  Gh1 P06880 2 156.85 
KO/WT Ratio: Ratio between the expression levels of a given protein in CR-/- mice compared to CR+/+; 
Description: Protein description;  
Gene: Gene coding the identified protein; 
UniProt Accession: UniProt Accession number; 
Unique peptides: Number of unique peptides used to identify the protein; 
Score: Confidence score. 
 
To highlight the pathways and functional categories associated with loss of CR, 
we performed pathway analysis using the IPA software on the filtered proteomics data-
set. IPA identified alterations in the CR-/- proteome relevant to several neurological 
and neuromuscular disorders, including Huntington’s disease, Alzheimer’s disease 
and motor neuron diseases (Table 4.9). Cellular functions affected by loss of CR 
included cell death, microtubule dynamics and synaptic transmission (Table 4.9). The 
full list of functions and diseases identified by IPA, including the list of proteins 
identified for each category, can be found in Appendix 1.  
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In order to identify established molecular pathways affected in CR-/- mice, we 
used the IPA Canonical Pathways tool. Interestingly, the top pathways identified 
included mitochondrial dysfunction, Huntington’s disease, long-term potentiation and 
clathrin-mediated endocytosis (Table 4.10). 
 
Table 4.9: Selection of top diseases and cellular functions associated with the proteomic changes 
in CR-/- mice, as identified by IPA. 
IPA Diseases Annotation p-Value IPA Functions Annotation p-Value 
Disorder of basal ganglia 1.20E-23 organization of cytoskeleton 3.26E-18 
Neuromuscular disease 5.70E-22 cell death 6.20E-16 
Movement Disorders 7.03E-22 microtubule dynamics 4.02E-15 
Dyskinesia 1.98E-15 morphology of cells 7.46E-14 
Neurological signs 2.21E-15 transport of molecule 2.76E-12 
Huntington's Disease 1.33E-14 neurotransmission 1.43E-11 
Tauopathy 4.64E-11 proliferation of cells 2.58E-09 
Progressive motor neuropathy 2.93E-10 synaptic transmission 6.38E-09 
Alzheimer's disease 6.65E-10 differentiation of cells 8.07E-09 
Hereditary myopathy 1.98E-09 dendritic growth/branching 9.99E-09 
Autosomal dominant disease 3.30E-09 accumulation of filaments 1.22E-08 














Table 4.10: Top canonical pathways associated with the proteomic changes in CR-/- mice, as 
identified by IPA. 
IPA Canonical Pathways p-value Molecules 
Oxidative Phosphorylation 2.7E-10 ATP5J,SDHB,ATP5D,NDUFB7,ATP5O,COX5A,NDUFS6,NDUF
A12,NDUFS2,UQCRC1,NDUFS3 
Mitochondrial Dysfunction 3.0E-09 ATP5J,PDHA1,SDHB,ATP5D,NDUFB7,ATP5O,COX5A,NDUFS
6,NDUFA12,NDUFS2,UQCRC1,NDUFS3 







Unfolded protein response 1.2E-06 HSP90B1,HSPH1,HSPA1B,HSPA9,CANX,HSPA5 
14-3-3-mediated Signaling 2.0E-06 TUBB3,YWHAG,YWHAH,PDIA3,MAPT,TUBB2A,PLCB1,GFA
P 




Synaptic Long Term 
Potentiation 
1.8E-05 GRIN2B,CAMK2A,PDIA3,PPP3R1,GRIA2,PRKACA,PLCB1 
Lipid Antigen Presentation 
by CD1 
2.1E-05 AP2M1,PDIA3,CANX,AP2A2 







To complement the IPA analysis and help narrow down the most relevant pathways 
affected by loss of CR in synapses, we performed a second in silico analysis using the 
DAVID web tool. Functional Annotation Cluster analysis revealed an enrichment in 
proteins associated with structures such as vesicles, mitochondria and cytoskeleton (  
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Table 4.11). Pathways involved in stress response, synaptic transmission and 
mitochondria oxidative phosphorylation were also found to be enriched in the data-
set. Mapping of the data to established KEGG pathways (Table 4.12) revealed 
proteomic alterations relevant to neurodegenerative diseases such as Parkinson’s 
disease, Alzheimer’s disease, Huntington’s disease and Amyotrophic Lateral 
Sclerosis. In addition, mitochondrial and synaptic pathways, such as those involved in 




Table 4.11: Top functional clusters associated with the proteomic changes in CR-/- mice, as 
identified by DAVID analysis. 
DAVID Functional Annotation Cluster p-value 
Vesicle 2.57E-10 
Mitochondria 1.38E-08 
Nucleotide binding 1.00E-05 
Cytoskeletal part 4.47E-05 
Stress response 6.92E-05 
Synaptic transmission 7.24E-05 
Oxidative phosphorylation 1.41E-04 
Neurofilament 1.70E-04 
Chaperone 3.02E-04 
ATP metabolic process 7.08E-04 
 
 
Table 4.12: Top KEGG pathways associated with the proteomic changes in CR-/- mice, as 
identified by DAVID analysis. 
DAVID KEGG Pathways p-value Molecules 
Parkinson's disease 6.4E-08 ATP5J COX5A NDUFB7 UQCRC1 ATP5O SLC25A4 RPS27A 
SDHB UBA1 ATP5D NDUFS3 NDUFS2 SEPT5 NDUFS6 
Alzheimer's disease 3.9E-07 MAPT ATP5J GRIN2B COX5A NDUFB7 UQCRC1 ATP5O 
PLCB1 ATP2A2 SDHB PPP3R1 ATP5D NDUFS3 NDUFS2 
Huntington's disease 4.2E-07 ATP5J GRIN2B AP2M1 COX5A NDUFB7 UQCRC1 ATP5O 
SLC25A4 PLCB1 AP2A2 SDHB ATP5D NDUFS3 NDUFS2 
Oxidative phosphorylation 3.0E-06 ATP6V0D1 ATP5J SDHB NDUFB7 COX5A ATP5D ATP6V0A1 
NDUFS2 NDUFS3 UQCRC1 NDUFS6 ATP5O 
Citrate cycle (TCA cycle) 1.1E-03 SDHB ACLY CS SUCLA2 PDHA1  
Amyotrophic lateral 
sclerosis (ALS) 
1.5E-03 GRIA2 NEFM NEFL GRIN2B NEFH PPP3R1 
Butanoate metabolism 2.1E-03 BDH1 ACAT1 ABAT HADHA PDHA1 
Long-term potentiation 3.8E-03 GRIA2 CAMK2A PRKACA PLCB1 GRIN2B PPP3R1 
Tight junction 3.9E-03 ACTB PPP2R1A CSNK2A1 VAPA SPTBN1 ACTN1 CTNNA2 
MYH10  
Propanoate metabolism 9.9E-03 ACAT1 ABAT HADHA SUCLA2  
Prion diseases 1.5E-02 STIP1 PRKACA HSPA5 HSPA1B  
 
Altogether, IPA and DAVID analysis confirmed the involvement of CR in 
synaptic function and highlighted a role for the protein in mitochondria function and 
in neurodegenerative conditions, particularly Huntington’s disease and neuromuscular 
disorders. In this thesis, we have previously shown CR is important for the 
neuromuscular system, in particular to Wallerian degeneration (see Figure 4.4), and 
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there is published evidence linking CR to Huntington’s disease (Dong et al., 2012). 
Therefore, we decided to focus on the validation of the proteomics results associated 
with other relevant cellular functions, including how CR may influence synaptic 
transmission and mitochondria dysfunction. 
 
4.3.7. Loss of calretinin increases cell death by oxidative stress 
Pathway analysis using IPA indicated the canonical pathway of mitochondrial 
dysfunction was significantly affected in CR-/- mice (Table 4.10). A prediction 
analysis, performed on IPA, revealed that CR-/- mice are likely to be more sensitive to 
oxidative stress than CR+/+ mice (Appendix II). To test this hypothesis, we knocked-
down (KD) CR in cultured hippocampal neurons and applied an oxidative stress insult. 
In agreement with the proteomics results, a 20-30% KD of CR resulted in increased 
cell death caused by acute exposure to H2O2 (Figure 4.13 B-D). These results indicate 
that CR plays an important role in the control of oxidative stress and that even a small 





Figure 4.13: Loss of CR causes mitochondria dysfunction and oxidative stress. A) Quantification 
and representative western blots from cell lysates from control and CR KD cultures. 48h KD of CR in 
hippocampal neurons resulted in a ~25% decrease in the expression of CR. Bars represent mean  SEM, 
N=6 across two independent cultures, **p<0.01 unpaired two-tailed t-test. B) Representative images 
from control and CR KD hippocampal neurons exposed to H2O2. DAPI staining (blue) reveals that CR 
KD cells are more sensitive to H2O2 treatment. Note the increase in the fraction of dead cells (collapsed 
nuclei, indicated by arrow heads) when CR KD cells are exposed to 100 µM H2O2, but not when control 
cells are subjected to the same treatment. Scale bar = 50 µM. C) Quantification of % dead cells from 
experiments in C. Bars represent mean  SEM, N=6 across two independent cultures, **p<0.01 in two-





4.3.8. Exploring the effect of calretinin on synaptic function 
Given the dynamic behaviour of CR during synaptic activity and the strong 
indication that synaptic functions are affected in CR-/- mice, we wanted to investigate 
whether manipulating intracellular levels of CR would lead to changes in the dynamics 
of synaptic vesicle release and recycling. Therefore, we performed Synaptophysin-
pHluorin (SypHy; Figure 4.14) experiments in hippocampal cultures where CR had 
been overexpressed (OE) or knocked-down (KD). 
 
 
Figure 4.14: Use of pHluorins for the study of synaptic function. pHluorins are genetically encoded 
fluorescent probes that facilitate the study of neurotransmission in live neurons (Burrone et al., 2006, 
Sankaranarayanan et al., 2000). pHluorins consist of a synaptic vesicle protein, such as synaptophysin, 
modified to express an intra-luminal pH-sensitive GFP tag. Due to the difference in pH between the 
lumen of synaptic vesicles and the extracellular medium, pHluorins are used to infer the location of the 
synaptic protein they encode from fluorescent signals. When in synaptic vesicles, which have an acidic 
lumen (pH 5.5), pHluorins are quenched (1). However, during the fusion of synaptic vesicles with the 
plasma membrane after an action potential, pHluorins are exposed to extracellular medium (pH 7.4) and 
fluoresce (2). Upon vesicle retrieval and reacidification, pHluorins are once more quenched (3). The 
kinetics of increase and decrease in pHluorin fluorescent signals thus correlates with the kinetics of exo 




48h KD of CR lead to a 20-30% decrease in the expression levels of CR, 
consistently across cultures (Figure 4.13 B). SypHy experiments performed in KD and 
control treated cultures resulted in identical F/F0 traces during a stimulation with 300 
action potentials, at 10Hz (Figure 4.15). In addition, the peak fluorescence was 
comparable between the two conditions (Figure 4.15 C), indicating KD of CR did not 
produce an observable effect on the extent of exocytosis. When traces were normalized 
to the peak fluorescence for each condition, which allows us to look at the kinetics of 
SypHy retrieval, the traces and time constants () of vesicle retrieval following 
stimulation were identical between CR KD and control neurons (Figure 4.15 D, E). 
This suggests that modest KD of CR did not affect the kinetics of endocytosis. A 
similar experiment performed in cultures in which CR was OE, revealed the 
characteristic pattern of SypHy fluorescence during and following stimulation (Figure 
4.16 A, B). The peak fluorescence was similar between cultures treated with CR OE 
or an empty vector (Figure 4.16 C), as was the kinetics of vesicle retrieval (Figure 4.16 
D, E). 
Overall, these results indicate that OE and modest KD of CR was not sufficient 
to induce overt effects on the kinetics of exocytosis or endocytosis in hippocampal 
nerve terminals during a single stimulation of the readily releasable pool of synaptic 
vesicles. Nevertheless, these results should be interpreted with care as they don’t 
comprehensively cover the range of synaptic activity patterns characteristic of 





Figure 4.15: Reduced levels of CR do not affect synaptic vesicle exocytosis or endocytosis. A) False 
colour images from SypHy fluorescence in control and CR KD neurons before (Rest) and after 
(Stimulation) stimulation with 300 action potentials, and over 2 min after stimulation (Recovery). Arrow 
heads indicate nerve terminals. Scale bar = 5 µm B) SypHy traces normalised to the maximum 
fluorescence obtained with NH4Cl. Traces represent F/F0 mean  SEM, N=4, p>0.05 two-way 
ANOVA with Holm-Šídák post-test. C) Peak fluorescence during stimulation. F/F0 mean  SEM, 
N=4, p>0.05 unpaired two-tailed t-test. D) F/F0 traces normalized to peak fluorescence. Traces 
represent mean  SEM, N=4, p>0.05 two-way ANOVA with Holm-Šídák post-test. E) Time constant 




Figure 4.16: Increased levels of CR do not overtly affect synaptic vesicle exocytosis or endocytosis. 
A) False colour images from SypHy fluorescence in control and CR OE neurons before (Rest) and after 
(Stimulation) stimulation with 300 action potentials, and over 2 min after stimulation (Recovery). Arrow 
heads indicate nerve terminals. Scale bar = 5 µm. B) SypHy traces normalised to the maximum 
fluorescence obtained with NH4Cl. Traces represent F/F0 mean  SEM, N=5, p>0.05 two-way 
ANOVA with Holm-Šídák post-test. C) Peak fluorescence during stimulation. F/F0 mean  SEM, 
N=5, p>0.05 unpaired two-tailed t-test. D) F/F0 traces normalized to peak fluorescence. Traces 
represent mean  SEM, N=5, p>0.05 two-way ANOVA with Holm-Šídák post-test. E) Time constant 




4.4.1. Overview of results 
CR is a poorly characterized Ca2+ binding protein, primarily known for its high 
levels of expression in a subpopulation of interneurons. However, there have been 
indications in the literature pointing towards a broader role for CR in the nervous 
system and, in particular, in neurodegenerative pathways and synaptic stability. In this 
thesis, we had already shown that calretinin is upregulated in synapses from areas of 
the brain from CLN5 Batten sheep that are undergoing degeneration (Chapter 3). Here, 
we extended the influence of CR to the peripheral nervous system and demonstrated 
that deletion of CR in mice delays the onset of Wallerian degeneration in the peripheral 
nervous system. In addition, we extended the body of knowledge regarding CR’s 
expression and function in the mouse nervous system. In particular, we have shown 
CR is not exclusively found in interneurons but that it is also expressed at lower levels 
in hippocampal neurons and motor axons and synapses from the peripheral nervous 
system. In addition, in cultured mouse hippocampal neurons, CR is enriched in 
synaptic terminals, where it has a dynamic role and responds to activity-dependent 
stimulus. In agreement with our experimental findings throughout the chapter, 
proteomics analysis of synaptosomes from CR-/- mice revealed a significant role of CR 
in synaptic and mitochondrial function, in neurodegenerative conditions, such as 
Huntington’s disease, and in neuromuscular disorders. Altogether, we have established 
that CR is involved in neurodegenerative pathways at the synapse and that it plays an 




4.4.2. CR beyond the interneuron 
CR has so far been regarded as merely a protein enriched in a subpopulation of 
interneurons. However, a recent study has demonstrated the presence of CR in 
synapses from the mouse corticostriatal system and in Drosophila olfactory receptor 
neurons (Wishart et al., 2012). In this chapter, we have shown CR is highly expressed 
in tissues from the central and peripheral nervous systems of the mouse (Figure 4.1). 
In particular, CR is enriched in synaptic sites and is present in motor axons and 
neuromuscular synapses (Figure 4.3 and Figure 4.8). These findings have important 
consequences for the study of CR, as they demonstrate that CR is not expressed only 
in central interneurons and highlight the importance of regarding CR as a potential 
modulator of neuronal function throughout the CNS and PNS. 
 
4.4.3. CR and Wallerian degeneration 
The fact that CR is present in motor axons and neuromuscular synapses (Figure 
4.3) and the previous findings from (Wishart et al., 2012) indicating loss of CR delayed 
axonal degeneration in Drosophila, prompted us to explore the consequences of CR 
deletion to Wallerian degeneration in the mouse PNS. We found that CR-/- mice 
presented a delay in the initial phase of axonal degeneration, as assessed by the 
preservation of neurofilament structures (Figure 4.4). The initial breakdown of axonal 
connections was delayed by approximately 3 h, compared to CR+/+ mice. From then 
on Wallerian degeneration progressed along a similar, albeit delayed, time-course 
independently of the presence or absence of CR. Thus, CR seems to be particularly 
important in the initial stages of Wallerian degeneration in the PNS. The mechanisms 
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leading to the delay in Wallerian degeneration in CR-/- mice are not straightforward. 
Proteomics on CNS synaptosomes indicated loss of CR leads to changes in several 
cytoskeletal components and protein quality control mechanisms, including proteins 
of the ubiquitin proteasome system (eg. UCHL3 and UBA1). The combined functional 
effects of these changes are difficult to predict and to extrapolate to the PNS, although 
it is conceivable they could culminate in a delay of microtubule disassembly in CR-/- 
motor axons.  
Further experiments are needed to fully understand in which capacity CR 
influences Wallerian degeneration in the PNS. Nonetheless, these early results are 
encouraging and confirm that CR plays an active role in neurodegenerative pathways. 
In addition, IPA analysis was consistent with loss of CR being associated with several 
neuromuscular and movement disorders (Table 4.9), highlighting the importance of 
further exploring the role of CR in the PNS. 
 
4.4.4. CR and synaptic function 
The finding that CR is enriched at hippocampal synapses is of particular 
interest. It not only provides, for the first time, clear experimental evidence that CR is 
present in synaptic compartments of neurons, but it also shows that CR is particularly 
enriched in glutamatergic terminals (Figure 4.7). In addition, using label-free 
proteomics we identified glutamate receptors as being downregulated in CR-/- 
synaptosomes (Table 4.8). These facts offer clues towards a possible specialization of 
CR to meet the demands of excitatory synapses.  
Triggering synaptic activity in cultured hippocampal neurons, either via K+ or 
electrical stimulation, induced the temporary dispersion of CR from synaptic terminals 
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(Figure 4.9 and Figure 4.10). The reason why this happens in not clear, but it indicates 
that CR is enriched at synaptic sites during rest periods, where it may help maintain 
stable low free Ca2+ levels and interact with synaptic proteins, such as synapsin 1 and 
dynamin 1. The functional consequences of these interactions have yet to be explored. 
The mechanisms leading to the dispersion of CR from synaptic terminals could be 
directly related to Ca2+, since CR changes its conformation and Ca2+-binding 
properties according to the intracellular Ca2+ levels (Arendt et al., 2013, Kuznicki et 
al., 1995). Thus, it is possible that during periods of rest CR acts mainly as Ca2+-sensor 
and is preferentially localised to synaptic sites, where its localisation is possibly 
maintained by interactions with synaptic or cytoskeletal proteins. Upon arrival of an 
action potential, and consequent increase in Ca2+, CR’s conformation may change, 
altering protein-protein interactions, and CR is allowed to diffuse to areas outside the 
active zone, where it may buffer excessive Ca2+. 
Proteomics results revealed an involvement of CR in several steps of pathways 
involved in neurotransmission. There were changes in proteins associated with 
exocytosis (eg. syntaxin 1 and syntaxin binding protein 1), endocytosis (eg. AP2 
complex and dynamin 1), vesicle reacidification (eg. V-ATPase) and post-synaptic 
structures (eg. NMDA and AMPA receptors), which illustrate the broad range of 
influence of CR at the synapse. In addition, signalling proteins, including calcineurin 
and CaMKIIa, which help regulate synaptic function (Colbran and Brown, 2004, 
Marks and McMahon, 1998), were downregulated in CR-/- mice. We performed 
synaptopHluorin experiments in order to try clarify the contribution of CR to synaptic 
transmission (Figure 4.15 and Figure 4.16). However, the experiments were 
inconclusive. Although it was clear that CR is not required for synaptic transmission, 
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as expected from previous publications (Schurmans et al., 1997), we tested only a very 
specific stimulation paradigm, which is meant to stimulate the release of vesicles from 
the readily releasable pool. In addition, our levels of KD and OE might not have been 
sufficient to trigger a phenotype. To fully address possible effects of CR in the synaptic 
vesicle cycle, a more thorough study is therefore needed. Unfortunately, due to time 
constraints and low availability of animals, further synaptoHluorin experiments, 
including experiments in CR-/- mice, were not possible. 
Altogether, the work in this chapter presents novel exciting evidence 
highlighting the enrichment of CR in synaptic terminals, its dynamic behaviour during 
synaptic activity and its contribution to synaptic function pathways.  
 
4.4.5. Further insights into CR’s function from label-free 
proteomics 
The function of CR, besides its calcium buffering capabilities, is very poorly 
understood. Using label-free proteomics we were able to uncover some of the key 
cellular pathways CR might be involved in. Whether these are a direct consequence of 
loss of CR functional interactions or a result of impaired Ca2+ handling, remains to be 
addressed. Nonetheless, our results indicate CR participates, directly or indirectly, in 
important pathways for maintaining neuronal homeostasis. 
 
As expected, one consequence of the loss of CR would be poorer intracellular 
Ca2+ handling, with consequent increases in the vulnerability of cells to Ca2+ overload, 
poorer Ca2+ buffering by the ER and mitochondria, possibly leading to dysfunction in 
these organelles, and impairments in Ca2+-dependent signalling pathways. Indeed, we 
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found several such signalling molecules with altered expression in CR-/- mice, 
including calnexin, calcineurin and CaMKIIa (Table 4.8), as well as impairments in 
mitochondria function (Table 4.10 and Table 4.12). We were particularly interested in 
the proteomic changes in CR-/- mice which were consistent with impairments seen in 
neurodegenerative conditions, including Huntington’s disease, Parkinson’s disease 
and Alzheimer’s disease. Interestingly, the changes associated with these conditions 
were related with alterations in mitochondrial proteins, structural and cytoskeletal 
components and protein quality control mechanisms (Table 4.9 and Table 4.12). As 
previously discussed (see General Introduction), these cellular pathways are important 
for maintaining neuronal and synaptic homeostasis. 
We have shown that reduced levels of CR increased the sensitivity of cells to 
oxidative stress (Figure 4.13). This property of CR is likely to have practical 
consequences for neurodegenerative conditions where mitochondria dysfunction and 
oxidative stress are part of the pathophysiology of the disease (Lin and Beal, 2006). In 
fact, it has previously been shown that overexpression of CR was protective against 
oxidative stress in a cell model of Huntington’s disease (Dong et al., 2012). The 
pathways of ubiquitin-proteasome system and the unfolded protein response are also 
likely to be important for the influence of CR in neurodegeneration. Proteins involved 
in ER function and the unfolded protein response (eg. calnexin and HSPA5/Grp78) are 
down-regulated in CR-/- mice, suggesting an inhibition of the ER unfolded protein 
response responsible for the correct folding of newly secreted proteins (Walter and 
Ron, 2011). On the other hand, components of the ubiquitin proteasome system (eg. 
UBA1 and UCHL3) are similarly down-regulated. A combination of impaired protein 
folding and reduced protein degradation could promote the accumulation of misfolded 
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proteins in CR-/- mice and the formation of intracellular aggregates, with consequences 
for neurodegenerative conditions such as Parkinson’s disease and Huntington’s 
disease (Scheper and Hoozemans, 2015). Similarly, an increase in CR expression, as 
has been shown in CLN5 Batten sheep, could aggravate ER stress and potentiate the 
activation of apoptotic mechanisms (Merksamer and Papa, 2010). 
 
Altogether, the proteomics results highlight the importance of CR across 
several cellular pathways, including synaptic, mitochondria and ER function, as well 
as the regulation of cytoskeletal components. In addition, the overall results in this 
chapter demonstrate that CR is important beyond the interneuron and open several 
routes to better investigate the function of CR and how it contributes to neuronal 






Chapter 5. Identification of sfxn3 as a novel α-
synuclein-dependent mitochondrial protein 
involved in the maintenance of synaptic stability 
5.1. Introduction 
5.1.1. α-synuclein in neurodegenerative disorders 
α-synuclein belongs to a family of proteins primarily expressed in nervous 
tissue, which includes α-, β- and γ-synucleins (Clayton et al., 2007, Pears et al., 2007). 
Due to its involvement in neurodegenerative diseases α-synuclein is the most studied 
protein of the synuclein family. α-synuclein was identified as the non amyloid- 
component of amyloid plaques in Alzheimer’s disease (Iwai et al., 1995, Ueda et al., 
1993) and is the main component of Lewy bodies and Lewy neurites (Baba et al., 1998, 
Mezey et al., 1998). Lewy bodies are abnormal protein inclusions characteristic of a 
group of disorders collectively known as Lewy body diseases or synucleinopathies, 
which include dementia with Lewy bodies, PD and Multiple System Atrophy 
(Pollanen et al., 1993). Moreover, α-synuclein has been implicated as a genetic cause 
of Parkinson’s disease, with mutations and multiplications of the SNCA gene that 
encodes α-synuclein being associated with familial cases of the disease (Chartier-
Harlin et al., 2004, Krüger et al., 1998, Polymeropoulos et al., 1997, Singleton et al., 







5.1.2. Structure of α-synuclein 
α-synuclein is a 140 amino acid protein encoded by the SNCA gene. It presents 
a dynamic conformational structure which is believed to contribute to its pathological 
features (Burre et al., 2013, Mor et al., 2016). There are three well defined domains in 
the sequence of α-synuclein (Figure 5.1 A): 1) an N-terminal region with membrane-
binding properties responsible for α-synuclein binding to synaptic vesicles and 
mitochondrial membranes; 2) a central domain which includes the non-amyloid--
component (NAC) sequence required for protein aggregation; 3) and a soluble acidic 
C-terminal region through which α-synuclein interacts with other proteins (Mor et al., 
2016). 
Due to its conformational plasticity, α-synuclein has been shown to adopt 
several conformations and to assemble in multimeric and fibril-like structures (Figure 
5.1 B). α-synuclein is natively unfolded but has the ability to bind lipid membranes 
and other proteins. These interactions, required for the physiological functions of the 
protein, alter its structure and stabilize it in monomeric or functional multimeric forms 
(Bartels et al., 2011, Burre et al., 2014, Davidson et al., 1998, Wang et al., 2011). 
However, when α-synuclein is predominantly unbound in solution, it readily forms 
oligomers and aggregates over time (Burre et al., 2013). In addition, point mutations 
and post-translation modifications, such as phosphorylation and ubiquitination, affect 
the stability of the protein and potentiate the formation of aggregation-competent 
species (Burre et al., 2012, Lee et al., 2008a, Ono et al., 2011, Paleologou et al., 2010). 
α-synuclein oligomers act as seeds for the aggregation process and have the ability to 
spread between cells in a prion-like manner (Luk et al., 2012, Luk et al., 2009, Nonaka 
et al., 2010). As oligomers increase in size, they eventually form amyloid-like fibril 
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structures and aggregate into large protein inclusions, giving rise to Lewy Bodies (Mor 
et al., 2016). 
The high conformational flexibility of α-synuclein makes it prone to being 
structurally unstable, with devastating consequences for cell homeostasis (see below). 
As a result, it is believed that the levels of α-synuclein need to be tightly regulated, 
through control of protein synthesis and degradation, so as to avoid instigating the 
formation of toxic species (Lashuel et al., 2013, Mor et al., 2016). 
 
 
Figure 5.1: Conformation of α-synuclein. A) There are three main regions in the α-synuclein protein: 
i) the N-terminus of α-synuclein adopts an α-helix conformation upon binding to lipid membranes; ii) 
the NAC region can adopt a –sheet structure and is required and sufficient for the formation of protein 
aggregates; iii) the C-terminal region is unstructured and participates in protein-protein interactions. 
Image adapted from (Vamvaca et al., 2009). B) α-synuclein can adopt physiological and pathological 
conformations. Unfolded monomers and membrane-bound multimers are associated with the 
physiological functions of the protein. –sheet oligomers, amyloid fibrils and Lewy bodies are 
considered pathological species as they are associated with the neurotoxic effects of α-synuclein. Image 




5.1.3. Mechanisms of α-synuclein toxicity 
The strong evidence indicative of a detrimental effect of α-synuclein inclusions 
in vivo lead to the study of the toxicity of its overexpression and aggregation. It has 
been demonstrated that accumulation of α-synuclein aggregates is neurotoxic both in 
vivo and in vitro, with misfolded α-synuclein interfering with various cellular 
mechanisms, such as mitochondrial function, proteasomal activity, vesicle trafficking 
and synaptic transmission (Burre, 2015, Haelterman et al., 2014, Lashuel et al., 2013, 
Stefanis, 2012).  
Although a hallmark of the neurodegenerative processes in synucleinopathies, 
the presence of α-synuclein inclusions in neurons is not the only cause of pathology. 
In fact, several studies indicate that soluble oligomers of α-synuclein are more toxic 
than insoluble aggregates. For instance, stereotaxic lentiviral injection of α-synuclein 
variants prone to the formation of oligomers, rather than fibrils, results in more severe 
loss of dopaminergic neurons in rat models (Winner et al., 2011), modest 
overexpression of α-synuclein without formation of inclusions impairs synaptic 
functions (Nemani et al., 2010, Scott et al., 2010), and soluble α-synuclein oligomers, 
but not fibrils, promote dysfunction of mitochondrial complex I (Luth et al., 2014). 
From a disease-related perspective, it has been proposed that Lewy bodies may 
develop as a protective mechanism from the damaging effects of misfolded α-
synuclein. However, not only fibrils but also monomeric α-synuclein is sequestered 
into Lewy bodies, which may in turn aggravate neuronal dysfunction by loss of 
physiological pools of the protein (Kollmann et al., 2013, Qiao et al., 2008). Thus, it 
is important we clarify not only the mechanisms associated with the pathological 
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features of α-synuclein, but also how, in its functional form, this protein might 
contribute to neuronal homeostasis. 
 
5.1.4. α-synuclein contributes to synaptic function and stability 
Knockout studies in mice revealed that α-synuclein is not essential for the 
structural development of the CNS nor required for synaptic transmission (Abeliovich 
et al., 2000, Cabin et al., 2002). Instead, it seems to play a more long-term modulatory 
role, being involved in the regulation and maintenance of synaptic function. In nerve 
terminals, α-synuclein contributes to the regulation of synaptic vesicle recycling and 
mobility. Deletion or ablation of α-synuclein expression in mice has been shown to 
impair neurotransmitter release during prolonged repetitive stimulation and to reduce 
the availability of synaptic vesicles from the reserve pool (Cabin et al., 2002, Murphy 
et al., 2000). On the other hand, overexpression of α-synuclein inhibits 
neurotransmission and intersynaptic trafficking of vesicles (Nemani et al., 2010, Scott 
and Roy, 2012). In addition, α-synuclein affects dopamine metabolism. It interacts 
with tyrosine-hydroxylase and acts as a negative regulator of dopamine biosynthesis, 
so that increased levels of α-synuclein result in decreased production of this 
neurotransmitter (Liu et al., 2008, Perez et al., 2002). Moreover, α-synuclein is 
believed to modulate the function of the dopamine transporter DAT, although through 
unknown mechanisms, and to affect the density and activity of the vesicular dopamine 
transporter VMAT2 (Butler et al., 2015, Guo et al., 2008). 
The best characterized synaptic function of α-synuclein is, however, associated 
with its role in the regulation of neurotransmission by promoting SNARE-complex 
assembly (Burre et al., 2010, Chandra et al., 2004b). The chaperone activity of α-
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synuclein seems to be particularly important for neuronal homeostasis, as it rescues 
the extensive neurodegenerative phenotype caused by deletion of CSP-α (Chandra et 
al., 2005), which is mediated by SNAP-25 activity (Sharma et al., 2012). In addition, 
triple knockout of all the proteins from the synuclein family leads to an age-dependent 
neurodegenerative phenotype due to the destabilization of SNARE complexes (Burre 
et al., 2010).   
Further evidence for a neuroprotective role of α-synuclein comes from various 
studies not restricted to its chaperone function. For instance, deficit of α-synuclein 
expression was found to induce nigrostriatal degeneration in vivo (Al-Wandi et al., 
2010, Gorbatyuk et al., 2010), to reduce cell viability in cultured cerebellar granule 
neurons (Monti et al., 2007) and to lead to age-dependent deficits in dopamine 
metabolism (Al-Wandi et al., 2010). In addition, knock-down or loss of α-synuclein 
aggravates the neurodegeneration caused by various stimuli, such as oxidative stress 
(Quilty et al., 2006), 6-hydroxydopamine toxicity (Monti et al., 2007) and even 
transgenic expression of mutant A53T α-synuclein (Cabin et al., 2005).  
 
The evidence supporting the toxicity of α-synuclein overexpression and 
aggregation contrasts with the reports of its neuroprotective action. The dual function 
of α-synuclein suggests a distinct nature of its pathological and physiological 
functions, which is supported by the fact that the amino acid sequences responsible for 
α-synuclein toxicity and chaperone function have been mapped to different regions of 
the protein (Burre et al., 2012). Given the current efforts to develop therapeutic 
strategies that reduce α-synuclein aggregation and/or expression for the treatment of 
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Parkinson’s disease and related disorders it is essential we clarify the physiological 
role of this critical protein at the synapse.  
 
5.1.5. Aim 
α-synuclein is a well known regulator of synaptic stability and its contribution 
not only to the neuropathology of disorders such as Parkinson’s disease, but also to 
global mechanisms impacting on synaptic stability, makes it an extremely significant 
field to study. Importantly, α-synuclein itself is difficult to target therapeutically due 
to its conformational flexibility and to our current poor understanding concerning how 
to achieve a compromise between the physiological and neurotoxic effects of the 
protein (Lashuel et al., 2013). By improving our fundamental understanding about α-
synuclein one might expect to reveal pathways downstream of this protein that 
contribute to the maintenance of synaptic stability. These pathways could, in theory, 
be more attractive targets for developing synaptoprotective therapies. Thus, the aim of 
this chapter was to: 
 Identify new targets of α-synuclein function at the synapse; 
 Explore one downstream target of α-synuclein, sideroflexin 3, and 






5.2. Materials and Methods 
5.2.1. Animals 
C57Bl/6J (α-syn+/+) and C57Bl/6JOlaHsd mice (α-syn-/-), which carry a natural 
α-synuclein deletion (Specht and Schoepfer, 2001), were obtained directly from the 
University of Edinburgh managed rodent colonies. Sfxn3tm1b(KOMP)Wtsi mice (sfxn3-/- 
mice; http://www.mousephenotype.org/data/genes/MGI:2137679) were obtained 
from the Wellcome Trust Sanger Institute Mouse Genetics Project as part of the nPad 
MRC Mouse Consortium, and maintained on a C57Bl/6N background. All rodents 
were kept under standard husbandry conditions in animal facilities at the University of 
Edinburgh. Mice used for experiments were of mixed gender and 2 to 4 months old. 
All animal work was covered by appropriate licenses from the UK Home Office and 
approved by the University of Edinburgh Veterinary Services. All animals were 
sacrificed by Schedule 1 methods, either by cervical dislocation or overdose of 
anaesthetic by inhalation of isoflurane. 
 
5.2.2. Genotyping 
Genomic DNA was extracted as described in the General Materials and 
Methods. Details of the primers, reaction mixes and PCR programs used can be found 
in Table 5.1, Table 5.2 and Table 5.3, respectively. 
 
Table 5.1: Primers used for genotyping of sfxn3 mice. 
Primer Sequence 5' - 3' Size bp 
Common Forward  GGATCTGAGGACATTTGGGC   
WT Reverse CTGGGCAAAGGATCAGGAAG  344 





Table 5.2: PCR reagent mix. 
Reagent  μl per 1 reaction 
ddH20  8.9 
5x Green GoTaq Flexi Buffer (Promega) 3.5 
MgCl2 25mM (Promega) 0.9 
dNTP mix 10mM (Invitrogen)  0.4 
Forward Primer 10μM 0.7 
Reverse Primer 1 10μM  0.7 
Reverse Primer 2 10μM  0.7 




Table 5.3: PCR program for genotyping of Sfxn3-/- mice. 
Step Temperature (°C) Time 
1. Separation 94 5 min 
2. Denaturation 94 30 sec 
3. Annealing 58 45 sec 
4. Polymerization 72 45 sec 
Repeat 2-4 34x   
5. Final 72 5 min 
  12 ∞ 
 
5.2.3. Peripheral nerve lesions 
Peripheral nerve lesions were performed as described in Chapter 4, in mice 2-
3 month old. Briefly, mice were kept under anaesthesia by delivery of isoflurane via a 
face mask. A small incision was made at the level of the sciatic notch and a 1-2mm 
section of the sciatic nerve was removed. Following surgery all mice received an 
intramuscular injection of 4 mg/kg of the analgesic Rimadyl® and were allowed free 
access to food and water. Mice were sacrificed 12 hours to 6 days post-injury (12hpi 
to 6dpi). To ensure comparability of results extra care was taken regarding the 
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precision of the time point of analysis, anatomical location of the lesion and age of the 
mice. 
 
5.2.4. Immunohistochemistry of neuromuscular junctions in 
lumbrical muscles 
Immunostaining of lumbrical muscles was performed as described in Chapter 
4, with minor modifications to account for the fact that younger mice were used. 
Lumbrical muscles were dissected in PBS, fixed in 4% PFA in PBS for 20 min, 
permeabilised in 4% Triton X-100 in PBS for 90 min and blocked in 2% Triton X-100 
with 4% w/v BSA in PBS for 30 min. 2H3 and SV2 primary antibodies were incubated 
in block for 48 h at 4°C and secondary antibodies were applied for 2 h at RT, in PBS. 
Muscles were then exposed to 1.25 µg/ml -BTX in PBS for 10 min and mounted in 
Mowiol on glass slides. 
 
5.2.5. Electron microscopy   
Electron microscopy on sciatic nerves was performed as described in (Hunter 
et al., 2014). Immediately after sacrifice at 6dpi, sciatic nerves distal from the site of 
lesion and equivalent nerve portion from the contralateral uninjured limb were 
dissected in PBS and fixed in 4% PFA and 2.5% glutaraldehyde in phosphate buffer 
(0.1 M Na2HPO4, pH 7.4) for 48 h at 4°C. Nerve preparations were post-fixed in 1% 
osmium tetroxide (Electron Microscopy Sciences) for 30 min and dehydrated in an 
ascending alcohol series which included a 40 min treatment with 1% uranyl acetate in 
70% ethanol.  The nerves were incubated in propylene oxide for 1 h and embedded in 
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Durcupan resin. Ultra-thin transverse sections (~90 nm) were cut, collected in 
formvar-coated grids (Agar Scientific, UK) and stained with lead citrate (68 mM lead 
nitrate, 137 mM tri-sodium citrate, 160 mM NaOH) before imaging in a Philips CM12 
transmission electron microscope. 
 
5.2.6. Axonal and neuromuscular junction measurements 
For quantitative measurements of axonal parameters all electron micrographs 
were taken at 1150x magnification. A minimum of 100 myelinated axons per mouse 
from 5 images of randomly selected areas were analysed manually using ImageJ 
software, as described in (Sherman et al., 2012). Axon calibre and g-ratio were 
measured by manually drawing a line along the inner and outer borders of the myelin 
sheath of an axon. The perimeter of the lines drawn was measured and the axon calibre 
calculated as the diameter of a circular object with the same perimeter as the inner 
border. g-ratio was calculated as the fraction between the perimeters of the outer and 
inner borders.  
Neuromuscular measurements were obtained from individual endplates and 
muscle fibres from lumbrical muscles imaged at 40x magnification on an Olympus 
IX71 microscope. Images were captured by a chilled CCD camera (Hammamatsu 
C4742–96–12G04) and used for manual measurements on ImageJ, as described in 
(Murray et al., 2008). Measurements were taken from at least 50 endplates and 50 






5.2.7. Quantification of axonal and synaptic degeneration 
Axonal degeneration was assessed in electron micrographs by quantifying the 
percentage of axons from injured sciatic nerves at 6dpi that fell into each of one of five 
degeneration categories: 1 No degeneration: axon and myelin sheath appear intact; 2 
Early degeneration: myelin sheath is intact but the cytoplasm of the axon is becoming 
electron dense or its neurofilament distribution looks disorganized; 3 Intermediate 
degeneration: myelin sheath is mostly intact but the axon is clearly affected; 4 
Advanced degeneration: myelin sheath is becoming loose and the axon is clearly 
affected; 5 Complete degeneration: myelin sheath is completely degraded and it is not 
possible to distinguish the frontiers of the axon and myelin sheath. Degeneration 
categories were defined based on the observations from (Beirowski et al., 2004). For 
each individual mouse, a minimum of 100 axons were analysed and the percentage of 
each category was calculated from the pooled counts from 10 images from randomly 
selected areas of a section.  
 
Synaptic degeneration at the NMJ following sciatic nerve transection was 
manually assessed by quantifying the percentage of intact and degenerated NMJs in 
deep lumbrical muscles, as described in (Murray et al., 2008). The criteria used to 
quantify synaptic degeneration was as follows: intact NMJs had endplates fully 
occupied by pre-synaptic structures and were connected to intact axons; degenerated 
NMJs included fragmented NMJs, which showed occupied endplates but were not 
connected to an axon or the latter was fragmented, and vacant NMJs, which had no 
connected axons and did not colocalize with pre-synaptic structures. Over 100 NMJs 
from each of 4 lumbrical muscles per mouse were quantified. Quantification was 
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performed at 40x magnification on a Nikon eclipse 50i microscope with double filter. 
Representative images were captured in a Zeiss LSM 710 confocal microscope. 
For quantification of both axonal and synaptic degeneration at least 3 mice 
were used per genotype and the analysis was performed with the operator blind to the 
identity of each image. 
 
5.2.8. Proteomics by isobaric Tag for Relative and Absolute 
Quantitation (iTRAQ)  
iTRAQ proteomics and data analysis were performed as previously described 
(Roche et al., 2014, Wishart et al., 2012). Crude synaptosomes (see General Materials 
and Methods) from α-syn+/+ and α-syn-/- mice were homogenized in iTRAQ extraction 
buffer (6 M Urea, 2 M thio-urea, 2% CHAPS, 0.5% SDS, 10% protease inhibitors) 
and centrifuged for 25 min at 20,000g, 4°C. The supernatants from extracts from 4 
mice per genotype were pooled together and 100 μg of protein, as determined by BCA 
assay, were sent for isobaric tag for relative and absolute quantitation (iTRAQ) 
analysis at Dundee Fingerprints Proteomics (University of Dundee, UK). 100 μg of 
protein was labelled with tags: 114 and 116 α-syn+/+; 115 and 117 α-syn-/- and 
following processing were injected onto an Ultimate RSLC nano UHPLC system 
coupled to a LTQ Orbitrap Velos Pro (Thermo Scientific). Results were filtered to only 
include those proteins that were identified by at least 2 unique peptides and 
demonstrated a ≥15% change in protein levels in both α-syn+/+ vs α-syn-/- comparisons.  
iTRAQ proteomics results were examined using three software packages for in 
silico analysis:  Database for Annotation, Visualization and Integrated Discovery 
(DAVID; National Institutes of Health, USA); Ingenuity Pathway Analysis (IPA; 
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QIAGEN) and VarElect (LifeMap Sciences, USA). More information on these tools 
can be found on Chapter 4 and at http://www.ingenuity.com, 
http://david.abcc.ncifcrf.gov and https://ve.genecards.org, respectively. 
The iTRAQ results of the proteins with altered expression in α-syn-/- synapses 
were submitted to the IPA and DAVID software. We used the IPA software to 
determine the molecular pathways (Top Canonical Pathways) and disorders (Top 
Diseases and Disorders) most affected by loss of α-synuclein, as described in Chapter 
4. DAVID gene ontology (GO) analysis was used to assess the enrichment of GO terms 
in the samples analysed. Statistical analysis was performed by the software using the 
Exact Fisher’s Test. The VarElect web tool uses information from the GeneCard and 
MalaCards databases to relate genes to phenotypes and disease terms. This tool was 
used to select the fraction of the proteomics data that included proteins associated with 
the terms “mitochondria” and the group of terms “Parkinson’s”, “Parkinson”, “PD”, 
“synuclein” and “SNCA”. 
 
5.2.9. Culture of SH-SY5Y cells 
SH-SY5Y cells stably transfected with WT human α-synuclein were obtained 
from Dr. Tilo Kunath (University of Edinburgh). Briefly, SH-SY5Y cells were 
electroporated with a Tet-OneTM plasmid (Clontech) encoding full-length human α-
synuclein and a DOX-responsive clonal line was selected and maintained in complete 
culture media consisting of high-glucose DMEM media supplemented with 10% v/v 
FBS, 10 U/ml Penicillin/Streptomycin, 2 mM L-Glutamine, 1 mM Sodium Pyruvate 
and 2 µg/µl puromycin to select for stably transfect cells. Cells were maintained in an 
undifferentiated state and split every 3-5 days. Cells plated at a density of 104 cells/cm2 
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in uncoated plates or glass coverslips were differentiated in culture media with 10 µM 
Retinoic Acid for 5 days, with 50% of media changed at day 3. Following 
differentiation cells were washed twice with warm DMEM media and cultured 
thereafter in DMEM media supplemented with 1% Penicillin/Streptomycin and 2 
µg/µl puromycin. For induction of α-synuclein expression, culture media was 
supplemented with 10 µg/ml of Doxycycline. 
 
5.2.10. Isolation of mitochondria 
Crude mitochondria were purified from fresh mouse brain tissue using the 
Mitochondria Isolation Kit for Tissue (ab110169, abcam) following the 
manufacturer’s instructions. 
 
5.2.11. Fractionation of mitochondria 
Fractionation of mitochondria was performed as described in (Nishimura et al., 
2014). Undifferentiated SH-SY5Y cells cultured to 80-90% confluency on a T175 
flask were harvested and washed in ice-cold PBS. The cell pellet was resuspended in 
5 ml of Mitochondria Isolation Buffer (210 mM Mannitol, 70 mM Sucrose, 3 mM 
HEPES-KOH pH 7.4, 0.2 mM EGTA, protease inhibitors) and the cells disrupted by 
homogenization with 50-60 up-and-down strokes on a pre-chilled glass Dounce 
homogeniser. The homogenate was layered on an equal volume of 340 mM sucrose 
and centrifuged at 500g for 10 min at 4°C. The supernatant, now free of unbroken cells 
and nuclei, was centrifuged at 10,000g for 10 min at 4°C to recover mitochondria as a 
pellet. The mitochondria were resuspended in approximately 10 volumes of 0.15 
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mg/ml digitonin in Mitochondria Isolation Buffer, incubated on ice for 15 min, 
vortexing sporadically, and centrifuged at 10,000g for 10 min at 4°C. The solubilized 
outer mitochondrial membrane was recovered in the supernatant. The pellet, which 
contains mitoplasts (mitochondrial matrix encapsulated by the inner mitochondrial 
membrane) was resuspended in RIPA buffer, incubated on ice for 20 min and 
centrifuged at 20,000g for 20 min at 4°C to solubilize the inner mitochondrial 
membrane and matrix proteins. 
 
5.2.12. Isolation of purified synaptosomes 
For use in mitochondria respiration assays, purified synaptosomes were 
isolated from fresh brain tissue, using a protocol adapted from (Choi et al., 2009, 
Dunkley et al., 2008). A freshly dissected whole brain from an adult mouse was 
homogenized in 20 ml of ice-cold Isolation buffer (225 mM Sucrose, 74 mM Mannitol, 
1 mM EGTA, 5 mM HEPES, pH 7.4) using a PTFE dounce homogenizer, divided in 
two centrifuge tubes and centrifuged at 1,000g for 10 min at 4°C. For each tube, the 
supernatant was transferred to a new tube and the pellet resuspended in 10 ml of 
Isolation buffer and centrifuged as before. The supernatants were combined and 
centrifuged at 21,000g for 10 min at 4°C. The pellet was resuspended in 5 ml of 3% 
Percoll (GE Healthcare) in Isolation Media and carefully layered on top of a 
discontinuous Percoll gradient (layers of 24% and 10% Percoll in Isolation Media) in 
50 ml open top centrifuge tubes.  The gradients were centrifuged at 30,750g for 9 min 
at 4°C, with minimum acceleration and no deceleration on JA-25.50 fixed angle rotor 
in a Beckman Avanti JA-25 centrifuge. Following the centrifugation in Percoll 
gradients, synaptosomes were recovered from the band between 10% and 24% Percoll, 
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washed in 10 ml of ice-cold Ionic Media (140 mM NaCl, 20 mM HEPES, 1.2 mM 
Na2HPO4, 1 mM MgCl2, 5 mM NaHCO3, 5 mM KCl, 10 mM Glucose, pH 7.4) and 
centrifuged at 20,000g for 15 min at 4°C. The pellets from the duplicate preparations 
from the same animal were combined and resuspended in 2 ml Ionic Media. The 
protein concentration of the samples was determined using BCA assay. 
 
5.2.13. Mitochondrial Respiration Assays 
Measurements of mitochondria respiration rates were performed as described 
in (Choi et al., 2009, Subramaniam et al., 2014). 10 μg of synaptosomes per well (≥5 
technical replicas per sample) were loaded into wells of XFe24 V7 (Seahorse 
Biosciences) uncoated plates. The plate was centrifuged at 2,000g for 20 min at 4°C 
and 500 μl of Incubation Media (120 mM NaCl, 3.5 mM KCl, 1.3 mM CaCl2, 0.4 mM 
KH2PO4, 1.2 mM Na2SO4, 2 mM MgSO4, 4 mg/ml fatty-acid free bovine serum 
albumin, 15 mM Glucose, 10 mM pyruvate, 37°C) were added to each well prior to 
loading the cartridge into the XFe24 Seahorse Analyzer (Seahorse Biosciences), 
according to the manufacturer’s instructions. Oxygen consumption rates (OCR) were 
measured in groups of 2 cycles of 1 min wait, 1 min mix, 3 min measurements, with 
sequential injections between each 2 cycles. The pattern of injections followed 
protocols for two different assays.  In the coupling assay, samples were sequentially 
exposed to 4 μg/ml oligomycin (Oligo), 4 μM FCCP (FCCP) and 4 μg/ml antimycin 
A (AA); in the electron flow assay, sequential injection of 2 μM rotenone (Rot), 10 
mM succinate (Succ), 4 μg/ml antimycin A (AA) and 0.1 mM TMPD with 10 mM 
Ascorbate (TMPD), all in the presence of 4 μM FCCP. Immediately before and after 
the Seahorse runs, all wells were screened under a light microscope for signs of 
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detached synaptosomes. Any wells with areas of detachment were discarded from 
further analyses. 
For data analysis, OCR values for each injection step were calculated as the 
mean of the measurements of 2 cycles. Parameters for the coupling assay were 
calculated as follows: Basal: respiration before addition of any compound; ATP linked 
respiration: Basal– Oligo; Spare capacity: FCCP – Basal; Maximum capacity: FCCP 
– AA; Leak respiration: Oligo – AA; Non-mitochondrial respiration: AA. Respiration 
driven by individual mitochondrial complexes was inferred for the OCR values from 
the Electron Flow Assay as follows: Basal: uncoupled respiration before addition of 
any compound; Complex I: Basal respiration – Rot; Complex II/III: Succ – Rot; 
Complex IV: TMPD – AA. 
 
5.2.14. Mitochondrial enzymatic activity assays 
The enzymatic activity of the mitochondrial Complex I and Complex IV was 
determined using the Complex I Enzyme Activity Microplate assay kit (ab109721, 
abcam) and Complex IV Rodent Enzyme Activity Microplate Assay Kit (ab109911, 
abcam), respectively. Frozen purified synaptosomes were thawed on ice, centrifuged 
at 20,000g for 5 min at 4°C and processed according to the manufacturer’s instructions 
for each kit. Briefly, synaptosomes were lysed with 1% Lauryl Maltoside in the 
specific buffer of each assay, 25 µg (Complex I) or 75 µg (Complex IV) of protein 
was loaded onto the microplate wells and incubated for 3 h at RT (Complex I) or 
overnight at 4°C (Complex IV). Following two washes, the wells were loaded with 
assay solution and the absorbance read at 450 nm (Complex I) or 550 nm (Complex 
IV) on a GloMax (Complex I) or BioTek (Complex IV) microplate reader. All samples 
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were run in duplicates. The rate of change in optic density (OD) was calculated for 
each sample and normalized to the amount of protein in each well, as determined by 
BCA assay at the end of the experiment.  
 
5.2.15. Drosophila 
Drosophila melanogaster flies were raised on standard cornmeal food at room 
temperature. The elav-Gal4 and GMR-Gal4 driver strains were used with stocks 
obtained from the Bloomington Drosophila stock centre (IDs: Canton-S; y1 w67c23; 
P(EPgy2)CG6812EY02703; CG6812KK102815). Crosses were maintained at 22°C for 24 h 
before removal of adults and embryos were incubated in a water bath to increase levels 
and activity of the Gal4 proteins. Incubation temperatures were 25 or 30°C for low 
dose Tg(-OE/KD) or high dose Tg(+OE/KD), respectively.  
For immunohistochemistry analysis of NMJs, third instar larvae were dissected 
and fixed in Bouin's fixative (15:5:1 of saturated picric acid, 37% formaldehyde and 
glacial acetic acid) for 10 min. Fixed larvae were extensively washed in PBST (PBS 
with 0.1% TritonX-100) and blocked in 10% normal goat serum (Jackson 
ImmunoResearch) in PBST for 2 h at RT. Anti-HRP antibody was incubated overnight 
at 4°C and Cy3 secondary antibody was applied for 2 h at RT. Between incubations 
larvae were extensively washed in PBST. Fully stained preparations were mounted on 
glass slides in Vectashield antifade medium (Vector Laboratories). The NMJs on 
muscle 12 and on muscle 6/7 on segment 3 of both hemisegments of each larvae were 
imaged on Zeiss LSM 710 confocal microscope. Z-stacks were acquired at 0.5 μm 
steps at 40X magnification. IMARIS was used to determine the number and transverse 
diameter of the boutons on each NMJ. Individual NMJs were excluded from analysis 
133 
 
only if they had been damaged during dissection of the larvae or if they were obstructed 
by other fluorescently labelled structures. 
Experiments involving Drosophila were performed in conjunction with Laura 






5.3.1. Assessing the feasibility of using the peripheral nervous 
system to study α-synuclein at the synapse 
The peripheral nervous system (PNS) provides an ideal system to study 
degeneration of axons and synapses in close detail. The neuromuscular junction (NMJ) 
synapse is an easily accessible and well characterized synaptic structure, which can be 
manipulated in vivo to instigate neurodegeneration without causing a major systemic 
response to neuronal injury (Beirowski et al., 2004, Gillingwater et al., 2002).  In 
addition, peripheral nerve lesions have been widely used in the study of Wallerian 
degeneration and have proved very useful in finding new modulators of  synaptic 
stability, such as the Wlds mutation (Gillingwater and Ribchester, 2001). We therefore 
set out to assess whether we could use the PNS as a model system to study mechanisms 
downstream of α-synuclein which could be involved in the maintenance of synaptic 
and axonal stability.  
 
α-synuclein has been regarded as a critical protein in several neurodegenerative 
scenarios and its effect in the degeneration of the CNS has been extensively studied. 
The most well-established function for α-synuclein is its role in synaptic activity and 
facilitation of neurotransmitter storage and release in central synapses (Bellucci et al., 
2012, Lashuel et al., 2013). To the best of our knowledge, no studies have been carried 
out to access these properties of α-synuclein in the PNS. However, it has been 
suggested that α-synuclein may help regulate acetylcholine compartmentalization in 
motor neurons (Pelkonen and Yavich, 2011) and might contribute to modulate 
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Wallerian degeneration in the PNS (Siebert et al., 2010). In order to establish if 
Wallerian degeneration in the PNS is indeed affected by loss of α-synuclein we first 
wanted to validate and extend the findings from Siebert and colleagues (Siebert et al., 
2010), who proposed mice that lacking α-synuclein showed trends towards better 
preservation of axonal morphology following a sciatic nerve lesion. 
 
5.3.1.1. C57Bl/6JOlaHsd mice do not express α-synuclein 
To study the consequences of losing endogenous expression of α-synuclein on 
synaptic stability in the PNS we used C57Bl/6JOlaHsd mice (α-syn-/-). This mouse 
strain carries a natural deletion of the α-synuclein locus (Specht and Schoepfer, 2001) 
and has been used, in conjunction with the C57Bl/6J strain (α-syn+/+), to study the 
function of α-synuclein by several groups (Cabin et al., 2005, Siebert et al., 2010, 
Yavich et al., 2006, Yavich et al., 2004). 
Loss of α-synuclein expression from the CNS and PNS in α–syn-/- mice was 
confirmed by immunoblotting of protein extracts from brain and sciatic nerve. As 
expected, immunodetection of α-synuclein revealed the presence of a single 14kDa 





Figure 5.2 Deletion of α-synuclein in the CNS and PNS of α-syn-/- mice. Representative western blots 
showing α-synuclein protein levels in whole brain and sciatic nerve from α-syn+/+ and α-syn-/- mice, 
confirming the absence of α-synuclein in the α-syn-/- mice. Actin was used as a loading control. Each 
lane was loaded with 20 µg of protein. 
 
5.3.1.2. Absence of α-synuclein does not influence axonal and 
synaptic morphology in the PNS  
To establish if loss of α-synuclein leads to gross morphological alterations in 
axons and NMJs from adult mice, we performed electron and confocal microscopy 
studies of sciatic nerves and NMJs from hind limb lumbrical muscles, respectively. 
The ultrastructure of axons in the sciatic nerve was indistinguishable between 
α-syn+/+ and α-syn-/- mice (Figure 5.3 A). Qualitative assessment revealed the presence 
of unmyelinated and myelinated axons across a range of different calibres. In all 
myelinated axons, the myelin sheath was tightly wrapped around the axon, which in 
turn showed a clear cytoplasm with an even distribution of neurofilaments and the 
presence of intact mitochondria. Quantitatively, the density of myelinated axons did 
not differ between α-syn+/+ and α-syn-/- mice (Figure 5.3 B). In addition, the mean 
axonal diameter and myelin g-ratio, as well as the correlation between g-ratio and axon 





Figure 5.3: Loss of α-synuclein does not influence the morphology and myelination of axons in the 
sciatic nerve. A) Example electron micrographs from sections of the sciatic nerve. Individual axons 
showed intact neurofilament bundles (nf) and mitochondria (arrows). Myelin (m) was found to be tightly 
wrapped around all myelinated axons and Remak bundles (Rb) of small unmyelinated axons were also 
present in both mouse strains. Scale bar = 1 μm.  B) Density of myelinated axons is identical in α-syn+/+ 
and α-syn-/- mice. Data represented as mean  SEM, N=3, p>0.05, unpaired two-tailed t-test. C-D) Axon 
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diameter (C) and myelin g-ratio (D) were not influenced by the loss of α-synuclein. Data represented as 
mean  SEM, N=3, p>0.05, unpaired two-tailed t-test. E) Axon diameter plotted versus g-ratio showed 
identical distribution between genotypes. 
 
The morphological characteristics of NMJs were analysed in 
immunohistochemical preparations of lumbrical muscles. In both α-syn+/+ and α-syn-/- 
mice no major axonal abnormalities were observed and all motor endplates were fully 
innervated and occupied by pre-synaptic motor nerve terminals (Figure 5.4 A). 
Endplates had a pretzel-like appearance, characteristic of fully mature post-synaptic 
structures, and their approximate area was identical in the two genotypes (Figure 5.4 
B). In addition, the diameter of muscle fibres was not influenced by the loss of α-





Figure 5.4: Morphology of the neuromuscular junctions in conserved despite absence of α-
synuclein. A) Confocal micrographs of example NMJs from lumbrical muscles of the hind limb. Note 
that in both genotypes endplates (AchR) were fully occupied by overlying motor nerve terminals 
(labelled with antibodies against neurofilaments (NF) and synaptic vesicles (SV)). Scale bar = 10 μm. 
B, C) Quantification of endplate area (B) and muscle fibre diameter (C) showed no difference between 
α-syn+/+ and α-syn-/- mice. Data represented as mean  SEM, N=3, p>0.05, unpaired two-tailed t-test. 
 
5.3.1.3. Wallerian degeneration in the PNS occurs normally in the 
absence of α-synuclein  
To determine the influence of α-synuclein expression on the progression of 
axonal and synaptic degeneration we induced Wallerian degeneration of motor 
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terminals by transecting the sciatic nerve. Following axotomy, the nerve distal to site 
of injury, including its nerve terminals, degenerate in a progressive and well-
characterized manner that allows us to follow the course of both axonal and synaptic 
degeneration (Beirowski et al., 2004, Gillingwater et al., 2002). 
 
Axonal degeneration was assessed by electron microscopy of the distal sciatic 
nerve at 6dpi, a time point at which most axons will be undergoing degeneration 
(Beirowski et al., 2004, Gillingwater et al., 2002). Axons were classified according to 
their ultrastructural appearance into one of five categories representative of their state 
of degeneration. Analysis of electron micrographs showed a similar morphological 
appearance of axonal degeneration in the two mouse strains (Figure 5.5 A) with the 
distribution of degenerative axonal morphologies not differing between α-syn+/+ and 





Figure 5.5: Degeneration of the sciatic nerve is not influenced by the absence of α-synuclein. A) 
Representative electron micrographs of degenerating axons in the sciatic nerve at 6dpi. The 
morphological appearance of axonal degeneration was similar between α-syn+/+ and α-syn-/- mice. 
Numbers 1 to 5 indicate examples of axons belonging to the degeneration categories used to analyse 
different morphologies for quantitative analysis (see methods). Scale bar = 5 μm. B) Bar chart showing 
a similar distribution of degenerating axon morphologies in the sciatic nerve 6dpi in both genotypes. 
Data represented as mean  SEM, N=3, p>0.05, unpaired two-tailed t-test within each category. C) Loss 
of α-synuclein did not influence the mean axon degeneration score in the sciatic nerve 6dpi. Data 




As branches from the sciatic nerve provide axonal innervation to NMJs in the 
deep lumbrical muscles from the hindpaw, immunohistochemistry and confocal 
microscopy were used to assess synaptic degeneration in these muscles. Wallerian 
degeneration after nerve injury is instigated much earlier in distal motor nerve 
terminals than in the corresponding axons located in peripheral nerves leading to the 
majority of Wallerian degeneration being complete at NMJs within around 24hpi, 
depending on the distance of the nerve terminals to the site of lesion (Gillingwater and 
Ribchester, 2001, Miledi and Slater, 1970). The morphological characteristics of 
degenerating NMJs were identical between α-syn+/+ and α-syn-/- mice: pre-synaptic 
structures became progressively fragmented before being lost from the NMJ, with 
degeneration proceeding in a retrograde manner. Vacant endplates were first seen at 
12hpi and there was a gradual loss of NMJ innervation until 18hpi, when the vast 
majority of NMJs analysed were completely vacant (Figure 5.6 A). Quantification of 
the percentage of degenerated NMJs at several time-points following nerve injury 
revealed that the time-course of Wallerian degeneration was not influenced by the loss 
of α-synuclein (Figure 5.6 B). 
 
Overall, the results in this section argue against a significant influence of α-
synuclein on synaptic stability and/or degeneration in the PNS. Therefore, we decided 
to focus our research in the rest of this chapter on the CNS, where the importance of 





Figure 5.6: Rate of neuromuscular degeneration was not affected by loss of α-synuclein. A) 
Representative confocal micrographs of NMJs in lumbrical muscles at different time-points following 
sciatic nerve lesion (axons/nerve terminals, green; motor endplates, red). Note the progressive 
degeneration and loss of motor nerve terminals in both α-syn+/+ and α-syn-/- mice. Scale bar = 50 μm. 
B) Time course of nerve terminal degeneration at the NMJ following sciatic nerve lesion was identical 
in the two genotypes analysed. Data represented as mean  SEM, N=12 for “no injury”, N=3 for all 







5.3.2. Identification of novel α-synuclein targets at the synapse 
In order to uncover molecular mechanisms downstream of α-synuclein with 
the potential to mediate maintenance of synaptic function and stability, we quantified 
changes in the synaptic proteome of mice lacking α-synuclein. iTRAQ proteomics on 
crude synaptosomes isolated from the brain of α-syn+/+ and α-syn-/- mice identified 
2,615 individual proteins. Raw mass spectrometry data was filtered to leave only those 
proteins identified by at least two unique peptides and with expression levels 
consistently altered by more than 15% across two independent technical replicates. 
The 200 remaining filtered proteins (Table 5.4) were submitted to bioinformatics 




Table 5.4: Filtered proteomics data-set. 
KO/WT 
Ratio 







0.53 Solute carrier family 2, facilitated glucose 
transporter member 1  
Slc2a1 P17809 2 51.09 Y Y N / A 
0.55 NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 11, mitochondrial  
Ndufb11 O09111 3 198.87 Y N (Panelli et al., 2013) 
0.57 Syndecan (Fragment)  SDC4 I3PMU3 3 113.33 N N / A N / A 
0.63 Solute carrier family 39 (Zinc transporter), 
member 7  
Slc39a7 Q14C53 2 96.01 N N / A N / A 
0.63 Bcl-2-like protein 1 (Fragment)  Bcl2l1 A2AHX9 2 59.07 Y N (Akhtar et al., 2004) 
0.65 Zinc transporter ZIP6 (Fragment)  Slc39a6 D3Z7N4 2 48.40 N N / A N / A 
0.65 Glia maturation factor beta  Gmfb A7VJ98 3 184.00 N N / A N / A 
0.65 Eukaryotic translation initiation factor 5A-1  Eif5a P63242 5 139.47 Y Y N / A 
0.67 Immunoglobulin-binding protein 1  Igbp1 Q61249 2 155.33 N N / A N / A 
0.68 RWD domain containing 4A, isoform 
CRA_b  
Rwdd4a H3BJI4 2 61.28 N N / A N / A 
0.68 Microtubule-associated protein tau  Mapt P10637 20 1309.9
7 
Y N (Spires-Jones et al., 
2009) 
0.69 Centrin-2 (Fragment)  Cetn2 B1AUQ7 2 50.06 N N / A N / A 
0.69 Sodium-dependent phosphate transporter 2  Slc20a2 Q80UP8 3 159.55 N N / A N / A 
0.70 S100 calcium binding protein A1 
(Fragment)  
S100A1 Q9JL08 2 22.94 Y Y N / A 
0.71 ARP3 Actin-Related Protein 3 Homolog Actr3 Q3TGE1 11 765.22 N N / A N / A 
0.72 DnaJ homolog subfamily C member 8  Dnajc8 A2ALF0 2 60.57 N N / A N / A 
0.72 Metallo-beta-lactamase domain-containing 
protein 2  
 
G3X997 2 107.58 N N / A N / A 
0.72 mRNA, clone:2-63 (Fragment)  Gprc5b Q9JMF0 2 177.90 N N / A N / A 
0.72 Tropomodulin-2  Tmod2 Q9JKK7 4 181.60 N N / A N / A 
0.73 Sodium-dependent neutral amino acid 
transporter SLC6A17  
Slc6a17 Q8BJI1 2 62.77 N N / A N / A 
0.73 ATP synthase subunit e, mitochondrial  Atp5i Q06185 2 145.42 Y Y N / A 
0.73 Charged multivesicular body protein 3  Chmp3 Q9CQ10 2 59.10 N N / A N / A 
0.74 Solute carrier family 13 member 5  Slc13a5 Q67BT3 2 84.38 N N / A N / A 
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0.74 Sodium-dependent phosphate transporter 1  Slc20a1 Q61609 2 67.87 N N / A N / A 
0.74 Amyloid beta A4 precursor protein-binding 
family A member 1  
Apba1 B2RUJ5 5 137.31 N N / A N / A 
0.74 Calmodulin  Calm1 P62204 9 2240.5
4 
N N / A N / A 
0.74 RNA-binding protein  Tsn Q545E6 3 149.58 N N / A N / A 
0.74 Acyl-Coenzyme A binding domain 
containing 6  
Acbd6 Q14BV7 2 150.05 N N / A N / A 
0.74 Nucleobindin 2 Nucb2 Q3TV28 2 91.59 N N / A N / A 
0.75 Protein FAM49A  Fam49a Q8BHZ0 3 173.38 N N / A N / A 
0.75 Transcription elongation factor A protein-
like 3 (Fragment)  
Tceal3 A2AEC2 7 155.13 N N / A N / A 
0.75 Uncharacterized protein  
 
F2Z452 2 133.15 N N / A N / A 
0.75 Glutamate--cysteine ligase regulatory 
subunit (Fragment)  
Gclm F6VNW5 2 54.43 N N / A N / A 
0.76 Calcineurin B homologous protein 1  Chp1 P61022 4 235.87 N N / A N / A 
0.76 Tax1-binding protein 1 homolog  Tax1bp1 Q3UKC1 3 48.04 N N / A N / A 
0.76 Ectonucleotide 
pyrophosphatase/phosphodiesterase family 
member 5  
Enpp5 Q9EQG7 2 34.04 N N / A N / A 
0.76 Synaptosomal-associated protein 29  Snap29 Q9ERB0 3 112.44 N N / A N / A 
0.76 Translation initiation factor eIF-2B subunit 
epsilon  
Eif2b5 Q8CHW4 2 50.65 N N / A N / A 
0.77 Charged multivesicular body protein 4b  Chmp4b Q9D8B3 7 221.39 N N / A N / A 
0.77 Solute Carrier Family 16 (Monocarboxylate 
Transporter), Member 1 
Slc16a1 Q8BPS5 4 74.44 Y Y N / A 
0.77 MCG124812  Taok1 B2RX66 9 115.23 N N / A N / A 
0.77 Gamma-aminobutyric acid receptor subunit 
alpha-3  
Gabra3 P26049 4 177.85 N N / A N / A 
0.77 Neurabin-2  Ppp1r9b Q6R891 13 642.86 N N / A N / A 
0.77 MCG68069  Npm1 Q5SQB7 7 199.91 N N / A N / A 
0.77 Coiled-coil domain-containing protein 104 
(Fragment)  
Cfap36 Q5SNY8 2 79.71 N N / A N / A 
0.77 SERPINE1 MRNA Binding Protein 1 Serbp1 Q3UEI6 7 123.76 N N / A N / A 
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0.77 von Willebrand factor A domain-containing 
protein 5A  
Vwa5a Q99KC8 2 33.87 N N / A N / A 
0.77 Isoform Testis-specific of Angiotensin-
converting enzyme 
Ace P09470 3 78.17 Y N (Sonsalla et al., 
2013) 
0.77 Dynactin 2  Dctn2 Q3TPZ5 17 1040.3
2 
Y N (LaMonte et al., 
2002) 
0.77 Solute Carrier Family 1 (Glutamate/Neutral 
Amino Acid Transporter), Member 4 
Slc1a4 Q3US35 3 105.64 N N / A N / A 
0.77 Coatomer subunit epsilon  Cope O89079 3 77.74 N N / A N / A 
0.77 Myosin regulatory light chain 12B  Myl12b Q3THE2 3 106.53 N N / A N / A 
0.78 Syntaxin-4  Stx4 P70452 2 80.91 N N / A N / A 
0.78 Ran-specific GTPase-activating protein  Ranbp1 P34022 4 103.76 N N / A N / A 
0.78 Band 4.1-like protein 1  Epb41l1 A2AUK5 16 656.89 N N / A N / A 
0.78 EWS RNA-Binding Protein 1 Ewsr1 Q9CRS5 2 67.18 N N / A N / A 
0.78 Sodium/hydrogen exchanger (Fragment)  Slc9a6 Q80U52 3 172.47 Y Y N / A 
0.78 Neuromodulin  Gap43 P06837 17 1888.9
9 
N N / A N / A 
0.78 Protein 1110004F10Rik  1110004
F10Rik 
D6RI64 2 74.56 N N / A N / A 
0.79 E3 ubiquitin-protein ligase RBX1  Rbx1 P62878 3 106.92 N N / A N / A 
0.79 Eif3j protein (Fragment)  Eif3j Q2YDW1 4 79.93 N N / A N / A 
0.79 Endoplasmic reticulum resident protein 29  Erp29 P57759 5 194.18 N N / A N / A 
0.79 Glial fibrillary acidic protein  Gfap P03995 21 759.21 Y N (Maragakis and 
Rothstein, 2006) 
0.79 Eukaryotic Translation Initiation Factor 4B Eif4b Q3TDD8 12 508.52 N N / A N / A 
0.79 Endoplasmic Reticulum Protein 44 Erp44 Q3URM4 5 304.43 N N / A N / A 
0.80 Translationally-controlled tumor protein  Tpt1 P63028 6 466.43 Y N (Kim et al., 2001) 
0.80 Cytoplasmic dynein 1 intermediate chain 1  Dync1i1 O88485 13 413.11 N N / A N / A 
0.80 RNA-binding protein FUS (Fragment)  Fus G3UXT7 2 71.27 N N / A N / A 
0.80 Isoform 2 of Apoptosis-inducing factor 3 Aifm3 Q3TY86 6 169.04 Y N (Kohda et al., 2016) 
0.80 GDP-D-Glucose Phosphorylase 1 Gdpgp1 Q8C3E3 2 91.64 N N / A N / A 
0.80 Homer protein homolog 1  Homer1 Q9Z2Y3 16 689.18 N N / A N / A 
0.80 Solute carrier family 1 (Glial high affinity 
glutamate transporter), member 2  
Slc1a2 Q3UYK6 14 2942.5
9 
N N / A N / A 
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0.80 Ubiquitin-protein ligase E3A  Ube3a O08759 6 143.36 N N / A N / A 
0.81 Serine/threonine kinase receptor associated 
protein  
Strap B2RUC7 8 293.12 N N / A N / A 
0.81 E3 ubiquitin-protein ligase RNF34  Rnf34 Q99KR6 2 49.04 N N / A N / A 
0.81 Peflin  Pef1 Q8BFY6 2 45.46 N N / A N / A 
0.81 Sorbin and SH3 domain-containing protein 1  Sorbs1 Q62417 3 70.23 N N / A N / A 
0.81 Protein Ppp1r9a  Ppp1r9a H3BKQ7 16 580.30 N N / A N / A 
0.81 Lisch-like isoform 7  Ildr2 B5TVM9 2 110.49 N N / A N / A 
0.81 Ribosome maturation protein SBDS  Sbds P70122 3 60.65 N N / A N / A 
0.82 Secretogranin V, isoform CRA_b  Scg5 Q3TT51 4 113.06 N N / A N / A 
0.82 Proteasome subunit beta type (Fragment)  Psmb7 Q5D098 2 48.71 N N / A N / A 
0.82 Semaphorin-4A  Sema4a D3YWV5 2 57.35 N N / A N / A 
0.82 GRIP1-associated protein 1  Gripap1 Q8VD04 12 379.05 N N / A N / A 
0.82 WD repeat-containing protein 26  Wdr26 E0CYH4 2 61.42 N N / A N / A 
0.82 Cldn10 protein (Fragment)  Cldn10 Q921J6 2 96.17 N N / A N / A 
0.83 GTPase Activating Protein (SH3 Domain) 
Binding Protein 2 
G3bp2 Q3U931 4 109.58 N N / A N / A 
0.83 Isoform 2 of FXYD domain-containing ion 
transport regulator 6 
Fxyd6 Q9D164 2 144.70 N N / A N / A 
0.83 Sodium/potassium-transporting ATPase 
subunit alpha-2  
Atp1a2 D3YYN7 46 6589.8
8 
N N / A N / A 
0.83 Apoptosis repressor interacting with CARD  Nol3 Q53YU5 2 56.36 Y Y N / A 
0.83 Coiled-coil domain-containing protein 177  Ccdc177 Q3UHB8 7 208.58 N N / A N / A 
0.83 Heterogeneous Nuclear Ribonucleoprotein 
U (Scaffold Attachment Factor A) 
Hnrnpu Q3TGN5 6 245.04 N N / A N / A 
0.84 Deubiquitinating protein VCIP135  Vcpip1 Q8CDG3 4 110.13 N N / A N / A 
0.84 Protein Hook homolog 3  Hook3 Q8BUK6 5 128.20 N N / A N / A 
0.84 Isoform 2 of Voltage-dependent L-type 
calcium channel subunit beta-4 
Cacnb4 Q8R0S4 8 182.02 N N / A N / A 
1.16 60 kDa heat shock protein, mitochondrial  Hspd1 P63038 29 2122.0
6 
Y N (Magnoni et al., 
2013) 
1.16 Cofilin 1, non-muscle  Cfl1 Q544Y7 17 760.20 Y N (Schonhofen et al., 
2014) 
1.16 Niemann-Pick Disease, Type C2 Npc2 Q3U3C2 2 113.09 N N / A N / A 
149 
 
1.16 Tyrosine 3-monooxygenase  Th P24529 6 156.95 Y N (Zhu et al., 2012) 
1.16 Apolipoprotein, MICOS complex subunit 
Mic27 
Apool B1AV14 2 140.85 Y Y N / A 
1.16 Saccharopine Dehydrogenase (Putative) Sccpdh Q3ULN6 4 181.62 Y Y N / A 
1.16 Mitochondrial import receptor subunit T Tomm40 Q9QYA2 3 166.67 Y N (Bender et al., 2013) 
1.16 Nucleosome Assembly Protein 1-Like 5 Nap1l5 Q9CTE1 2 62.79 N N / A N / A 
1.16 Dynactin subunit 3  Dctn3 Q9Z0Y1 3 72.24 N N / A N / A 
1.16 Mitochondrial pyruvate carrier 1  Mpc1 D3YWY6 2 130.20 Y Y N / A 
1.16 Sideroflexin-3  Sfxn3 Q3U4F0 9 567.75 Y Y N / A 
1.16 Thymidylate kinase  Dtymk P97930 5 103.94 Y Y N / A 
1.16 Aldo-Keto Reductase Family 1, Member A1 
(Aldehyde Reductase) 
Akr1a1 Q3UJW9 5 209.70 Y N (Tseveleki et al., 
2010) 
1.17 Albumin 1 (Precursor)  Alb Q546G4 26 1290.2
3 
Y N (Pisani et al., 2012) 
1.17 Translation elongation factor (Fragment)  Tsfm Q8VDE3 4 285.49 Y Y N / A 
1.17 RIKEN cDNA 2900041A09, isoform 
CRA_a  
Tppp Q3URG1 4 188.15 Y N (Olah and Ovadi, 
2014) 
1.17 Protein LSM12 homolog  Lsm12 Q9D0R8 4 188.03 N N / A N / A 
1.17 Acetyl-CoA Acetyltransferase 1 Acat1 Q3TQP7 19 1100.0
6 
Y Y N / A 
1.17 39S ribosomal protein L12, mitochondrial  Mrpl12 Q9DB15 5 159.63 Y Y N / A 
1.17 Isocitrate dehydrogenase [NAD] subunit 
alpha, mitochondrial  
Idh3a Q9D6R2 13 978.55 Y Y N / A 
1.17 Glutamate decarboxylase  Gad1 Q548L6 7 246.00 Y N (Trifonov et al., 
2012) 
1.18 Succinyl-CoA ligase [ADP/GDP-forming] 
subunit alpha, mitochondrial  
Suclg1 Q9WUM5 5 159.11 Y Y N / A 
1.18 Glutamate decarboxylase  Gad2 Q548L4 4 163.52 N N / A N / A 
1.18 Biliverdin reductase B (Flavin reductase 
(NADPH))  
Blvrb Q3U6G1 2 93.97 N N / A N / A 
1.18 Reticulocalbin-1  Rcn1 Q05186 2 115.90 N N / A N / A 
1.18 Nucleoside diphosphate kinase  Nme1 Q5NC81 9 601.42 Y Y N / A 
1.18 Tumor protein D53  Tpd52l1 O54818 2 56.45 N N / A N / A 
1.18 Cdc42 effector protein 4  Cdc42ep
4 
Q9JM96 3 115.19 N N / A N / A 
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1.19 ATP-dependent Clp protease proteolytic 
subunit  
Clpp Q8CF81 3 134.37 Y Y N / A 
1.19 MCG122050  Tbca Q5I0U7 3 82.03 N N / A N / A 
1.19 Prostamide/prostaglandin F synthase  Fam213b Q9DB60 3 134.93 N N / A N / A 
1.19 Guanine nucleotide-binding protein subunit 
gamma  
Gng5 Q3UKC8 2 78.00 N N / A N / A 
1.19 Lysosomal alpha-glucosidase  Gaa P70699 3 132.10 Y N (Lim et al., 2015) 
1.19 Delta(3,5)-Delta(2,4)-dienoyl-CoA 
isomerase, mitochondrial  
Ech1 O35459 2 81.25 Y N (Long et al., 2016) 
1.19 Protein lin-7 homolog A  Lin7a Q8JZS0 7 273.46 N N / A N / A 
1.19 Estradiol 17-beta-dehydrogenase 8 
(Fragment)  
H2-Ke6 G3UX44 3 223.52 N N / A N / A 
1.19 MC3T3-E1 calcyclin  S100a6 Q545I9 2 71.27 N N / A N / A 
1.20 Isoform 3 of Synapsin-1 Syn1 O88935 18 1764.6
5 
N N / A N / A 
1.20 NAD(P)H-hydrate epimerase  Apoa1bp Q8K4Z3 3 163.45 Y Y N / A 
1.20 NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 4  
Ndufb4 Q9CQC7 6 183.48 Y N (McFarland et al., 
2008) 
1.21 Enoyl-CoA hydratase, mitochondrial  Echs1 Q8BH95 8 346.60 Y Y N / A 
1.21 Isobutyryl-CoA dehydrogenase, 
mitochondrial  
Acad8 D3YTT4 3 199.17 Y Y N / A 
1.21 Peroxiredoxin-1 (Fragment)  Prdx1 B1AXW5 10 362.02 Y N (Lee et al., 2008b) 
1.21 Succinyl-CoA ligase [ADP-forming] subunit 
beta, mitochondrial  
Sucla2 Q9Z2I9 17 1068.7
2 
Y Y N / A 
1.21 Pyruvate dehydrogenase E1 alpha 1  Pdha1 Q3UFJ3 20 1534.4
8 
Y Y N / A 
1.21 Ermin  Ermn Q5EBJ4 3 134.80 N N / A N / A 
1.22 Superoxide dismutase  Sod2 Q3U8W4 6 130.01 Y N N / A 
1.22 Cofilin 2 Cfl2 Q3UHW9 7 352.99 N N / A N / A 
1.22 Microtubule-associated proteins 1A/1B light 
chain 3A  
Map1lc3
a 
Q91VR7 3 95.67 Y N (McFarland et al., 
2008) 
1.22 Aldehyde dehydrogenase X, mitochondrial  Aldh1b1 Q9CZS1 4 105.96 Y Y N / A 
1.22 Dynamin 2 Dnm2 Q3TBU6 15 958.66 N N / A N / A 
1.22 Succinyl-CoA:3-ketoacid-coenzyme A 
transferase  
Oxct1 Q3UK61 9 666.20 Y Y N / A 
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1.23 Synapsin-2  Syn2 Q64332 16 2141.8
5 
N N / A N / A 
1.23 Electron transfer flavoprotein subunit alpha, 
mitochondrial  
Etfa Q99LC5 11 873.14 Y Y N / A 
1.23 GrpE protein homolog 1, mitochondrial  Grpel1 Q99LP6 6 133.16 Y Y N / A 
1.23 Casein kinase II subunit beta  Csnk2b G3UXG7 2 60.49 N N / A N / A 
1.23 Transcription elongation factor B 
polypeptide 2  
Tceb2 P62869 4 138.39 N N / A N / A 
1.23 Isocitrate dehydrogenase 3 (NAD+), gamma 
(Fragment)  
Idh3g Q684I8 6 331.74 Y Y N / A 
1.23 Isoform 2 of Vesicle-associated membrane 
protein 1 
Vamp1 Q62442 6 435.09 Y N (Sevlever et al., 
2015) 
1.23 Protein ETHE1, mitochondrial  Ethe1 Q9DCM0 3 125.61 Y N (Tiranti et al., 2004) 
1.24 Malate dehydrogenase, mitochondrial  Mdh2 P08249 16 3361.2
4 
Y Y N / A 
1.24 Isoform 2 of Plakophilin-4 n Pkp4 Q68FH0 5 126.42 N N / A N / A 
1.24 Solute Carrier Family 25, Member 27 Slc25a27 Q9CX10 3 128.37 Y Y N / A 
1.25 Methylmalonate-semialdehyde 
dehydrogenase [acylating], mitochondrial  
Aldh6a1 Q9EQ20 11 375.66 Y Y N / A 
1.25 Clathrin, Light Chain B Cltb Q3TJ95 13 497.83 N N / A N / A 
1.25 NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 3  
Ndufa3 Q9CQ91 2 79.46 Y N (Poche et al., 2016) 
1.25 Ubiquilin 1 Ubqln1 Q3T992 6 191.51 N N / A N / A 
1.26 Destrin (Fragment)  Dstn A8QKB4 10 389.49 N N / A N / A 
1.26 Rho GTPase-activating protein 1  Arhgap1 Q5FWK3 5 134.35 N N / A N / A 
1.26 Aromatic-L-amino-acid decarboxylase 
(Fragment)  
Ddc Q5SUV9 3 212.30 N N / A N / A 
1.27 Isovaleryl-CoA dehydrogenase, 
mitochondrial  
Ivd Q9JHI5 10 291.17 Y Y N / A 
1.27 NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 10, mitochondrial  
Ndufa10 Q99LC3 7 335.89 Y N (Lake et al., 2016) 
1.27 Ester hydrolase C11orf54 homolog  
 
CK054 3 58.86 N N / A N / A 
1.27 GTP:AMP phosphotransferase AK4, 
mitochondrial (Fragment)  
Ak4 A2ARF6 2 138.36 Y N (Liu et al., 2009b) 
1.27 Fatty acid-binding protein, brain  Fabp7 P51880 2 152.26 N N / A N / A 
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1.27 Histone H3 (Fragment)  H3f3a E0CZ27 2 54.78 N N / A N / A 
1.28 Endophilin-B2  Sh3glb2 A2AWI7 14 492.69 N N / A N / A 
1.28 Superoxide dismutase [Cu-Zn]  Sod1 P08228 7 954.48 Y N (Kaur et al., 2016) 
1.29 ES1 protein homolog, mitochondrial  D10Jhu8
1e 
Q9D172 6 225.28 N N / A N / A 
1.29 NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 6  
Ndufa6 Q9CQZ5 4 141.05 Y N (McFarland et al., 
2008) 
1.29 Ubiquitin-Conjugating Enzyme E2N Ube2n A2RTT4 6 196.19 N N / A N / A 
1.30 Mitochondrial ATP synthase epsilon subunit 
(Fragment)  
Atp5e G8DXN9 2 46.14 Y N (Alves et al., 2015) 
1.30 Mitochondrial import inner membrane 
translocase subunit TIM16  
Pam16 Q9CQV1 2 56.43 Y Y N / A 
1.31 Sorting nexin-3  Snx3 D3Z789 4 63.94 N N / A N / A 
1.32 ATP synthase subunit  Atp5o Q9DB20 8 543.69 Y N Lacovelli 2016 
1.32 S100 calcium binding protein A13  S100a13 Q545H7 3 106.20 N N / A N / A 
1.32 Iron-sulfur cluster assembly enzyme ISCU, 
mitochondrial  
Iscu Q9D7P6 3 95.44 Y Y N / A 
1.33 Peptidyl-prolyl cis-trans isomerase F, 
mitochondrial  
Ppif Q99KR7 3 127.97 Y N (Warne et al., 2016) 
1.34 Lin-7 Homolog C Lin7c Q3TTY6 5 141.42 N N / A N / A 
1.35 Mitochondrial import inner membrane 
translocase subunit Tim10 B  
Timm10
b 
D3YVK5 2 110.87 Y Y N / A 
1.36 Mitochondrial intermembrane space import 
and assembly protein 40  
Chchd4 Q8VEA4 3 93.65 Y Y N / A 
1.36 Desmoplakin  Dsp E9Q557 21 351.44 N N / A N / A 
1.37 Cytochrome c oxidase subunit 5B, 
mitochondrial  
Cox5b P19536 8 653.00 Y N (Chung et al., 2013) 
1.37 Histone H4 (Fragment)  
 
Q6B822 2 69.41 N N / A N / A 
1.39 Cryab protein  Cryab Q52L78 2 95.40 Y N (Liu et al., 2015) 
1.39 Profilin-2  Pfn2 Q9JJV2 2 205.71 N N / A N / A 
1.40 UPF0598 protein C8orf82 homolog  
 
Q8VE95 2 63.79 N N / A N / A 
1.41 Histone H2B (Fragment)  Hist1h2b
j 
A0JLV3 3 199.21 N N / A N / A 
1.42 Histidine triad nucleotide-binding protein 1  Hint1 P70349 3 62.50 N N / A N / A 
1.43 Peptidyl-prolyl cis-trans isomerase  Ppia Q3TE63 7 327.00 Y N (Kaur et al., 2016) 
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1.44 Beta-synuclein  Sncb Q91ZZ3 9 966.78 Y N (Chandra et al., 
2004a) 
1.46 Fatty acid binding protein 5, epidermal  Fabp5 Q497I3 6 173.10 N N / A N / A 
1.47 Fatty acid binding protein 3, muscle and 
heart  
Fabp3 Q5EBJ0 4 168.23 N N / A N / A 
1.50 Heme-binding protein 1  Hebp1 Q9R257 2 73.66 N N / A N / A 
1.99 Peroxiredoxin 5 Prdx5 Q3UWS9 5 330.85 Y N (Davey and Bolanos, 
2013) 
KO/WT Ratio: Ratio between the expression levels of a given protein in α-syn-/- mice compared to α-syn+/+. Average of two technical replicas;  
Description: Protein description;  
Gene: Gene coding the identified protein; 
UniProt Accession: UniProt Accession number; 
Unique peptides: Number of unique peptides used to identify the protein; 
Score: Confidence score; 
Mitochondria Evidence: N: No. Y: Yes. Evidence that a given protein is localises in mitochondria; or that it influences or is influenced by mitochondrial function;  
Novel: N: No; Y: Yes; N/A: Not Applicable. Evidence that a given protein has previously been associated with α-synuclein, Parkinson's Disease or Neurodegeneration in general. 




IPA analysis revealed an extensive involvement of α-synuclein in 
neurodegenerative scenarios (Table 5.5), ranging from neuromuscular disorders and 
dementia to particular diseases such as Parkinson’s, Alzheimer’s and Huntington’s 
diseases. Remarkably, all of these conditions have previously been associated with 
synaptic dysfunction (see General Introduction). Performing a more focused analysis to 
identify individual cellular pathways affected by loss of α-synuclein revealed a very 
strong involvement of mitochondrial canonical pathways, including mitochondria 
dysfunction, oxidative phosphorylation and tricarboxylic acid (TCA; Krebs) cycle (Table 
5.6). Gene ontology (GO) annotation analysis using DAVID confirmed the enrichment in 
terms associated with mitochondrial functions (Table 5.7) and filtering the data using the 
VarElect engine revealed a striking enrichment of proteins (74 out of 200) belonging to 
mitochondrial pathways (Table 5.4). This finding provides significant experimental 
support for the hypothesis that α-synuclein has important physical and/or functional 
interactions with mitochondria (Haelterman et al., 2014, Nakamura, 2013). Further 
bioinformatics analysis of these 200 mitochondrial proteins identified 37 proteins not 
previously associated with α-synuclein or neurodegeneration (Table 5.8, Figure 5.7). 
These proteins were therefore considered to represent potential novel α-synuclein-









Table 5.5: Top diseases and disorders affected in α-syn-/- mice. 
Diseases and Disorders P-value 
Movement Disorders 4.06E-15 
Neuromuscular disease 5.00E-13 
Huntington's Disease 4.15E-09 
Schizophrenia 2.41E-09 
Dementia 2.33E-05 
Alzheimer's disease 4.60E-05 
Parkinson's disease 9.16E-08 




Table 5.6: Top canonical pathways affected in α-syn-/- mice. 
Canonical pathways P-value 
Mitochondrial Dysfunction 9.36E-08 
TCA Cycle II (Eukaryotic) 2.01E-06 
Glutamate Dependent Acid Resistance 9.64E-05 
Oxidative Phosphorylation 1.15E-05 
RhoA Signaling 1.68E-04 
 
 
Table 5.7: Gene Ontology annotation enrichment. 
DAVID GO annotation P-value 
Generation of precursor metabolites and energy 2.30E-09 
Transmission of nerve impulses 8.13E-07 
Oxidation reduction 2.23E-06 
Synaptic transmission 2.96E-06 
Regulation of neurotransmitter levels 3.92E-06 




Figure 5.7: Graphical representation of the filtering steps taken during the analysis of iTRAQ 
proteomics data. Y-axis represents the mean fold change, from two technical replicates, of each protein in 
-syn-/- synaptosomes when compared to control -syn+/+ synaptosomes. “Unfiltered” column includes all 
2,615 proteins identified by iTRAQ. “Filtered” column contains the subset of identified proteins which met 
the selection criteria of being identified by more than 1 unique peptide and being altered by more than 15% 
in two technical replicates. Since mitochondrial pathways were shown to be some of the most affected in 
-syn-/- mice, the 200 filtered proteins were further selected to include only mitochondrial proteins 
(“Mitochondrial” column, 74 proteins). Mitochondrial proteins were further filtered to include proteins not 
previously associated with -synuclein or neurodegeneration. These group of 37 proteins, here referred to 











Table 5.8: Novel proteins identified to belong to α-synuclein dependent pathways. 
UniProt Description 
Q9DB15 39S ribosomal protein L12, mitochondrial  
Q3TQP7 Acetyl-CoA Acetyltransferase 1 
Q9CZS1 Aldehyde dehydrogenase X, mitochondrial  
B1AV14 Apolipoprotein, MICOS complex subunit Mic27 
Q53YU5 Apoptosis repressor interacting with CARD  
Q06185 ATP synthase subunit e, mitochondrial  
Q8CF81 ATP-dependent Clp protease proteolytic subunit  
Q99LC5 Electron transfer flavoprotein subunit alpha, mitochondrial  
Q8BH95 Enoyl-CoA hydratase, mitochondrial  
P63242 Eukaryotic translation initiation factor 5A-1  
Q99LP6 GrpE protein homolog 1, mitochondrial  
Q9D7P6 Iron-sulfur cluster assembly enzyme ISCU, mitochondrial  
D3YTT4 Isobutyryl-CoA dehydrogenase, mitochondrial  
Q9D6R2 Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial  
Q684I8 Isocitrate dehydrogenase 3 (NAD+), gamma (Fragment)  
Q9JHI5 Isovaleryl-CoA dehydrogenase, mitochondrial  
P08249 Malate dehydrogenase, mitochondrial  
Q9EQ20 Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial  
D3YVK5 Mitochondrial import inner membrane translocase subunit Tim10 B  
Q9CQV1 Mitochondrial import inner membrane translocase subunit TIM16  
Q8VEA4 Mitochondrial intermembrane space import and assembly protein 40  
D3YWY6 Mitochondrial pyruvate carrier 1  
Q8K4Z3 NAD(P)H-hydrate epimerase  
Q5NC81 Nucleoside diphosphate kinase  
Q3UFJ3 Pyruvate dehydrogenase E1 alpha 1  
Q9JL08 S100 calcium binding protein A1 (Fragment)  
Q3ULN6 Saccharopine Dehydrogenase (Putative) 
Q3U4F0 Sideroflexin-3  
Q80U52 Sodium/hydrogen exchanger (Fragment)  
Q8BPS5 Solute Carrier Family 16 (Monocarboxylate Transporter), Member 1 
P17809 Solute carrier family 2, facilitated glucose transporter member 1  
Q9CX10 Solute Carrier Family 25, Member 27 
Q9Z2I9 Succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial  
Q9WUM5 Succinyl-CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial  
Q3UK61 Succinyl-CoA:3-ketoacid-coenzyme A transferase  
P97930 Thymidylate kinase  
Q8VDE3 Translation elongation factor (Fragment)  
 
To select individual proteins from the short-list of 37 to be prioritised for further 
analyses, we performed extensive literature searches to uncover those with potential links 
with PD and/or related forms of neurodegeneration. Using this approach, Sideroflexin 3 
(sfxn3) was identified as a protein of particular interest (Figure 5.8). Microarray studies 
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reported that levels of sfxn3 transcripts or protein were altered in the substantia nigra of 
PD patients and in rodents subjected to a 6-hydroxydopamine lesion (Charbonnier-
Beaupel et al., 2015, Fuller et al., 2014, Simunovic et al., 2009). In addition, a related 
protein (sfxn1) interacts with connexin 32, mutations in which cause a variant of Charcot-
Marie-Tooth disease (Bergoffen et al., 1993, Fowler et al., 2013), reduced levels of the 
sfxn1 protein have been reported in patients with Alzheimer’s Disease (Minjarez et al., 
2016), and sfxn2 is deregulated in dopaminergic cells in response to rotenone treatment 
(Jin et al., 2007). Sfxn3 belongs to a family of proteins (sideroflexins 1-5) that are putative 
iron transporters, with predicted transmembrane domains and mitochondrial localization 
(Fleming et al., 2001, Li et al., 2010). The functional role of these proteins, however, 
remains unexplored.  
 
 
Figure 5.8: Schematic overview of experimental design and workflow. Crude synaptosomes were 
isolated from α-syn-/- and α-syn+/+ and submitted to iTRAQ proteomics. Filtering of the raw data and 
bioinformatics pathway analysis revealed an enrichment in proteins belonging to mitochondrial pathways. 
Further analysis of data to include only proteins not previously associated with neurodegeneration or α-
synuclein function allowed us to reach a small list of novel proteins with potential to cooperate with α-
synuceiln to regulate synaptic function and stability. A search of the published literature indicated sfxn3 




Levels of sfxn3 protein were increased in synapses from α-syn-/- mice (Table 5.4 
and Figure 5.9), suggesting that sfxn3 expression is inversely correlated with α-synuclein. 
To confirm this, we over-expressed α-synuclein in stably transfected SH-SY5Y cells. 
Exposure of SH-SY5Y cells to Doxycycline (DOX) for 24h led to a robust increase in the 
expression of α-synuclein (), which was accompanied by a significant decrease in the 
levels of sfxn3 protein (Figure 5.10). Thus, sfxn3 levels are bi-directionally regulated by 
α-synuclein. 
 
Figure 5.9: Validation of sfxn3 upregulation in -syn-/- mice. Sfxn3 protein levels were significantly 
upregulated in synaptosomes from -syn-/- compared to -syn+/+ controls. Bars represent mean ± SEM, 






Figure 5.10: -synuclein regulates the levels of sfxn3. A) α-synuclein levels are increased in the presence 
of Doxycycline (+DOX). Actin was used as loading control. Bars represent mean ± SEM, n9 across three 
different cultures, ****p<0.0001, unpaired two-tailed t-test. B) Levels of sfxn3 protein were significantly 
reduced in SH-SY5Y cells overexpressing WT α-synuclein induced by Doxycycline (+DOX). Actin was 
used as loading control. Bars represent mean ± SEM, n9 across three different cultures, ***p<0.001, 
unpaired two-tailed t-test. C) Representative western blots from A and B are shown for n=3 per treatment. 
 
5.3.3. Sfxn3 is a mitochondrial protein enriched in the inner 
mitochondrial membrane 
Sfxn3 is predicted to be a mitochondrial protein (Pagliarini et al., 2008), but direct 
experimental evidence for its tissue/cellular expression and subcellular localisation is 
currently lacking. We used western blotting to analyse expression levels of sfxn3 protein 
in the mouse nervous system and peripheral tissues (Figure 5.11). Sfxn3 was highly 
expressed in the brain, both in synaptic and non-synaptic fractions, in spinal cord and in 
peripheral nerve. It was also present in liver and kidney, but was not detectable in skeletal 
muscle or cardiac muscle. Thus, sfxn3 is not a ubiquitously expressed protein, being 





Figure 5.11: Sfxn3 is not ubiquitously expressed. Representative western blot showing sfxn3 expression 
across several tissues from an adult wild-type mouse. Cox IV was used as a mitochondrial marker. All lanes 
were loaded with 30 μg of protein. 
 
Isolation of mitochondrial and cytosolic fractions from mouse brain indicated that 
sfxn3 was expressed exclusively in mitochondria (Figure 5.12 A). Furthermore, 
differential extraction of mitochondrial outer membrane and mitoplasts, using a mild 
digitonin solubilisation of isolated mitochondria from SH-SY5Y cells, revealed that sfxn3 
was localised to the mitoplast fraction (Figure 5.12 B). Given the presence of 
transmembrane domains in the sfxn3 protein (Li et al., 2010), we conclude that sfxn3 is 
preferentially localised to the inner mitochondrial membrane. 
 
 
Figure 5.12: Sfxn3 is a protein of the inner mitochondrial membrane. A) Sfxn3 was exclusively 
localised to mitochondrial, but not cytosolic, fractions isolated from mouse brain. As expected, -synuclein 
(-syn) was found in both fractions. Cox IV was used as a mitochondrial marker and GAPDH as a cytosolic 
marker. Both lanes were loaded with 5 μg of protein. B) Sfxn3 was exclusively localised to the inner 
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mitochondrial membrane. Outer mitochondrial membrane (OMM) and mitoplasts (Mit.) were isolated from 
undifferentiated SH-SY5Y cells. VDAC2 was used as a marker for the OMM and ATP5A as a marker for 
the inner mitochondrial membrane and mitoplasts. 
 
5.3.4. Sfxn3 is not required for basal mitochondrial bioenergetics 
functions 
The presence of sfxn3 in the inner mitochondrial membrane prompted us to ask 
whether sfxn3 plays a role in canonical bioenergetic pathways, including oxidative 
phosphorylation. To test this, we isolated purified synaptosomes from WT (sfxn3+/+), 
HET (sfxn3+/-) and sfxn3-KO (sfxn3-/-) mice and performed mitochondrial respiration 
assays using a Seahorse XFe24 Analyzer. Mitochondria bioenergetic functions can be 
comprehensively investigated by performing two assays: the coupling assay and the 
electron flow assay (see Materials and Methods, Figure 5.13 A). The coupling assay tests 
the ability of mitochondria to cope with basal energetic requirements and short bursts of 
high energetic demand. The electron flow assay assesses the individual activity of 
complexes I, II/III and IV of the electron transport chain (ETC). 
During the coupling assay, oxygen consumption rates (OCR) during basal 
respiration were similar between WT, HET and KO mice (Figure 5.13 B, C). 
Accordingly, the fraction of ATP-linked respiration was comparable between mice of all 
genotypes (Figure 5.13 D). Uncoupling of mitochondria using FCCP induced a similar 
increase in OCR in WT, HET and KO mice (Figure 5.13 B, C), with equivalent respiration 
rates associated with spare and maximum respiratory capacity (Figure 5.13 D). This 
indicates synapses from both sfxn3 HET and KO mice are able to cope with basal energy 
requirements and to sustain high levels of ETC activity during acute stress (such as acute 
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administration of FCCP). In the electron flow assay, the activity of each mitochondrial 
complex was tested under the sustained influence of FCCP, to stimulate maximum strain 
of the ETC. Sfxn3 KO mice showed a trend towards reduced activity of mitochondrial 
complexes I-IV, which achieved statistical significance for complex I and complex II/III 
(Figure 5.13 E-G). The performance of HET mice was comparable with WT, suggesting 
that a very significant reduction in sfxn3 levels is likely required to impact on ETC 
function.  
Altogether, these results suggest sfxn3 is not required for mitochondrial 
bioenergetics pathways at the synapse, as basal mitochondrial respiration was unaffected 
by the absence of sfxn3. However, prolonged exposure to the mitochondria uncoupler 
FCCP unmasked subtle impairments in the function of individual ETC complexes, 
suggesting that loss of sfxn3 might impact on the capacity of mitochondria to cope with 





Figure 5.13: Sfxn3 is not required for oxidative phosphorylation. A) Schematic of the mitochondria 
respiratory chain. Mitochondria complexes I-V form an integral part of the mitochondrial inner membrane. 
Substrates such as malate and pyruvate stimulate the production of NADH2 via the Krebs cycle, whereas 
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succinate preferentially boosts the production of FADH2. The reduction of the nucleotides NADH2 and 
FADH2 at complex I and II, respectively, provides electrons to be used in the process of oxidative 
phosphorylation. Electrons (e-) travel from complex I and/or II to complex IV, where they are combined 
with O2 to produce H2O. Oxygen consumption rates can thus be used to infer the activity of the ETC. As 
electrons are fed into the ETC, protons (H+) are transferred through the inner membrane, creating a 
differential of potential between the mitochondrial matrix and inter membrane space, known as the 
mitochondrial membrane potential (m). It is the driving force of the H+ gradient that stimulates the 
ATPsynthase, also known as complex V, to produce ATP. The activity of the ETC can be manipulated by 
the addition of substrates or inhibitors. Providing malate/pyruvate or succinate to mitochondria will 
instigate the activity of complexes I and II, respectively, whereas TMPD acts as an artificial electron donor 
which feeds complex IV directly. On the other hand, complexes I, IV and V can be inhibited in the presence 
of rotenone, antimycin A and oligomycin, respectively. The m is abolished by FCCP and, as there is no 
proton driving force for the ATPsynthase to function, this results in the induction of maximum activity by 
complexes I-IV, in order to attempt to restore m. ETC activity can be monitored using a Seahorse 
Analyzer. A Seahorse Analyzer provides a plate based assay in which the levels of oxygen are measured 
over time and different compounds and substrates can be added to wells containing mitochondria, 
organelles or cell preparations. It thus provides an ideal platform to study mitochondria bioenergetics in 
detail in real time. B-D) Coupling assay showed no differences in oxygen consumption rates in 
synaptosomes isolated from WT, HET and sfxn3-KO mice (B, C). Dashed vertical lines in A indicate the 
time of injection of Oligomycin (Oligo), FCCP (FCCP), and Antimycin A (AA). Traces and bars represent 
mean ± SEM, N=3-5, p>0.05 in One-Way ANOVA with Tukey post-test. D) Bioenergetics parameters 
derived from C. ATP: ATP-sensitive respiration, SP: spare respiratory capacity, MC: maximum respiratory 
capacity, LR: leak-respiration, NMR: non-mitochondrial respiration. Data are represented as mean ± SEM, 
N=3-5, p>0.05 in One-Way ANOVA with Tukey post-test. E-G) Electron flow assay revealed a trend 
towards reduction of ETC activity driven by individual mitochondrial complexes (E, F). Dashed vertical 
lines in E indicate the time of injection of rotenone (Rot), succinate (Succ), Antimycin A (AA) and TMPD. 
Traces represent mean ± SEM, N=3-5. Bars represent mean ± SEM, n=3-5, p>0.05 in One-Way ANOVA 
with Tukey post-test. G) Calculation of respiration driven by complex I, complex II/II and complex IV 
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indicates a specific reduction in complex I and complex II/III activity in KO mice compared to WT and 
HET. Data are represented as mean ± SEM, N=3-5, *p<0.05 in One-Way ANOVA with Tukey post-test. 
 
To evaluate if the subtle effects in mitochondria respiration prompted by reduced 
levels of sfxn3 were due to the enzymatic activity or abundance of key ETC proteins, we 
performed enzymatic assays on immunocaptured Complex I and Complex IV. The rates 
of NADH and cytochrome c oxidation revealed identical enzymatic activities of Complex 
I and Complex IV, respectively, in synaptosomes from WT and sfxn3 KO mice (Figure 
5.14). Quantitative western blotting for ATP5A (a component of ATPsynthase), and the 
Complex I and Complex IV proteins NDUFB8 and cox IV indicated that no compensatory 
changes were occurring in these ETC proteins in sfxn3 KO mice compared to WT 





Figure 5.14: Enzymatic activities of mitochondrial Complex I and Complex IV are not affected by 
loss of sfxn3. A) Complex I activity measured by tracking the absorbance of oxidised NADH. For each 
time point traces represent mean ± SEM, N=3. B) Rate of Complex I activity derived from A shows the 
enzymatic activity of Complex I is not compromised in sfxn3 KO mice. Data are represented as mean ± 
SEM, N=3, p>0.05 in unpaired two-tailed t-test. C) Complex IV activity measured by tracking the 
absorbance of reduced cytochrome c. For each time point traces represent mean ± SEM, N=3. D) Rate of 
Complex IV activity derived from C show the oxidation of cytochrome c is not affected in sfxn3 KO mice. 





Figure 5.15: Levels of key electron transport chain proteins are not altered in sfxn3 KO mice. 
Quantitative Western blotting (A) and representative blots (B) of the levels of key ETC proteins indicate 
they are not altered in synaptosomes from WT and sfxn3 KO mice. Actin was used as a loading control. 
Data are represented as mean ± SEM, N=3, p>0.05 unpaired two-tailed t-test. 
 
Taken together, the set of experiments performed in this section suggests that, 
although sfxn3 is not essential for oxidative phosphorylation pathways and does not 
impact on the enzymatic activity of mitochondrial complexes I and IV, it may play a 
modest role during sustained elevated activity of the ETC. 
 
5.3.5. Sfxn3 influences synaptic morphology at the Drosophila 
neuromuscular junction 
Given the close association between α-synuclein and sfxn3, we wanted to 
establish whether sfxn3 contributes to pathways regulating synaptic stability. We used 
the Drosophila UAS/Gal4 system to generate tissue-specific over-expression and knock-
down of sfxn3 in third instar larval neurons using the pan-neuronal driver elav-Gal4.  
High-dose overexpression of sfxn3 (Tg( +OE)) led to a significant reduction in 
the number of synaptic boutons, accompanied by an overall increase in mean bouton 
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diameter, at NMJs from muscle 6/7 and muscle 12 (Figure 5.16). The increase in bouton 
diameter was due to a preferential loss of small sized boutons. This fact was particularly 
striking at NMJs from muscle 12, in which there was a visible marked reduction in 
projections containing type II boutons (Figure 5.16). To confirm that these changes in 
synaptic morphology were occurring as a direct result of changes in sfxn3 levels, we 
repeated our analyses with a low dose overexpression of sfxn3 Tg(–OE). These 
experiments confirmed no alterations in any of the neuromuscular parameters analysed 
(Figure 5.16). Furthermore, analysis of eye morphology in Tg(+OE) flies showed no overt 
phenotype (Figure 5.17). The Drosophila eye is a robust and sensitive read-out for 
identifying neurodegeneration (Sanhueza et al., 2015), suggesting that over-expression of 






Figure 5.16: Sfxn3 regulates synaptic morphology at the neuromuscular junction in Drosophila 
larvae. A, B) Representative images from NMJs on muscle 6/7 (A) and muscle 12 (B) of control (Control) 
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and transgenic third instar larvae with low and high overexpression of sfxn3, Tg(-OE) and Tg(+OE) 
respectively. Note the reduction in small boutons in Tg(+OE) NMJs (arrow heads). Grey: HRP. Yellow: 
boutons. Scale bar = 10 μm. Reduction in the number of boutons and increase in mean bouton diameter on 
NMJs from muscle 6/7 (C,D) and muscle 12 (F,G) overexpressing sfxn3 (Tg(+OE)). Bars represent mean 
± SEM, N=8-12, **p<0.01, ***p<0.001 in One-Way ANOVA with Tukey post-test. Distribution of the 
diameter of boutons from NMJs on muscle 6/7 (E) and muscle 12 (H) shows a specific reduction of small 
size (<1.5 μm) boutons in NMJs from Tg(+OE) larvae. Data are presented as mean ± SEM, N=8-12. 
 
 
Figure 5.17: Drosophila eye is not affect by overexpression of sfxn3. Representative images of the eye 
from control and Tg(+OE) flies demonstrating no overt phenotype. 
 
As expected, low-dose knock-down of sfxn3 (Tg(-KD)) did not produce overt 
defects in NMJ morphology (Figure 5.18 A-H). However, high-dose knock-down 
(Tg(+KD)) lead to highly variable phenotypes in nerve terminals from both muscles 6/7 
and 12 (Figure 5.18 I). Knock-down induced either collapse and striking degeneration of 
NMJs, or considerable sprouting of small sized boutons. At muscle 12, it was particularly 
clear that many NMJs had an increase not only in satellite boutons but also in boutons 
with morphological characteristics of type II boutons. In some cases, NMJs from muscle 
6/7 presented extremely small boutons, even though these are not characteristics from 
NMJ 6/7. The extreme variability of the phenotypes observed is incompatible with 
reliable quantification of any morphological parameters, thus no quantitative data are 
presented for Tg(+KD) experiments. Qualitative observations suggest, nonetheless, that 
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reduction of sfxn3 in Drosophila larvae destabilises the NMJ, leading to collapse of the 







Figure 5.18: Sfxn3 down-regulation affects synaptic stability at the neuromuscular junction in 
Drosophila larvae. A, B) Representative images from NMJs on muscle 6/7 (A) and muscle 12 (B) of 
control and transgenic third instar larvae with low knock-down of sfxn3, Tg(-KD). Grey: HRP. Yellow: 
boutons. Scale bar = 10 μm. C-H) Consistent number of boutons, mean bouton diameter and distribution 
of bouton diameter from control and Tg(-KD) NMJs from muscle 6/7 (C, D, E) and muscle 12 (F, G, H). 
Bars represent mean ± SEM, N=7-12, p>0.05 in One-Way ANOVA with Tukey post-test. I) Variable 
phenotypes observed in Tg(+KD) nerve terminals from muscles 6/7 and 12. Note the appearance of 
degenerating NMJs and collapsed structures (b, e) as well as highly ramified NMJs with abundant small 





5.4.1. Overview of results 
α-synuclein plays a central role in Parkinson’s disease, where it contributes to the 
vulnerability of synapses to degeneration. However, the mechanisms through which it 
controls synaptic stability and degeneration are not fully understood. First, we tested the 
possibility of using the PNS to study mechanisms downstream of α-synuclein that could 
contribute to the maintenance of synaptic stability, but the lack of any overt synaptic 
phenotypes in the PNS of mice lacking α-synuclein suggested that a focus on CNS 
phenotypes would be more biologically relevant. Therefore, we focused our research in 
the CNS, where a role for α-synuclein has been well established. Comparative proteomics 
on synapse enriched fractions from α-syn+/+ and α-syn-/- mouse brain tissue identified 
robust perturbations of the synaptic proteome in the latter, with bioinformatics analysis 
revealing an enrichment of proteins contributing to mitochondrial pathways. One protein 
we identified in this screen was sideroflexin 3 (sfxn3). Biochemical characterization of 
sfxn3 confirmed that it is a mitochondrial protein preferentially localized to the inner 
mitochondrial membrane. Loss of sfxn3 did not overtly disturb the mitochondrial electron 
transport chain but experimental manipulation of sfxn3 levels in Drosophila larvae 
revealed a robust effect on synaptic stability at the level of the neuromuscular junction. 
Thus, our findings suggest that sfxn3 represents a novel α-synuclein-dependent 




5.4.2. α-synuclein does not overtly affect morphology and Wallerian 
degeneration of axons and nerve terminals in the peripheral 
nervous system 
We found that deletion of α-synuclein did not impact on the morphological 
development or stability of axons and synapses in the PNS (Figure 5.3, Figure 5.4). In 
addition, when challenging these structures with a degeneration stimulus, via axotomy of 
the sciatic nerve, we found that endogenous levels of α-synuclein had no influence on the 
temporal or morphological characteristics of degenerating axons and neuromuscular 
synapses in the PNS (Figure 5.5 and Figure 5.6). These observations indicate that α-
synuclein is not required for the basal stability of peripheral axons or neuromuscular 
synapses and that it does not overtly influence the process of Wallerian degeneration in 
the PNS in vivo. 
 
Our finding that loss of α-synuclein had no influence on the progression of 
Wallerian degeneration in the PNS is in contrast to a previous similar study. Siebert and 
colleagues (Siebert et al., 2010) have suggested that α-synuclein may promote axonal 
degeneration in the PNS by looking at the preservation of axons and myelin sheaths in 
axotomized sciatic nerves from mice of several strains expressing varied levels of α-
synuclein, including the strains we used in our study. However, their observations with 
respect to the progression of Wallerian degeneration were self-conflicting. Following 
nerve injury, they reported an increase in the number of preserved axons in α-synuclein 
null mice, which we identify as α-syn-/- in our study. However, this increase was 
accompanied by a higher density of axons in contralateral uninjured nerves when 
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compared to α-syn+/+ mice, invalidating the comparison. Furthermore, they found a 
similar extent of axonal degeneration between transgenic mice overexpressing α-
synuclein or genetically engineered α-synuclein knockout mice and their respective 
littermate controls, arguing against a significant influence of endogenous α-synuclein in 
the process of Wallerian degeneration in the PNS. By using electron microscopy we were 
able to perform a more thorough analysis of healthy and axotomized sciatic nerves of α-
syn+/+ and α-syn-/- mice. Both mouse strains were indistinguishable in all parameters 
assessed, including axon density and progression of Wallerian degeneration. In addition, 
we extended our study to include synapses, the neuronal compartment most affected by 
α-synuclein function, and found that neuromuscular terminals degenerated at the same 
rate regardless of the loss of α-synuclein.  
 
Studies of transgenic mice over-expressing human full-length or mutant A53T α-
synuclein have reported spontaneous nerve damage, denervation of NMJs or skeletal 
muscle atrophy (Martin et al., 2006, van der Putten et al., 2000). The difference in 
conclusions between these over-expression studies and our current loss-of-expression 
study could possibly be explained by α-synuclein toxicity in the PNS being caused by 
non-physiological effects associated with its excessive accumulation. In fact, the 
physiological and neuropathological characteristics of α-synuclein have been associated 
with different molecular mechanisms and distinct regions of the protein (Burre et al., 
2012). The stability of PNS neurons could therefore possibly be affected by the formation 
of α-synuclein inclusions in transgenic mice without this being associated with a toxic 
gain-of-function of the protein. Accordingly, abnormal or aggregated α-synuclein 
disturbs axonal transport (Chu et al., 2012, Saha et al., 2004), which is a well-known 
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trigger of nerve damage and neurodegeneration (Coleman, 2005, De Vos et al., 2008). On 
the other hand, one of the few documented effects of physiological levels of α-synuclein 
on the PNS is the improvement of neuromuscular degeneration in CSP-α knock-out mice, 
which is mediated by α-synuclein’s chaperone function (Chandra et al., 2005). 
 
5.4.3. Mitochondrial pathways are affected by loss of α-synuclein  
Comparative proteomics on synapses isolated from α-syn-/- mouse brain identified 
mitochondrial proteins as primary targets of α-synuclein deletion at CNS synapses. This 
is in agreement with a growing body of evidence suggesting that α-synuclein is an 
important regulator of mitochondrial function (Haelterman et al., 2014, Nakamura, 2013, 
Protter et al., 2012). In fact, a fraction of α-synuclein is associated with mitochondria (Li 
et al., 2007, Nakamura et al., 2008). Although believed to be primarily localized to the 
outer mitochondrial membrane, α-synuclein can be imported into mitochondria, via a 
process that is usually seen when variants of α-synuclein are expressed in transgenic 
animals or cell lines (Devi et al., 2008, Nakamura et al., 2011).  
The role of α-synuclein in mitochondria function is still under investigation. 
Several groups have reported decreased complex I activity in PD patients and animal and 
cell models of α-synuclein pathology (Devi et al., 2008, Liu et al., 2009a, Parihar et al., 
2008, Subramaniam et al., 2014). In addition, α-synuclein has also been found to increase 
oxidative stress and impair pathways involved in mitochondria fragmentation and 
mitophagy (Hsu et al., 2000, Kamp et al., 2010, Nakamura et al., 2011, Winslow et al., 
2010). Deletion or knock-down of α-synuclein, on the other hand, partially decreases the 
susceptibility of some animal and cell models to Parkinson’s toxin models, such as MPTP 
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and rotenone (Dauer et al., 2002, Klivenyi et al., 2006, Schluter et al., 2003, Zharikov et 
al., 2015).  
Given the need to broaden our knowledge about how α-synuclein affects 
mitochondria, we extended our analysis of the proteomics data to reveal novel proteins 
not previously reported to broadly impact on neurodegenerative pathways or to interact 
with α-synuclein. We were able to identify 37 proteins with the greatest potential to be 
novel modulators of α-synuclein function in mitochondria. This list of proteins (Table 
5.8) can be used to help interpret findings about α-synuclein and explore new mechanistic 
routes. We were particularly interested in sfxn3, as an extensive literature search revealed 
sfxn3 and proteins from the sideroflexin family are involved in neurodegenerative 
pathways (Charbonnier-Beaupel et al., 2015, Fowler et al., 2013, Fuller et al., 2014, 
Minjarez et al., 2016, Scifo et al., 2013, Simunovic et al., 2009). 
 
5.4.4. Sfxn3 is a novel α-synuclein-dependent mitochondrial protein 
We found sfxn3 levels were bi-directionally regulated by α-synuclein (Figure 5.9 
and Figure 5.10). α-synuclein null mice have increased levels of sfxn3 in synapse 
enriched fractions, whereas SH-SY5Y cells overexpressing α-synuclein showed a 
decrease in the expression of sfxn3. The nature of the cooperation between α-synuclein 
and sfxn3 is not clear. On possibility is that α-synuclein interferes with the import of sfxn3 
into mitochondria, since α-synuclein has been found to inhibit the import of nuclear 
encoded mitochondrial proteins through a pathological interaction with TOM20 (Di Maio 
et al., 2016). In support of this, we found several mitochondrial import proteins, such as 
TIM10B, TIM16, TOM40 and MIA40, to be upregulated in α-synuclein null mice 
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compared to WT controls (Error! Reference source not found.). Thus, it could be e
xpected that levels of α-synuclein inversely correlate with the levels of some proteins of 
the inner mitochondrial membrane and mitochondrial matrix, of which sfxn3 might be 
one. 
Nonetheless, at a functional level, it seems likely that sfxn3 acts downstream of 
α-synuclein. In support of this, α-synuclein overexpression has been found to affect the 
activity of mitochondria complex I (see above). We have reason to believe that reduced 
levels of sfxn3 could also modestly impair complex I activity under specific physiological 
conditions (Figure 5.13). Therefore, although still very speculative at this point, a 
relationship could exist in which the levels of α-synuclein indirectly regulate the 
availability of sfxn3. Reduction of sfxn3 could, in turn, be responsible for some of the 
negative effects of α-synuclein overexpression on complex I and/or other mitochondrial 
functions.  
 
5.4.5. Function of sfxn3 in mitochondria 
Loss of sfxn3 was not found to alter basal mitochondrial bioenergetics or the 
enzymatic activity of complex I and IV in young adult mice (Figure 5.13 B-D, Figure 
5.14). However, sustained exposure to FCCP revealed subtle negative effects in oxidative 
phosphorylation, suggesting that sfxn3 deficiency could lead to impairments in the ability 
of the ETC to sustain prolonged high levels of activity (Figure 5.13 E-G). This is unlikely 
driven by defects in the oxidation of NADH, as the diaphorase activity of complex I was 
unaffected in enzymatic tests (Figure 5.14), but could be due to impairments in the 
electron flow machinery, such as in the integrity of iron-sulfur clusters (ISC). ISC are the 
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units responsible for the transfer of electrons along the ETC. Impairments in their 
assembly and altered levels of intracellular iron result in defects in ETC activity and 
oxidative stress (Rouault, 2012). Interestingly, elevated levels of iron are characteristic 
of PD and sideroflexins are proposed to be iron transporters (Fleming et al., 2001, Zecca 
et al., 2004). Furthermore, ISC assembly proteins and antioxidant proteins, such as 
peroxiredoxins, were upregulated, similarly to sfxn3, in α-syn-/- mice (Table 5.4), 
suggesting regulation of iron might be a common feature between these changes. In sfxn3-
/- mice, a failure in iron import/export from mitochondria, due to loss of the proposed iron 
transport function of sxn3, could therefore potentially lead to impairments in the ETC. 
Specific experiments assessing the iron status of tissue from sfxn3-/- mice, as well as a 
better characterization of the influence of sfxn3 in oxidative phosphorylation, are 
nonetheless required before any theories can be drawn about the function of sfxn3. 
 
5.4.6. Implications of sfxn3 for synaptic stability and Parkinson’s 
Disease 
Manipulation of sfxn3 levels in Drosophila larvae lead to robust negative effects 
on the stability of the neuromuscular junction (Figure 5.16, Figure 5.18). Increasing sfxn3 
expression caused a consistent reduction in the number of boutons, whereas knock-down 
of the protein resulted in variable, striking defects in synaptic morphology. These 
experiments suggest that sfxn3 is important for synaptic development and/or maintenance 
of synaptic stability in Drosophila. The fact that both under and overexpression of sfxn3 
destabilized synaptic morphology, indicates that a tight balance of the levels of sfxn3 is 
required to maintain synaptic form and function. 
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In contrast to what we saw in Drosophila, sfxn3-/- mice do show overt 
neuromuscular phenotypes. sfxn3-/- mice are viable and do not present observable motor 
deficits during the first months of life. In addition, neuromuscular junctions from their 
lumbrical muscles are morphologically very similar to those of young WT mice (data not 
shown). It will be important to formally assess motor function and synaptic morphology 
and function in young and aged sfxn3-/- mice. As with α-syn-/- mice, it is possible that 
effects of sfxn3 deletion are more prominent in aged animals or in specific regions of the 
nervous system. In addition, the contrast between the Drosophila experiments and the 
sfxn3-/- mice could be due to different compensatory mechanisms being triggered in the 
two species. It is well known that Drosophila do not express α-synuclein. If sfxn3 and α-
synuclein cooperate to maintain synaptic function and stability it is conceivable that in a 
system where one is missing, manipulation of the other will result in more pronounced 
phenotypes.  
 
Given the relationship between α-synuclein and sfxn3, increased levels of α-
synuclein in PD are likely associated with decreased sfxn3. Indeed, microarray 
experiments performed on samples from the subtantia nigra of PD patients showed a 
decrease in sfxn3 transcripts compared to healthy controls (Simunovic et al., 2009). If 
proven useful, manipulation of sfxn3 could be used therapeutically to modulate some of 
the effects of α-synuclein that contribute to PD, instead of α-synuclein being targeted 
directly, a strategy that has not proven easy. First, however, we need to better understand 





Chapter 6. General Discussion 
6.1. Overview of results 
The goal of the work developed in this thesis was to identify and explore novel 
proteins with potential to modulate synaptic stability in neurodegenerative conditions. In 
that regard, we performed three sets of experiments with the following main findings: 
- Chapter 3: We demonstrated that synapses are affected in a large model of 
neurodegenerative disease, the CLN5 Batten sheep, and validated our initial 
targets for further study, calretinin and -synuclein, as changed in this animal 
model. This provided useful novel information about the neuropathology of 
CLN5 Batten disease. In addition, gave us confidence that we were working 
with targets with potential to modulate neurodegeneration in large animals 
and, therefore, likely to be relevant to human conditions; 
- Chapter 4: We explored the function of calretinin and its contribution to 
neurodegenerative pathways. We have shown calretinin is more widely 
expressed than reported in the literature and, particularly, that it is enriched in 
synapses. In addition, we showed calretinin presents activity-dependent 
properties and that loss of its expression in mice results in delayed Wallerian 
degeneration in the PNS and proteomic changes in brain synaptosomes 
consistent with impairments in cytoskeletal, synaptic and mitochondrial 
functions; 
- Chapter 5: We explored downstream targets of -synuclein and identified 
sfxn3 as an -synuclein-dependent mitochondrial protein able to 
independently regulate synaptic morphology in Drosophila. 
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6.2. Implications for translational research 
In Chapter 3 we explored synaptic pathology in a large animal model of 
neurodegenerative disease, the CLN5 Batten sheep. Not only we provided further insight 
into this disease model, which has not previously been characterized at the molecular 
level, but we also made a significant contribution to our ability to translate research from 
small animal models, such as Drosophila, through to rodents and large animal models of 
disease, such as sheep. The ability to work with tissue from large animals and to 
consistently identify changes at the protein level is extremely important when aiming to 
translate the abundant research performed in rodents to studies using human post-mortem 
or biopsy tissue. In addition, the confirmation that findings from mouse studies are 
applicable to studies in sheep is an important step for ensuring the applicability of the 
work performed in rodents or smaller animals to similar conditions in humans. Working 
with small animals is a valid option and continues to be preferable to most research groups 
from a time-frame and economic point of view. However, translational research would 
greatly benefit from confirmation studies performed in large animal models, such as the 
one performed in Chapter 3. 
 
6.3. Novel targets contributing to synaptic function and 
stability 
In Chapters 4 and 5 we presented work designed to explore novel molecular 
targets able to modulate synaptic stability in vivo. We have identified two candidates 
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(calretinin and sfxn3) which we show, for the first time, are directly involved in 
neurodegenerative pathways at the synapse. 
 
In chapter 4, we established that calretinin is more widely expressed than 
previously believed and demonstrated that it is enriched at synapses, where it responds to 
synaptic activity and helps to regulate synaptic functions. In addition, we showed 
calretinin has the capacity to modulate neurodegenerative pathways. In particular, loss of 
calretinin was able to delay Wallerian degeneration but, on the other hand, aggravated 
cell death by oxidative stress. Thus, a compromise needs to be achieved when 
manipulating the levels of calretinin. Nonetheless, stabilizing the levels of this protein in 
conditions such as Batten disease, where calretinin is naturally upregulated during the 
course of disease, may help delay the loss of synapses characteristic of this condition 
without causing negative effects. Overall, our findings provide an important addition to 
the literature and place calretinin in the spotlight for future neurodegeneration research, 
where further in vivo and in vitro studies in models of neurodegenerative disease will help 
clarify the possibility of manipulating calretinin to obtain therapeutic benefits.  
 
In chapter 5, we identified and characterized a novel mitochondrial protein (sfxn3) 
which functions downstream of -synuclein at the synapse. Given the strong involvement 
of -synuclein in the pathophysiology of Parkinson’s disease and it’s role in synaptic 
stability (Lashuel et al., 2013), our findings can help not only to further our understanding 
about the mechanisms involved in the initiation and progression of Parkinson’s disease, 
but also to better understand the contribution of -synuclein-dependent mechanisms to 
synaptic function and stability. Furthermore, sfxn3 was able to independently affect the 
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development/stability of neuromuscular synapses in Drosophila, indicating it could be an 
important modulator of synaptic stability across disease models. Therapies aimed at 
stabilizing the levels of sfxn3 may therefore prove beneficial for a range of 
neurodegenerative conditions, not limited to Parkinson’s disease.  
 
Taken together, this work identifies calretinin and sfxn3 as new modulators of 
synaptic stability and provides the basis for further studying their contributions to 
synaptic function and neurodegenerative mechanisms. 
 
6.4. Conclusion 
Taken together, the work in this thesis provides important new insights into 
underexplored molecular mechanisms involved in synaptic function and stability, and 
highlights the need and usefulness of continuing to explore new modulators of synaptic 
function and vulnerability. Moreover, it emphasizes the importance of synapses in the 
pathophysiology of neurodegenerative conditions across species and provides methods to 
study synaptic pathology in large animals, therefore supporting the translation of research 
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Appendix I – IPA results from CR-/- proteomics 
Top 50 list of Functions and Diseases associated with the proteomic changes 
identified in CR-/- mice. Functions and Diseases output from IPA was divided into 
Functions and Diseases tables, Table 25 and Table 26 respectively.  
 
 
Table 25: Top functions associated with the proteomic changes in CR-/- mice, as identified by IPA. 
IPA Functions Annotation p-Value Molecules 















































































morphology of neurons 4.52E-12 CAMK2A,CAPZB,CKB,CTNNA2,CTNND2,DNM1,DPYSL5,GDAP
1,GDI1,LGI1,MAP2,MAPT,MBP,MYH10,NEFH,NEFL,NEFM,NPT
N,PACSIN1,PAK3,PLEC,PLXNA4,SH3GL2,STX1B,SYNGAP1 














































morphogenesis of neurites 1.15E-09 CAMK2A,CAPZB,CTNNA2,CTNND2,DNM1L,DPYSL5,LGI1,MAP
T,MYH10,NEFH,NEFL,NEFM,NPTN,PACSIN1,PDIA3,PLXNA4,SV
2A,SYNGAP1,VAPA,YWHAH 









branching of neurites 4.26E-09 CAMK2A,CAPZB,CTNNA2,CTNND2,DNM1L,DPYSL5,MAPT,NE
FH,NEFL,NEFM,NPTN,PACSIN1,PDIA3,PLXNA4,SV2A,SYNGAP
1 





abnormal morphology of 
axons 
5.93E-09 CKB,LGI1,MAPT,NEFH,NEFL,NEFM,PLEC,PLXNA4,SH3GL2 















formation of filaments 9.45E-09 ADD1,CAPZB,CNP,GFAP,GNAO1,GPI,HSPA5,INA,MAP2,MAPT,
MBP,MIF,NEFH,NEFL,NEFM,PAK3,STMN1,SYNPO 
dendritic growth/branching 9.99E-09 CAMK2A,CAPZB,CTNNA2,CTNND2,DNM1L,DPYSL5,MAPT,NE
FH,NEFL,NEFM,NPTN,PACSIN1,SV2A,SYNGAP1 
organization of nervous 
tissue 
1.16E-08 CTNND2,INA,MBP,NEFH,NEFL,NEFM,NPTN,PAK3 
accumulation of filaments 1.22E-08 ACAT1,MAP2,MAPT,NEFH,NEFL,PLEC 
quantity of neurons 1.85E-08 CAMK2A,CANX,CAPZB,DNM1,DNM1L,GNAO1,GRIN2B,MAPT,
MIF,NEFH,NEFL,NEFM,NPTN,PACSIN1,PAK3,PCLO,SH3GL2,ST
X1B 









Table 26: Top diseases associated with the proteomic changes in CR-/- mice, as identified by IPA. 
IPA Diseases Annotation p-Value Molecules 




































Alzheimer's disease 6.65E-10 ABAT,ACLY,ACTB,CAMK2A,CANX,CNP,DNM1L,GFAP,GRIA2,G
RIN2B,HSPA5,HSPA9,IGSF8,MAPT,NEFH,NEFL,PAK3,PRKACA,RT
N3,SH3GL2,STIP1,SV2A,VPS35 






















Mitochondria dysfunction pathway mapped by IPA highlighting the increased 
sensitivity of mitochondria from CR-/- mice to oxidative stress. Green coloured proteins 
are down-regulated in the proteomics data-set (Table 4.8), whereas red proteins are up-
regulated and grey proteins were identified but their expression levels are not altered. 
Orange and blue lines or proteins indicate interactions that are predicted to be activated 
or inhibited, respectively. Yellow lines represent interactions that have not been 
consistently predicted. Overall, the mitochondria dysfunction map highlights changes in 
the oxidative phosphorylation chain in CR-/- mice and predicts that oxidative stress 
pathways should be activated by loss of CR. 
 
 
 
 
 
